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ABSTRACT
TROY TRYGSTAD Pharm. D., M.B.A.: An Analysis of the North Carolina Nursing Home 
Polypharmacy Initiative
(Under the direction of Dale Christensen, Ph.D.)
This dissertation is an evaluation of the North Carolina Polypharmacy Initiative 
(Initiative).  The Initiative was a demonstration project that remunerated nursing home 
consultant pharmacists for value-added drug regimen reviews using a claims-generated 
patient profile that flagged targeted drugs and drug classes for review.  
Shewhart’s PDSA (Plan-Do-Study-Act) cycle is used as the framework to guide this 
evaluation.  The Initiative brought about three distinct PDSA cycles throughout its history.  
The first was the pilot project, and the second was a statewide endeavor, while the third 
continues through other programs and settings in North Carolina.  It is the goal of this 
dissertation to inform the planning stage of future PDSA cycles of pharmacist services in 
nursing home settings.  
Three formal evaluations of the initiative were conducted.  The first evaluation, a 
before-after without comparison group study found a per member per month (PMPM) drug 
cost savings of $30.33 due to initiative activities.  The second, a before-after with 
comparison group study found a PMPM drug cost savings of $19.04.  The third, a before-
after with propensity matched comparison group found a PMPM drug cost savings of $21.36.  
Flags (alerts) were reduced for two types of alert categories across all evaluations and their 
sub-group evaluations. The first, alerts for drugs on the Prescription Advantage List (PAL) 
iv
were substantially reduced with a percentage reduction of 19.2% for all persons having a 
pharmacist review.  The PAL list a voluntary preferred drug list sponsored by North Carolina 
Medicaid.  The second, alerts for drugs on the Clinical Initiatives List were also substantially 
reduced with a percentage reduction of 9.6% for all residents having a pharmacist review.  
The Clinical Initiatives List was a list of drugs submitted by consultant pharmacy 
organizations that were targeted for cost-effectiveness and quality concerns.  Overall, Phases 
1, 2 and 3 of the Initiative produced consultant pharmacist reviews for 19,144 nursing home 
residents.  These reviews generated 17,545 recommendations that resulted in greater than 
10,000 drug changes.
Findings from this dissertation support the conclusion that a targeted program using 
pharmacists to review patient profiles may be quickly launched and expeditiously conducted
across large numbers of patients, at least in long-term-care settings.
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1CHAPTER 1
DISSERTATION SCOPE
    This dissertation presents an overall evaluation of the North Carolina Polypharmacy 
Initiative (Initiative).  The Initiative was a demonstration project that remunerated nursing 
home consultant pharmacists for value-added drug regimen reviews using a claims-generated 
patient profile that flagged targeted drugs and drug classes for review.  
    Shewhart’s PDSA (Plan-Do-Study-Act) cycle is used as the framework to guide this 
evaluation.  The Initiative brought about three distinct PDSA cycles throughout its history.  
The first was the pilot project, which was used for planning and justification of the statewide 
implementation of the Initiative.  The second PDSA cycle, Phase 1 of the statewide program 
was of sufficient success to warrant pilot projects in other settings within the state.  The third 
and final PDSA cycle occurred with Phases 2 and 3 and could be replicated throughout many 
other programs and settings either nationally our through initiatives not affiliated with the 
North Carolina Polypharmacy Initiative.  
    As pharmacist intervention programs such as this Initiative begin to proliferate, 
guidance from previous experience is prudent.  It is the goal of this dissertation to inform the 
planning stage of the third PDSA cycle.  To this end, the main objective of this work is to:
21) Determine if the Initiative was successful in reducing drug expenditures while 
simultaneously maintaining or improving the quality of care received by 
nursing home patients
The overall objective will be met by accomplishing the following sub-objectives:
A) Determine if pre-determined potential drug therapy problems 
decreased  following pharmacist action
B) Determine if drug costs decreased following pharmacist action
C) Determine if hospitalization rates either decreased or remained 
constant following pharmacist action
D) Establish which pharmacist actions and in which sub-groups patients 
experienced the greatest decrease in alert rates
E) Establish which pharmacist actions and in which sub-groups patients 
experienced the greatest decrease in drug costs 
    After these objectives are met, I continue with interpretation and comment on these 
findings in the context of the PDSA cycle.  I end the dissertation by offering lessons learned 
and provide suggestions for developing future drug review services: both generally for 
ambulatory settings and specifically for Medicare recipients receiving drug coverage through 
prescription drug plans (PDPs) beginning in 2006.  Finally, I outline six policy implications 
resulting from the findings of this dissertation.
3CHAPTER 2
THE PROBLEM OF POLYPHARMACY IN THE ELDERLY
2.1 Quality
    Elderly persons are especially vulnerable to drug-related problems.  Drug-related 
morbidity and mortality have been identified as major problems in the elderly, and the two 
major causes are therapeutic failure (i.e., inadequate drug therapy) and adverse drug 
reactions.1-4A study of 1492 nursing homes in five states showed that 33% of residents 
received at least one potentially inappropriate drug.5 Two studies in particular have 
documented a link between elderly hospital readmissions and drug related problems in 18%-
28% of the cases.6,7 Compounding the problem is high prescription drug use; elders are at 
greater risk for experiencing sub-optimal drug therapy (i.e., polypharmacy, inappropriate use, 
or underutilization), which can lead to therapeutic failure or adverse drug reactions.8-10 The 
risk of adverse drug reactions increases with the number of regularly scheduled 
medications.11
    Among residents of long-term care facilities, potential drug therapy problems 
(PDTPs) are magnified because of the typical resident’s more frail state of health, and greater 
use of prescription drugs.  Several studies have noted the prevalence of drug related problems 
in nursing home settings.12-19 Studies have also shown that pharmacists are effective at 
reducing the number of drug related problems.20,21
42.2 Cost
    National attention has been directed to the problem of rapidly rising costs of 
medications for the greater part of the last two decades.  Growing pressure from Medicare 
recipients, especially those with fixed income, led to a crescendo of pleas for drug coverage 
over the past decade.  Subsequent passage of the Medicare Modernization Act of 2003 
(MMA 2003) provided prescription drug coverage beginning in 2006.   Medicare will soon 
become the largest single payor of drug benefits in the United States, with a projected $70 
billion in expenditures in 2006.22
5CHAPTER 3
THE GENESIS OF THE NORTH CAROLINA POLYPHARMACY INITIATIVE
3.1 Escalating Medicaid Drug Expenditures 
    Prior to MMA 2003, State Medicaid programs were bearing the brunt of rising 
prescription drug costs for low income nursing home residents.  State Medicaid programs and 
insurers faced a double-digit rise in prescription drug costs per insured person.  Within NC, 
Medicaid costs approximated $ 7.4 billion per year in 2003, 23 with prescription drugs 
approximating $ 1.2 billion per year.24 The drug component was rising at rate of 17% 
annually.25 Of particular interest to this dissertation, the elderly accounted for only 11% of 
enrollees26, but 32% of all prescription drug costs prior to the implementation of MMA 
2003.27 Countercyclical demands of Medicaid’s fiscal requirements compounded the problem 
of escalating per member per month drug expenditures.  In periods of economic recession, 
governmental income tax receipts shrink as a result of declining personal as well as corporate 
income.  Simultaneously, more citizens become eligible for means-tested Medicaid benefits, 
putting further strain upon state budgets.  In North Carolina, two cost-reduction strategies 
emerged from this period of budgetary strain: 1) reduce provider fees (pay less for services) 
2) reduce drug costs (pay less for products).  
3.2 AccessCare Network of Physicians (Community Care of North Carolina)
   In response to the possibility of a reduction in provider fees, physician groups began 
to solicit proposals for a program that would help constrain drug expenditures within the 
6most costly strata of Medicaid recipients, nursing home residents.  AccessCare, a component 
of Community Care of North Carolina (CCNC) physician provider system, was chosen to 
generate possible strategies to this end.  AccessCare is one of the largest provider networks 
within CCNC, representing approximately 1,500 physicians in 200 group practices, 14 
counties and 20 communities throughout the state North Carolina.  AccessCare has been 
responsible for administering many demonstration projects within North Carolina Medicaid 
since 1991.  CCNC operates through collaborative agreements with local community 
organizations and physician group practices that work together to enhance the quality and 
control costs of care for Medicaid recipients.  CCNC providers are care for nearly 70% of the 
State’s Medicaid enrollees.
3.3 The Long-Term-Care Pharmacy Alliance
The North Carolina Long Term Care Pharmacy Alliance is a group that is broadly 
representative of pharmacists serving nursing homes throughout the state.  Long-term-care 
pharmacies were concerned that reduction in both dispensing fees (fees charged for the 
service of dispensing of the drug product) as well as drug product reimbursement (the 
amount paid for the drug product itself) would be particularly burdensome.  Motivated by the 
possibility of a reduction in operating margins together with the emergence of a group of 
primary care providers willing to work collaboratively, long-term-care pharmacists began to 
generate ideas for a polypharmacy reduction program in nursing homes using their network 
of pharmacists and pharmacy organizations.  These pharmacists were familiar with the 
patients in their respective nursing homes, and had existing relationships with physicians 
providing care at each site, allowing such a program to gain broader acceptance with fewer 
hurdles to prevent implementation.
73.4 Program Scope and Objectives
   Initially, the polypharmacy reduction program was conceived as a short-term, single 
intervention activity in response to a cyclical decline in Medicaid fiscal health.  However, the 
AccessCare network, along with other CCNC network provider groups, had a engaged in 
many types of demonstration projects that ultimately changed processes of care provided by 
primary care givers in North Carolina.  The institutional memory these projects created along 
with the networks’ predisposition for progressive care processes ultimately nurtured the 
development of the pilot project and ultimately the statewide initiative.  Thus, the 
AccessCare network conceived and launched a polypharmacy program that aimed to 
demonstrate the long-term viability of a value-added drug regimen review system that would 
be conducted by consultant pharmacists working in collaboration with the attending 
physician. This program was titled The North Carolina Medicaid Polypharmacy Initiative 
(Initiative).  Key to this long-term viability was a formal evaluation of the cost-effectiveness 
of the Initiative and its ultimate effect on drug expenditures.  Additionally, stakeholders (i.e., 
NC Medicaid, CCNC providers) sought to determine that the Initiative would be scalable, 
expeditiously disseminated to all nursing homes in the state), and continuously modified to 
respond to both the needs of North Carolina Medicaid as well as the prescription drug 
marketplace.   Most importantly, physicians, pharmacists, and administrators strongly 
believed that any endeavor to reduce drug costs could be conducted while preserving the 
quality of care provided to patients.  
    As a result of these requirements, the PDSA (Plan-Do-Study-Act) framework was 
chosen to guide the evaluation and continuously improve of the Initiative.
8CHAPTER 4
TESTING THE EFFECT OF CHANGE IDEAS ON THE PERFORMANCE OF THE 
HEALTHCARE SYSTEM: SHEWHART’S PDSA CYCLE
4.1 Walter A. Shewhart’s PDSA cycle 
    Walter Shewhart introduced “statistical control” to Bell Telephone laboratories in the 
1920’s, and to the world in 1931 through his seminal work, Economic Control of Quality of 
Manufactured Product.28 He became known as the “Godfather of Total Quality 
Management” for promoting continuous improvement through recycling through the PDCA 
(Plan-Do-Check-Act) framework.  It was the continual and perpetual use of critical appraisal 
and subsequent implementation of the cycle which compelled manufacturing industries such 
as automakers to adopt his strategies to improve their products.  Later coined the PDSA 
(Plan-Do-Study-Act) cycle (Figure 4.1), and expanded upon by his colleague at Bell 
Laboratories, W. Edwards Deming, the process was applied in “real-time” and most recently 
in a more general manner, was found to be applicable to all products and services.
Figure 4.1  The Shewhart-Deming PDSA Cycle
Plan
DoStudy
Act
9    The hallmark of the PDSA cycle is its repetitive evaluation of real-world experiences.  
This feature makes employment of the PDSA cycle compelling for evaluation and 
improvement of an intervention program such as a polypharmacy reduction program in 
nursing homes where drug regimens are subjected a quality review at scheduled intervals.29    
Furthermore, the cycle emphasizes effectiveness over efficacy, through process improvement 
and transformation.  Many researchers agree that an operational gap exists between closely 
monitored and controlled randomized clinical trials (RCTs) environment and resource and 
behavioral constraints of the health care marketplace.  However, the PDSA framework does 
not stop at emphasizing effectiveness.  The findings from a program’s Study or analysis of 
what was Done are to be Acted upon and inform the next cycle’s Planning phase. 
4.2 Theodore Speroff’s Healthcare Application
    While PDSA techniques began to infiltrate manufacturing industries in the 1930’s, 
only recently have they been applied in service industries, with healthcare among the more 
newly emerging areas of PDSA principles.  Theodore Speroff, an epidemiologist by training 
was one of the first healthcare researchers to apply PDSA techniques in a healthcare setting.  
He rendered a set of guidelines for appraisal and publication of quality improvement 
research.30 His focus was on application of research findings to real world practice.  As 
Speroff and colleagues put it in their guidelines publication, “The focus on implementation in 
everyday practice is the single most important factor that distinguishes quality improvement 
from traditional evaluative research”.30 moreover, they note that traditional observational 
research stops short of applying findings in the Study stage, whereas quality improvement 
research uses those findings to implement and operationalize “change ideas”30 resulting from 
past evaluations.  The authors of these guiding principles purport the PDSA cycle to be “the 
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application of the scientific method to implement and test the effects of change ideas on the 
performance of the health care system”.   Three core activities as outlined by Speroff to guide 
both researcher and administrator:
1) To seek an understanding of the sources of systematic as well 
as unwanted and unnecessary variation
2) To implement cost-effective strategies to reduce unwanted 
variation
3) To produce organization-wide knowledge on structured 
approaches to change process and improve outcomes
4.3 Initiative PDSA Cycles
In the planning and launch of a demonstration project in nursing homes in North 
Carolina, leaders of the Initiative implicitly adopted these core activities. First, they needed 
to acquire an understanding of the main drivers of prescription drug costs within their patient 
population.  Any unnecessary variations from the standard of care had to be identified to 
clarify specific operational objectives.  Second, it was imperative to understand what 
perpetuated these deviations and find a cost-effective manner in which to reduce the 
incidence of sub-optimal prescribing.  Activities one and two are of no value unless the third, 
dissemination of knowledge is successfully performed.   If proven successful, the 
proliferation of the Initiative to other geographic locations, settings, and populations will 
ultimately decide its success or failure.  As such, I strive in this dissertation to employ all 
three activities from inception of the initiative, its pilot project, Phases 1, 2, and 3 of the 
statewide initiative to the guidance provided for future Initiatives addressing Polypharmacy 
via drug review (Figure 4.2).
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Figure 4.2  The North Carolina Polypharmacy Initiative’s PDSA Cycles
Plan
DoStudy
Plan
DoStudy
Act Plan
DoStudy
Act
The Pilot Project 
(Nursing Homes)
The Statewide 
Initiative       
(Nursing Homes)
Other settings 
(Assisted Living) 
(Ambulatory Elderly) 
(Medicare Part D)
The North Carolina Polypharmacy Initiative’s PDSA Cycles
1.
2.3.
4.
5.6.
7.
    While I make use of all three core activities in this dissertation, the primary focus is 
to the second core activity (Study) stage of the PDSA cycle.  Its aim, to employ robust 
statistical techniques to rigorously evaluate the success of the Initiative in reducing drug 
costs while simultaneously ensuring the standard of care has not been compromised, will be 
accomplished  through quasi-experimentation and statistical matching of study and 
comparison subjects. The results herein are intended to inform programmatic planning and 
budgetary outlays for future PDSA cycles. 
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CHAPTER 5
PLANNING AND DEVELOPMENT OF A CHANGE IDEA: SUPPLEMENTARY 
REVIEW OF PATIENT DRUG THERAPY REGIMENS
5.1 Engendering Value-Added Reviews to Reduce Drug Costs
   To meet program objectives of drug cost reduction and maintained or improved drug-
related quality, Initiative administrators determined that using existing infrastructure of 
pharmacists and prescribers in already employed in long-term-care settings would be most 
expedient.  Program administrators determined that a supplemental review that emphasized a 
critical appraisal of both sub-optimal therapy as well as sub-optimal value could most 
effectively be carried out by a pharmacist-prescriber team that was already engaged in 
ongoing reviews.  
5.2 History and Context of OBRA 87
   Beginning in the 1970s, federal regulations were adopted that required monthly drug 
regimen reviews (DRR) be conducted in long-term care facilities by consultant pharmacists 
at least once per month.29 Subsequent revisions to the Omnibus Reconciliation Act (OBRA 
87) required that this review be accomplished in collaboration with the attending physician.  
These regulations contained explicit requirements for reviewing therapy for targeted drugs 
and drug classes with a high probability of overuse or inappropriate use in long term care 
settings.  While such reviews have resulted in improved care since first mandated16, there 
seems to be room for improvement 1and a more comprehensive approach based aimed at 
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optimizing both the type and use of all drugs taken by the elderly seems prudent. Program 
administrators believed that augmenting the existing drug regimen review process with a 
supplementary review that targeted drugs and drug classes not explicitly addressed by OBRA 
87 legislation would lead to reductions in total drug costs while simultaneously improving 
the quality of therapies prescribed.  
5.3 OBRA 90: Drug Utilization Review and Population Level Interventions
    The passage of OBRA-90 placed additional drug utilization review (DUR) 
requirements on state Medicaid programs.   The legislation compelled states to establish 
committees and systems to conduct retrospective and prospective review patterns of drug use 
believed to be problematic in ambulatory enrollees.  Prospective reviews are defined as 
review activities occurring at the time the prescription is dispensed, while retrospective 
reviews are focused on periodic reviews of prescribing and drug usage patterns based on 
claims data. 
    Prospective DUR is most widely employed through pharmacy-based computer 
algorithms that alert the dispensing pharmacist to potential drug therapy problems (PDTPs) 
during online adjudication of claims.  While the alert is patient-level, it is not patient-
specific.  Alerts are usually drug-specific and sometimes drug-condition-specific, but are 
rarely customized based upon the characteristics and nuances of the individual patient.  This 
deficiency is most pronounced in the high incidence of false positive alerts.31 Retrospective 
DUR is operationally less standardized and is managed at the state level.  Typically, work is 
done at the committee level with an emphasis on patterns of drug use with interventions of 
various types to achieve the desired result.  The most common intervention is through 
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advisory letters to physicians.  To date, retrospective DUR activities have emphasized 
reviews of drug therapy based upon population-level observation.
5.4 Using Administrative Claims to Generate Targeted Alerts
    Program administrators set out to design a program that combined the state-level, top-
down administration characteristics of retrospective DUR activities with patient-level, 
pharmacist-driven activities typical of OBRA-97 DRR reviews.   During Phase I, records 
were retrieved and examined for Medicaid recipients’ prescription usage in 13 selected 
nursing homes served by physicians in the AccessCare network.  Patient drug profiles for 
each nursing home were then created.  Algorithms were developed to screen patient records 
for signs of potential inappropriate and/or polypharmacy drug therapy problems such as 
therapeutic duplication, inappropriate drugs being used (based on the Beers drug list), 
multiple prescribers, and higher than normal drug usage.  The consultant/ pharmacist verified 
the completeness of the patient database as well as the completeness of the drug profile for 
each patient during the first visit to the nursing home facility.  The consultant/pharmacist 
reviewed and confirmed the patients’ prescription regimen and then made recommendations 
to prescribers.  
Based on the consultant/pharmacist recommendations, the prescriber was to decide on 
one of three alternatives: (1) no change/recommendation rejected, (2) recommendation 
accepted, or (3) recommendation accepted with other changes.  Consultant/pharmacists were 
to document their process activities, including: which patients were reviewed, the type of 
recommendation made, whether or not the recommendations were accepted, and what drug 
therapy changes were made.   Supplemental notes, records, and hard copies of the 
recommendation orders were maintained by participating pharmacist-physician pairs to 
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verify the integrity of the databases and maintain consistency of data entry across nursing 
homes.
5.5 Implementing the Nursing Home Pilot Project
    Beginning in March 2002, the pilot program was launched in 13 nursing homes.  The 
intervention consisted of a drug therapy management service provided by a pharmacist-
physician team. The team 1) reviewed drug profiles and other medical records of Medicaid 
patients in nursing homes, 2) determined if a drug therapy problem existed, 3) recommended 
a change, and 4) followed up to determine if the change was implemented.  
    A variety of drug regimen review approaches to this review were allowed.  Most 
pharmacists superimposed the profile review onto their monthly DRR reviews.   Some 
pharmacists initiated a separate review cycle incident to the Initiative.  In five of the nursing 
homes in one particular county, medical residents were utilized as part of the pharmacist-
physician team. In some of the homes, both targeted as well as non-targeted residents were 
reviewed. In other homes, recommendations were reviewed with Access II and III Medical 
Directors.  Subsequently, the pharmacist/consultant and medical directors met with attending 
physicians to discuss specific recommendations. 
    Pharmacists reviewed patients only after obtaining permission of the Department of 
Medical Assistance and the nursing homes as well as their Medical Directors and attending 
physicians.  Confidentiality agreements were in place as a condition for Medicaid enrollee 
and providers participation.
    All review documents were returned to AccessCare Inc. for evaluation.  To assess 
cost impact, each specific drug recommendation was tracked and labeled as to whether or not 
it led to a therapy change, discontinued drug or added drug for each patient.  For each drug 
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change (addition or deletion), its cost impact was calculated by determining the average 
baseline drug cost per month and projecting these costs to the after period (one year).  The 
data source for determining costs was baseline Medicaid claims data for three months prior to 
the start of the intervention (i.e., November 1, 2001 to January 31, 2002) in the pilot nursing 
homes.   All projected drug costs were determined by taking the average amount paid by 
Medicaid for a month’s supply of each prescription identified by its unique drug name and 
dose (if available).  
    A payor perspective was used, focusing on the amount paid by Medicaid to 
pharmacies. While North Carolina Medicaid has a 6 prescription per patient per month 
benefit cap, many elderly patients had exceeded this cap under an exception procedure.   
Some patients without documented exemptions may have nevertheless received prescriptions 
but their drug claims (greater than 6 drug fills) were paid directly by the nursing home.  
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CHAPTER 6
RESULTS FROM THE NURSING HOME PILOT PROJECT
6.1 Pilot Project Results
    Of the 13 pilot nursing homes, all but one completed the intervention and provided 
data available by the end of the requested period.  Results for the remaining 12 homes are 
briefly summarized below.32 A more detailed report if the findings from the pilot project are 
found in Appendix C.
Baseline Use: Medicaid nursing home patients used, on average, 6.1 prescriptions per 
month (median = 6, standard deviation = 3.3, range = 1-18).  The average cost of a single 
prescription for a 30 day supply of a drug $54.81.  The average cost per patient per month 
for prescription drugs was $336.68 (median cost = $269.19)
Frequency of Recommendations: Consultant/pharmacists reviewed 673 Medicaid 
patients in 12 of the assigned 13 nursing homes (One of the nursing homes did not report 
back results)  The pharmacist-physician team made drug change recommendations for 
37.7% (254/673) of all patients reviewed. 
Frequency of Changes:   Of the 4,134 prescriptions reviewed, 408 (10%) had a 
recommendation for some type of change.  Of the 408 drug change recommendations 
made by the consultant/pharmacist, 236 (57.8%) were acted upon (accepted or rejected) 
by the physician.  A recommendation to discontinue (D/C) a drug occurred in 124 or 
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30%, and another 69 (17%) involved a recommendation to change therapy from one drug 
to another. 20 drugs were added to patients’ regimens for new indications.
Drug Cost Savings: The baseline costs for one month of prescription drug usage 
across 12 nursing home sites was $226,588.  The resultant cost after the reviews was 
$217,143, representing a 4.2% savings of $9,445 for the first month.  An annualized 
gross annual savings of $113,340 would be achieved assuming these changes in drug 
therapy persisted for the entire year for all patients reviewed.  
Cost Minimization Ratio: Subtracting the $8,700 cost to hire pharmacist 
consultants and reimburse special physician consultant panels for their review services, 
the first year annual savings to costs ratio is estimated at 13 to 1.  
6.2 Informing the Statewide Implementation of the Polypharmacy Initiative
    Analyzing the results from the pilot study enabled project administrators to make 
informed changes before the rollout of the Statewide Initiative.  PDSA cycles are recurring, 
and the study phase was immaterial without actionable results to inform the next cycle.  The 
pilot program was formed loosely, without rigid construction, to identify alternative 
strategies that reduce drug costs.  This strategy enabled a viable and practicable model to 
emerge that could be replicated many times over for the Statewide Initiative.  Several notable 
points were found in the analysis of the results from pilot project study. 
    Variation in Intervention Intensity:  There was considerable variation in the 
number of reviews conducted by consultants/pharmacists.  In some cases, all of the patients 
in a home were reviewed.   Some homes (five nursing homes in one particular county), only 
targeted patients (i.e., those flagged with possible drug therapy problems) were reviewed, 
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whereas all patients who where Medicaid eligible received reviews in other homes.   Across 
nursing homes, the number of patients reviewed ranged from 12 to 195.
    There was also variation across nursing homes in the percentage of patients receiving 
change recommendations by the consultant-pharmacist team.  Though the team in aggregate 
made some type of recommendation for change in drug therapy for 37.7% (254/673) of the 
patients reviewed, the percentage of patients with problems identified and recommendations 
made ranged from 5% to 100% across nursing homes.
    Variation in Intervention Provider:  Interventions were initiated by consultant 
pharmacists in most homes.  However, in five of the nursing homes in one particular county, 
medical residents were utilized as part of the pharmacist-physician team.  In these homes, 
recommendations were reviewed with Access II and III Medical Directors.  Subsequently, 
the pharmacist/consultant and medical directors met with attending physicians to discuss 
specific recommendations.   
    Variation in Recommendation Type:  The drugs most frequently involved in drug 
discontinuation and change decisions were, in descending order of frequency:  Prevacid, 
Prilosec, Celebrex, Zyprexa, and Norvasc.  However, quite often consultant pharmacists 
made differing recommendations for drugs in the same class.  While differing therapeutic 
rationales may have driven this divergence, it was frequently the case that pharmacists and 
physicians who initiated interventions tended to make the same types of recommendations 
and drug changes.  Despite the variation in recommendation type and alternative drug 
preference, the average savings from a prescription discontinuation was $57.68 for a month’s 
supply.  The average savings for the replacement of one drug with another was $33.23 for a 
month’s supply.
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    Acceptance of Recommendations:  Across nursing homes, 42% of 
recommendations to change therapy were either ignored or rejected.  In four homes, all 
recommendations were accepted by prescribers.  Yet one home garnered 56 
recommendations without any acceptance from prescribers.  The cause of this success 
disparity was not determined.  
    Time to Intervention:  Patient profiles were generally returned in a timely fashion 
(within three months of program initiation).  However, given the time-sensitive nature of the 
interventions and resultant costs savings projections, the pilot project analysis made evident 
the need for better tracking of the time of the intervention.  Both the date of the 
recommendation as well as the date of the follow-up would be needed to accurately track 
intervention activities, and follow-up for laggard profile reviews.
    North Carolina Medicaid’s Six-Prescription Limit:  There was considerable 
variation across nursing home settings in terms of the number and costs of prescriptions 
consumed by elderly residents. Findings showing that nursing home patients used a high 
number of drugs at high cost to Medicaid are consistent with what is generally known about 
elderly nursing home patients’ drug use patterns nationally.  The finding that patients used a 
median of 6 prescriptions per month indicates that at least half of them obtained drugs 
through an exceptional use procedure or had their medications covered directly by the 
nursing home itself.   It became evident through feedback from pharmacists in the field that 
the vast majority of persons using more than 6 prescriptions per month had filed and received 
an exemption from this limit.  Thus the likelihood of drug use not captured in administrative 
claims was low.  However, program administrators suggested that all drugs, including over-
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the-counter medications be reported on patient profiles provided in future Initiative cycles to 
accurately and comprehensively depict resident drug use.  
    Variable Overall Success Across Homes:  Considerable variation was observed 
across homes with regard to intervention intensity and success.  The reasons for this variation 
were not entirely clear.  It was not determined why the pilot program was more successful in 
some of the nursing homes than in others, especially recognizing that all have, by regulatory 
requirement, review and quality assurance systems in place as outlined in OBRA 87 
regulations and updates.  It may be that consultants typically audited for safety, compliance, 
quality, and legalities or liabilities/risk exposure but gave less emphasis to cost effectiveness.  
In this pilot, however, a special emphasis was given to the potential for cost savings.   
Secondly, perhaps “another pair of eyes” provided by the pharmacist-physician team detected 
more problems or more opportunities for drug cost savings.  Third, it may have been that 
problems/opportunities were previously detected or noted in records by consulting 
pharmacists, but simply not acted upon because of the lack of follow-up. 
6.3 Major Findings
A. Baseline drug use was significant, especially for enrollees using greater than 
18 prescription fills in 90 days
B. Individual variation existed in number of recommendations, recommendation 
type, reviewer type, and success
C. Substantial numbers of recommendations could be garnered in this setting and 
with this approach
D. Substantial savings resulted recommendations when accepted
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E. The six prescription limit was inconsequential to overall results, but 
nonetheless needs to be addressed in future phases of the Initiative
F. More emphasis on follow-up would be required for future phases of the 
Initiative
G. Monitoring of the review process throughout its life-cycle will help maintain 
Initiative inertia and ensure quality reviews
H. Requirements for follow-up are critical to recommendation attribution and 
subsequent program measurement and evaluation  
6.4 Lessons Learned from the Pilot Project
    Given the results of the pilot project, it became apparent that a program of review of 
Medicaid nursing home patients by pharmacist-physician consultants was cost-beneficial 
based solely on drug cost savings.  Assuming that the drug use experiences of other NC 
Medicaid nursing home patients is similar to those in these homes, there seemed to be an 
opportunity to expand the Initiative and attempt to optimize therapy among NC nursing home 
Medicaid patients.  Using a value-added, supplemental review had proven successful through 
piloting. 
    Additionally, the findings supported the role of pharmacists working collaboratively 
with physicians in this activity. A recent Cochrane database review indicated that clinical 
pharmacists, working collaboratively with physicians, can be effective in addressing drug 
related problems among patients.33 These studies imply that interventions of the type 
conducted in this pilot study have the potential for additional savings from reduced 
hospitalizations and other health care system costs.
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    The pilot project results suggest that having pharmacist-physician review teams make 
periodic visits to targeted nursing homes may improve both the quality and cost of drug 
therapy reviews.  These findings supported the conclusions of other researchers that drug 
therapy received by the elderly could be improved from a qualitative as well as a cost-
effectiveness standpoint.  Based upon those conclusions, the statewide initiative was 
approved by the Division of Medical Assistance (Medicaid) with the approval of the Office 
of Rural Health and Demonstration Projects.
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CHAPTER 7
ACTING ON THE FINDINGS OF THE PILOT PROJECT AND PLANNING FOR 
THE STATEWIDE INITIATIVE
7.1   Programmatic Changes Resulting from the Findings of the Pilot Project
    One of the resulting themes of the pilot project was a lack of standardization in terms 
of which patients received (e.g. targeted patients, all Medicaid patients, or all patients in the 
home), who conducted the reviews (e.g., traveling pharmacists, physicians, or both; on-site 
consultant pharmacists). and what the focus of those reviews (e.g.,  which drugs and/or drug 
classes would be emphasized for review).   Conducting a statewide initiative with review of 
greater than 10,000 residents would require a more streamlined approach that utilized a more 
well-defined intervention that was reproducible and measurable.  Some programmatic 
changes included:
    Emphasis of consultant pharmacists as point persons for coordinating profile 
reviews:  To decrease the lag time to review and recommendation, existing consultant 
pharmacists were chosen as the primary coordinators of review activities.  Reasons for this 
decision included: Existing consultant pharmacists would be were familiar with coordinating 
reviews at both the dispensing settings as well as on-site, through scheduled OBRA-87 
required DRRs.   Additionally, the long-term-care pharmacy market in North Carolina was 
relatively concentrated and top-heavy, with five organizations responsible for DRR reviews 
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of greater than 70% of the state’s nursing home residents, making it easier to coordinate and 
efficiently implement new review requirements.  All nursing home pharmacy consulting 
organizations were members of the Long-Term-Care Pharmacy Alliance that had endorsed 
the initiative prior to the pilot project.  Unlike the pilot project, thousands of patients in 
hundreds of homes would require review.  A relatively small number of uniformly-trained 
pharmacists could review drug profiles for the majority of Medicaid enrollees in nursing 
homes in a short period of time (2-3 months), reducing time to launch and program uptake. 
    A more well-defined patient profile:  To aid in the efficiency and yield of profile 
reviews, AccessCare collaborated with the NC Long Term Care Pharmacy Alliance to 
develop an action plan and a Toolkit© for consulting pharmacists. The Toolkit© contained 
instructions for documenting consultations and explained the screening criteria used to select 
(flag) drugs for attention (Figure 6.1).  The Toolkit was introduced consultant pharmacists to 
the project during two one-hour group meetings and one hour-long conference call in 
September and October 2002.  Pharmacists were provided with the Toolkit©, and received 
individual training from the lead consultants in their organizations.   Each consultant 
pharmacist was provided with a Toolkit© as well as printed drug profiles of screened patients 
which contained computer-generated prompts for selected drugs and classes of drugs. 
    The Toolkit and patient profile were developed to ensure consistency of interventions. 
Since many different pharmacists were involved in this project, these two documents 
provided a guide and standard procedure for documenting interventions.  The toolkit criteria 
were used to prompt the pharmacist to review specific drug(s) or classes of drugs that had the 
potential to achieve cost-savings as well as increased quality of care in targeted patients. The 
first criterion was receipt of a drug generally considered to be inappropriate for use in the 
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elderly (Beers drug list).3  A second criterion was receipt of a drug on the CCNC Prescription 
Advantage List (“PAL”), which encourages substitution of less expensive drugs within a 
therapeutic class.  For each of the ten drug classes represented on the list, certain medications 
offered potential cost-savings to the Medicaid program (PAL-1) while others either offered 
no clear cost advantage (PAL-2) or would incur significant costs (PAL-3). The third criterion 
was receipt of a drug on a list of ‘Clinical Initiatives.’ This list was developed by the 
consultants participating in this project, and included 16 drugs and/or drug classes that have 
the potential for quality improvement and cost savings.   The list was derived from NC 
Medicaid’s Top 100 drugs by expenditures for fiscal year 2001.  Examples include the 
review of proton pump inhibitors for appropriate length of therapy and possible switch to a 
H2 receptor blocker, and the evaluation of residents taking chronic sleep aids for a possible 
drug holiday or discontinuation.   By soliciting input from both prescribers as well as 
pharmacists, each had ownership in the review process, greatly enhancing the acceptance of 
the PDTP alerts and the Initiative as a whole.
    To further diminish review ambiguity and increase the specificity of the subsequent 
analyses, the recording procedures were altered to be more specific and all-encompassing of 
the potential universe of recommendation and result-types (Figure 7.1).  Consultant 
pharmacists were asked to record both the result of the review (i.e., the recommendation) and 
the result of the intervention (i.e. the outcome) onto a specially prepared documentation form 
(i.e. The Intervention Tool™).  The following types of problems were documented:  
Unnecessary Drug Therapy, More Cost Effective Drug Available, Wrong Dose/Delivery, 
Potential for Adverse Drug Reaction, Needs Additional Therapy, and Other Problem.  The 
following intervention results were coded:  Dose/Delivery Changed, Drug Added, Drug 
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Changed (from one to another), Drug Discontinued, No change, and Other. If an intervention 
resulted in drug therapy change of any type, the original drug, dose, and quantity was noted 
as well as the changed drug, dose, and quantity.  Drug, dose and quantity were also reported 
for each new drug added for previously untreated indication.
    Overall, the patient profile for the statewide initiative was designed to reduce 
unwanted variation in response.  In line with the traditional manufacturing roots of PDSA, 
the profile utilizes a standardized format, with replicable and structured data sources.
Figure 7.1  Example Resident Profile
 Nursing Home PolyPharmacy Project - Patient Profile Page 1 of 4 5/7/2003Patient Name Medicaid ID
First Name:Patient ID:
DOB:
Last Name:
Age:Gender:
Nursing Home Practice:
Avg # of Drugs/month: Avg monthly drug $:F 82 7.67 $625.85xx/xx/xxxx


Nursing Home Name and Number
XXXXXXX XXXXXXX XXXXXXX
Drug Class
Fill
Date
Medication
Amount 
Paid
Date
Prescriber PAL
Potential
Theraputic
Duplication
Beers 
List
> 65
Problem 
Type
Date
Results 
Type
Date
Clinical 
Initiatives/Q
uality 
Consider 
Length of 
treatment*
New Drug 
and 
Strength
Confidential - For record validation only. Not for inclusion in chart. Please return to 
A  B  C
D  E  F  G
1  2  3
4  5  6ANALGESICS, 
NARCOTIC
ULTRACET TABLET $164.96
d
7/30/02
Prescriber
Name
A  B  C
D  E  F  G
1  2  3
4  5  6ANTINAUSEANTS METOCLOPRAMIDE 10MG 
TABLET
$11.818/16/02
Prescriber
Name
A  B  C
D  E  F  G
1  2  3
4  5  6ANTISPASMODIC-
ANTICHOLINERGIC
S
HYOSCYAMINE 0.375MG 
TAB SA
X$16.046/5/02
Prescriber
Name
A  B  C
D  E  F  G
1  2  3
4  5  6ANTI-
ULCER/OTHER 
GASTROINTESTINA
L PREPS
NEXIUM 40MG CAPSULE PAL 3 
Prefer 
Protonix
X$131.328/7/02
Prescriber
Name
A  B  C
D  E  F  G
1  2  3
4  5  6BRONCHIAL 
DILATORS
ALBUTEROL .83MG/ML 
SOLUTION
PAL 1$16.708/9/02
Prescriber
Name
A  B  C
D  E  F  G
1  2  3
4  5  6DIURETICS FUROSEMIDE 40MG 
TABLET
$7.52
a
8/29/02
Prescriber
Name
Problem Type (Circle all that apply)
A. Unnecessary Drug Therapy
B. More Cost Effective Drug Available
C. Wrong Dose or Strength
D. Drug has High Potential for ADRs
E. Needs Additional Therapy
F. Not a problem at this time
G. Other - Any other problem not listed above
Results Type (Circle all that apply)
1. Dose/Delivery Changed - Dosage or administration was changed
2. Drug Added - New drug was added for previously untreated 
indication.
3. Drug Change - Drug was changed from one to another.
4. Drug Discontinued - Drug was discontinued or was changed to PRN.
5. No Change - Physician Responded  but did not make any changes.
6. Other - Any result not listed above.
Medication Superscripts
a. Recommended check for K+ need
b. Recommended use with Ca+ supplement.
c. Recommended check for FE+ need
d. Recommended check for Stool Softener need
e. Recommend check for Folic Acid therapy.
f. Recommend check for supplemental calcium need..
g. TB test needed?
h. Does patient have BPH and HTN? Consider Cardura.
i. Consider dose reduction/excessive dose.
PAL Codes
PAL Code 1 - Preferred Drug
PAL Code 2 - No Preference
PAL Code 3 - Avoid
PA                 - Prior Authorization 
Required
*Please refer to toolkit for further explanation.    
    Targeting reviews:  Rather than generate profiles for all Medicaid enrollees residing 
in long-term-care facilities, program administrators chose to employ a targeted approach.  
For phase I, all persons having more than 18 drug fills in 90-days had profiles generated and 
sent to consultant pharmacists for review activities (Figure 7.2).  This decision was based 
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upon a two-fold motivation:  1) Initiative funds could not bear to compensate pharmacists for 
the total number of potential reviews for a long-term-care Medicaid population of greater 
than 25,000 and 2) Targeted reviews were believed to be more cost-beneficial based upon the 
results of the pilot project.  The primary rationale for reviewing targeted patients was to 
increase the percentage of patients receiving recommendations to maximize return on the 
payments to pharmacists for review activities.  Furthermore, an evolving set of alerting 
algorithms would be desirable given changes in practice, drug cost and patient setting.  This 
evolution over time is consistent with the PDSA cycle process.  Each cycle should have 
renewed targeting strategies since practice standards and resource use for given products and 
services change over time.
    Prospective Interventions:  Consultant pharmacists approached program 
administrators about performing prospective interventions in addition to targeted 
retrospective profile reviews.   They argued that retrospective profile reviews target and 
address potential problems well after the problematic drug(s) are dispensed.  An earlier 
review (i.e. targeting the first dispensing of a new prescription order) would delay the 
detection of a potential drug therapy problem and/or miss an additional drug cost savings 
opportunity.    Their arguments were persuasive, and the Initiative agreed to pay for both 
types of interventions ensured that high-use patients as well as low-use patients with a high 
probability for review success (Figure 7.2)
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Figure 7.2  Targeting Strategy
All patients in Nursing Facilities
18+ Rx in 3 mo
Flagged
    
Action-driven vs. results-driven incentives:  It is advantageous to review the 
decisions regarding payment rules under the Initiative in the context of health care industry 
practices.  Two general types of payment incentives have developed in the health care 
industry over time.  Action driven incentives such as payment for procedures performed 
reward caregivers for their services, for example, number and type of visits or interventions 
performed.  In contrast, results driven incentives such as “pay for performance” programs 
reward providers for achievement of pre-specified metrics.  Both types of remuneration for 
services can align patient-provider incentives to achieve better care.  The Initiative employed 
both of these types of incentives. 
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    Pharmacists were compensated for all profile reviews completed, regardless of the 
resultant outcome of the review.  This action driven incentive encouraged widespread 
adoption of the Initiative by providing front-end compensation for services performed.  If 
Initiative administrators had required results driven payment for profile reviews, many 
pharmacist consultant organizations may have seen the up-front costs of establishing a 
successful review process to be too burdensome to participate in the Initiative, and would 
have incentivized them to intervene in patients which they had a strong a priori belief that 
their interventions would result in positive results (i.e., drug changes).  Pharmacists were 
compensated at a per retrospective profile review at the rate of $12.50 in phase I of the 
Initiative.  This level of compensation seemed reasonable since targeted reviews would occur 
at the time of a separately funded regularly scheduled OBRA-87 drug regimen review.
    Conversely, payment only for services performed without providing an incentive 
might have led to stale reviews without diligent effort to vigorously uncover PDTPs.  Thus, a 
results-driven prospective payment system was set up alongside the action-driven profile 
reviews.  Pharmacists were allowed to bill for interventions occurring at the time of 
dispensing for drugs ordered for patients not targeted in Phase I of the Initiative, or for new 
drugs ordered for targeted patients.  Compensation was allowed if the drug order was 
changed or not dispensed as a result of dispensing pharmacist review.  These “line-item” 
interventions were compensated at the rate of $6.50 per drug. 
    Using both action-driven and results-driven incentives provided a balance of 
motivations among pharmacists and their organizations.  Furthermore, the payment system 
was set up to ameliorate start-up costs associated with the disruption in workflow caused by 
the implementation of the Initiative in the consultant organizations.  One-time overhead 
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payments were granted to participating pharmacies to encourage participation.  All of these 
elements of payment in combination are believed have aided in the widespread adoption and 
success of the program from the beginning of the Initiative.
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CHAPTER 8
OPERATIONALIZING A STATEWIDE PHARMACIST REVIEW PROGRAM
8.1 Toolkit Orientation
    Consultant pharmacists were oriented to the project during a group meeting in 
October 2002.  Pharmacists were provided with the specially prepared Toolkit©, and received 
individual training by nursing home consulting organization administrative personnel.  
Individual orientations in person and by teleconferencing were also given for those 
consultant-pharmacists unable to attend the group orientation.  
8.2 Meeting with Prescribers and Administrators
    Meetings with prescribers and administrators both within Medicaid as well as 
Medical Directors at nursing facilities were held in the Fall of 2002 to elicit their support and 
advocacy for Phase 1 of the Initiative.  Attendees learned about the results of the pilot 
program, the potential qualitative and economic value of the program were it successful, and 
detailed plans for Phase 1 of the statewide intervention.  
8.3 Profile Generation
    Two weeks prior to the rollout of the Statewide Initiative, Medicaid prescription 
claims data was retrieved from the archival vendor.  As is typical of the administrative data 
archival process, a two-week lag time was required before data became available for use in 
the Initiative.  Three months of data beginning three and one-half months prior to profile 
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generation and ending at two weeks prior to rollout were acquired.  Prescription claims data 
were aggregated into an electronic profile using the SQL programming software.  This 
process took approximately one day of computer processing since programming was written 
prior to the acquisition of claims.   Once resident profiles were electronically generated, three 
days of printing ensued.  Ultimately, greater than 10,000 eligible profiles were printed.   With 
multiple pages per profile, and in many instances multiple pages of drug listings, printing and 
sending profiles to consultant pharmacists became the rate limiting step in the process once 
data was acquired from the vendor.
8.4 Workflow that Mimics the PDSA cycle
   The PDSA cycle provides an ideal framework for assessing the steps followed 
designing, demonstrating, and evaluating this Initiative.  This cycle is illustrated in Figure 
8.1.  Planning activities such as determination of criteria for profile-based alerts and 
eligibility for review precede the application of claims data to generate patient profiles.  After 
profiles are sent, utilized and returned for evaluation, an analysis of the effect of a given 
cycle is studied and acted upon until the next cycles planning phase.  
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Figure 8.1  Program Workflow
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CHAPTER 9
DESCRIPTIVE RESULTS FROM PHASE 1 OF THE NORTH CAROLINA 
POLYPHARMACY INITIATIVE
9.1 Pharmacist Reported Data
    Pharmacists were required, as a condition of payment, to record problem types 
(including “no problem”), results types (including “no change”) and new drugs and strengths 
when introduced.   Documentation was required for both complete profile as well as 
individual drug reviews regardless of its retrospective or prospective nature.  Thus, upwards 
of 10,000 documents were returned to AccessCare for payment and ultimately, entry into a 
primary data set for analysis.  
    A computerized data entry program was created to assist in data processing.  
Pharmacy students were hired as data-entry personnel.   They were selected over non-
medically trained personnel because of their familiarity with prescription drugs and 
nomenclature.   Each person was screened for their proficiency in interpreting hand written 
documentation.  When written documentation was insufficient to make an absolutely clear 
determination of the intended notation, profiles were marked for further review in the 
computerized data entry program.  These determinations were ultimately made by licensed 
pharmacists.  Less than 3% of all drug documentations and/or recommendation types 
required pharmacist interpretation.  Data reported in this chapter are derived from this 
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primary data source with the exception of Table 9.1, for which administrative claims data 
was used as a source.
9.2 Phase 1 Scope
9.2.1 Number of pharmacists, nursing homes, residents and counties
    One-hundred and ten consulting pharmacists participated in the first phase of the 
Initiative with a total of 253 nursing homes served by a participating consultant pharmacy 
organization participating.  Ninety-three of North Carolina’s 100 counties had nursing homes 
participating in Phase I of the Initiative.   There were 25,783 residents in nursing homes in 
the state of North Carolina at the time of screening and profile generation (Figure 9.1).  Of 
the 12,173 residents failing the screen of greater than or equal to 18 prescription fills in 90 
days, 9,208 resided with pharmacy consultant organizations that expressed interest in taking 
part in the Initiative.  
9.2.2 Profiles generated, sent and returned
    Prescription profiles were generated from Medicaid claims data and sent to consultant 
pharmacists for 9208 patients, representing 75.6% (9,208/12,173) of all residents in North 
Carolina failing a screen of greater than 18 prescription drug fills in the 90-day period 
preceding the rollout of the statewide Initiative (Figure 9.1).  Pharmacists returned 82% 
(7,548/9,208) of all profiles generated.  After excluding 1,204 (13%) patients who were 
discharged or deceased prior to initial reviews, and 532 (5.8%) resident profiles held out 
from the Initiative due their inclusion in an ongoing, unrelated study, a response rate of 85% 
(6,344/7,472) was observed, with 1,128 profiles unreturned.  
37
Figure 9.1  Residents Screened, Profile Generation, Distribution and Receipt
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9.2.3 Residents selected for reviews by pharmacists
    Another 1,743 residents were introduced to the Initiative through prospective 
interventions.  Interventions were considered prospective if they occurred under one of two 
circumstances:  1) a review was performed in lieu of a profile (the resident passed the screen 
for profile generation, yet the pharmacist sought to make a recommendation) or 2) a resident 
had a profile that did not list a drug for which pharmacists desired to make a recommendation 
(drugs are customarily added and removed residents’ regimens over time, and there was a lag 
period of time from profile generation to profile review, creating the opportunity to intervene 
on these newly prescribed drugs).  1,743 residents met the former criteria with 1,399 
residents meeting the later (Figure 9.2).  
    There is a historical and relatively constant rate of discharge or death in North 
Carolina nursing homes of 36% per year.   Thus, approximately 2,300 new residents entered 
homes during the three month review period and pharmacists chose to make 
recommendations for many of those new residents.  Of the 1,743 residents receiving 
recommendations without the direction of a computer generated profile, 45.3% (789/1,743) 
were new residents not subject to screening prior to the review period.  The remaining 954 
(54.7%, 9,54/1743) were residents that resided in the home during the review period, passing 
the screen.  These residents were selected for review by pharmacists without the aid of a 
profile.  In total, 8,807 nursing home residents in North Carolina were subject to reviews 
performed by consultant pharmacists in Phase 1 of the Statewide Initiative.
9.2.4 Types of reviews received by residents
    Of the 8,087 residents receiving reviews by consultant pharmacists, recommendations 
were offered for 71% (5,746/8,087) of them, with successful recommendations (drug change 
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accepted by prescriber) garnered by 51.4% (4,162/8,087) of residents receiving reviews
(Figure 9.2).  For residents with retrospective profile reviews, 47.1% (2,990/6,344) 
ultimately had a drug change.  Among those residents selected for review by pharmacists 
prospectively, 67.2% (1,172/1,743) had changes in drug therapy resulting from 
recommendations as recorded by pharmacists.  There were 1,399 residents who had both a 
retrospective, claims generated profile review in addition to prospective recommendations 
based upon drugs not used during the baseline period.  These residents were considered to 
have had “dual” type interventions.  In total, the three types of interventions possible were: 1) 
Prospective-Only 2) Retrospective-Only and 3) Dual-Type (prospective and retrospective).
Figure 9.2  Residents Receiving Reviews, Recommendations and Drug Changes by Type 
of Intervention
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9.2.5 Baseline characteristics
    Table 9.1 presents the baseline characteristics for residents with reviews, by type.   In 
order to obtain comparable baseline characteristics among intervention types, criteria were 
imposed to limit the analysis to only those residents who: 1) were Medicaid eligible for the 
three month period leading up to the review period, 2) resided in a nursing home for the three 
month period leading up to the review period, and 3) had not been deceased or discharged up 
to the time of review.  All patients having a profile generated and reviewed met these criteria.  
Similarly, all 954 residents passing the screen, but selected by pharmacists for review met the 
criteria.
    For the 7,298 residents with baseline data, 74.9% (5,464/7,298) were female and 
68.5% (5001/7,298) where white with an average age of 77.8.  An average of $1,444.73 in 
paid pharmacy claims from an average of 26.97 drugs was utilized during the 90-day pre-
review screening period.  Notably, one resident had $99,630.33 in baseline drug costs and 
thus, the mean and standard deviation are highly skewed for the overall group as well as the 
group with retrospective-only reviews, underscoring the importance of using median results 
and non-parametric testing when outliers skew the distribution.  As expected, residents with 
prospective-only type reviews utilized fewer than half of the drugs of their targeted 
counterparts with profiles.  The resulting $702.06 average drug cost for the 90-day pre-period 
is also less than half of the drug costs incurred by residents receiving retrospective-only and 
dual-type interventions.  
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Table 9.1 Baseline Characteristics of Residents Receiving Reviews by Type 
(N=8,087)
Characteristic       All Residents               Residents with         Residents with             Residents with          
      with Reviews                Retrospective  Dual Retrospective and         Prospective      
                                                                                       Reviews Only    Prospective Reviews          Reviews Only       
         (N=7,298)*                    (n=4,945)             (n=1,399)                      (n=954)*
Sex, # (%) 
  Male       1834 (25.13)  1269 (25.66)             327 (23.37)      238 (24.95)
  Female       5464 (74.87)           3676 (74.34)           1072 (76.63)                 716 (75.05)
Race, # (%)
  White       5001 (68.53)                  3411 (68.98)             994 (71.05)                 596 (62.47)
  Other       2297 (31.47)                  1534 (31.02)             405 (28.95)     358 (37.53)
Age, years, mean ±SD             77.78 ± 12.46                77.37 ± 12.62               77.53 ± 12.22              80.26 ± 11.62
         (median)              (80.0)        (80.0)             (80.0)           (82.0)
# of prescription fills,       
3 mo. period, mean ±SD          26.97 ± 11.22                 28.76 ± 9.96          30.84 ± 10.56               12.00 ± 4.82
         (median)              (25.0)        (26.0)          (28.0)                        (12.0)
amount of paid claims,   
$ in 3 mo., mean ±SD           $1444.73 ± 1489**       $1526.48 ± 1681**      $1662.23± 987.44       $702.06 ± 478.99
         (median)          ($1247.67)                   ($1304.19)             ($1473.87)       ($608.49)
* Of the 1,743 residents receiving only prospective reviews, 954 maintained baseline eligibility throughout the 3 
month baseline period prior to screening and reviews and resided in a nursing home during that time
**One resident had $99,630.33 in baseline drug costs and thus the mean and standard deviation for “amount of  paid 
claims” are unduly affected and focus should be given to median values
Note: Administrative claims were used as a data source
9.3 Descriptive Results
9.3.1 Overall response 
    Overall, 8087 residents with consultant pharmacist reviews generated 9883 
recommendations for a drug change (Table 9.2), or an average of 1.22 recommendations per 
resident.    The most frequent reason cited for change was for the substitution of a more cost-
effective therapy representing 55.4% (5473/9883) of all recommendations to change therapy.  
    A total of 6115 changes in drug therapy occurred as a result of recommendations by 
consultant pharmacists (Table 9.3), or an average of 0.84 drug changes per resident with 
review.
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    Approximately two-thirds of all recommendations were accepted, with 61.9% (6115/9883) 
of suggested therapy changes resulting in changed therapy.  The most common result was 
that of a change from one drug to another, representing 55.9% (3418/6115) of resulting 
changes in drug therapy.
Table 9.2 Recommendations for Changed Therapy by Type (N=8,087 residents)
Problem Type Frequency (%)               Average Number per 100 residents*
Unnecessary Drug Therapy 1887 (19.0) 23.3
More Cost Effective Drug Available 5473 (55.4) 67.7
Wrong Dose or Strength   734 (7.4)   9.1
Drug has High Potential for ADRs   936 (9.5) 11.6
Needs Additional Therapy   234 (2.7)  2.9
Other-Any other problem not listed above     619 (6.3)  7.7
Total 9883 (100)            122.2
ADR= Adverse Drug Reaction
*  Denominator is the total number of residents receiving a completed review by consultant pharmacists
Note: Pharmacist report was used as a data source
Table 9.3 Resultant Changes in Therapy by Type (N=8087 residents)
Frequency (%)             Average Number per 100 Residents*
Dose/Delivery Changed   852 (13.9) 10.5
-Dose or administration was changed
Drug Added     97 (1.7)   1.2
-Drug added for untreated indication
Drug Change 3418 (55.9) 42.3
-Drug was changed from one to another
Drug Discontinued 1748 (28.6) 21.6
-Drug was discontinued or changed to PRN
Total** 6115 (100) 75.6
*  Denominator is the total number of residents receiving a completed review by consultant pharmacists
** A result type of  “Other-Any result not listed above” occurred in 1,111 instances but was not considered to be 
verified drug changes.
Note: Pharmacist report used as a data source.
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9.3.2 Response by Intervention Type
    Overall, an average of 1.21 recommendations were made per resident with any review 
resulting in 0.74 drug changes per resident (Table 8.3).  Residents with retrospective-only 
type reviews received the fewest recommendations per resident (0.99) and drug changes 
(0.57), whereas residents with dual-type interventions garnered the greatest rate of 
recommendations (2.05) and resultant drug changes per patient (1.31).
Table 9.4 Response by Intervention Type (N=7,298)
              All Residents        Residents with           Residents with           Residents with          
              with Reviews         Retrospective Dual Retrospective and     Prospective      
                                                                                        Reviews Only   Prospective Reviews      Reviews Only       
                (N=7,298)*              (n=4,945)           (n=1,399)                  (n=954)*
Recommendations       8850         4878              2869     1103
-per resident                     (1.21)                     (0.99)                        (2.05)                         (1.16)
Drug Changes       5425                       2822              1828       775
-per resident                             (0.74)                     (0.57)                        (1.31)     (0.81)
* Of the 1,743 residents receiving only prospective reviews, 954 maintained baseline eligibility throughout the 3 
month baseline period prior to screening and reviews and resided in a nursing home during that time
Note: Administrative claims were used as a data source
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CHAPTER 10
METHODOLOGICAL CONSIDERATIONS FOR EMPIRICAL EVALUATIONS OF 
PHARMACIST SERVICES
10.1 Methodological Considerations
    The objective of this dissertation is to determine if the Initiative was effective in 
reducing drug expenditures while simultaneously maintaining or improving the quality of 
care received by nursing home patients in North Carolina.  At first glace, this proposition 
may seem relatively straightforward given readily available primary data (patient profiles) as 
well as secondary data sources (administrative claims data) with large samples sizes brought 
about by the broad scope and successful launch of the Initiative.  Yet observational studies 
suffer from methodological limitations unique to their design, setting, and treatment.  
Tantamount is their universal failure to assure that unmeasured and maldistributed risk 
factors do not induce biased results.  This dissertation attempts to minimize, to the greatest 
extent possible, this threat to internal validity that has plagued many prior studies of 
pharmacist services in real world settings to date. 
10.1.1 Intention-To-Treat versus On-Treatment Analysis
    Intention-to-treat (ITT) analysis is a compelling research strategy employed to 
increase the internal validity of experimental studies.  It requires the researcher to steadfastly 
retain subject subjects by including all initially enrolled subjects and their results in the final 
45
analysis regardless of circumstance or adherence.34 Gerard Dallal identifies four major lines 
of justification for intention-to-treat analysis34:
1) Intention-to-treat simplifies the task of dealing with suspicious outcomes, that 
is, it guards against conscious or unconscious attempts to influence the results 
of the study by excluding odd outcomes.  
2) Intention-to-treat guards against bias introduced when dropouts are related to 
the outcome.
3) Intention-to-treat preserves the baseline comparability between treatment 
groups achieved by randomization.
4) Intention-to-treat reflects how treatments will perform in the population by 
ignoring adherence when the data are analyzed.
   These are persuasive reasons to employ ITT analysis for empirical evaluation of the 
Statewide Initiative.  It is now widely accepted among researchers conducting randomized 
clinical trials (RCT) that ITT analysis is superior to on-treatment analysis (OT), where only 
those receiving treatment or otherwise finishing the study are accounted for in the results.
Yet there are practical challenges and methodological risks associated with 
employing an ITT approach for an evaluation of a program of this type and scope.  First, the 
Initiative was neither conceived as nor conducive to an RCT.  The Initiative was formed as 
voluntary program for consultant pharmacist organizations.  Response to solicitations for 
involvement was a great success with 235 homes with roughly 80% of the states residents 
responding with reviews.  Attempts to randomize homes within participating pharmacy 
providers would have been difficult, if not impossible to practically employ.  Prescribers and 
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pharmacists would have practiced in “experimental” as well as “control” homes, increasing 
the likelihood of spillover or contamination effects.   Further, as in most real-world settings, 
the administrative goal was very pragmatic: to initiate a program that produced desired 
results in the shortest time frame possible, and not to conduct a prolonged and rigorous 
randomized study. 
Dallal’s first three justifications deal with a misdistribution of risk factors between 
subject and comparison homes.  In the absence of an RCT protocol with randomization, his 
first three points are moot.  For the Initiative, there was never an attempt (experimental or 
otherwise) to create baseline comparability.  Thus, there was no comparability to maintain by 
subjecting study inclusion to ITT based upon Dallal’s first three principles.  Of importance to 
this analysis, the absence randomization does not preclude the use of non-randomized 
comparison groups, or the determination of comparison groups that maintain homogenous 
distributions of risk between subject and comparison homes.  Because no active attempt was 
ever undertaken to achieve a prospective control group, the preservation of this non-existent 
control group is non-sensical.  For the observational researcher, the burden of baseline 
comparison lies within retrospective statistical adjustment or comparison group matching, 
not within the preservation of prospective randomization.
Dallal’s fourth and final justification for ITT analysis, performance in a population, 
speaks to a chosen research focus: emphasizing either efficacy or effectiveness.  For the 
purposes of the initiative, we may be interested in both efficacy as well as effectiveness.  
This issue is addressed in the next chapter.  
Based upon the requisite need for retrospective statistical adjustment and matching of 
a comparison group, the first three of Dallal’s ITT justifications are moot with respect to the 
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Initiative.  Further, an OT analysis offers diminished potential of committing a Type II error.  
One of the disadvantages of ITT analysis is its tendency to be biased toward the null with 
treatments having low adherence and/or response, even in the face of high efficacy in sub-
populations.  
Unlike RCTs of drug products where the active agent is highly standardized, 
pharmacist services are often unique to each participating pharmacist in their focus, actions, 
and results.  Add to this diversity of response, a historical 36% dropout rate due to death or 
discharge in the nursing home setting in North Carolina and an ITT analysis of the Initiative 
becomes quite likely to bias toward the null.  An OT analysis of the Initiative is more likely 
to prevent type II errors in hypothesis testing due to low adherence and/or specific response.  
Dallal’s own appraisal suggests that program with high efficacy may have low effectiveness 
if adherence is low.  
Depending on the research question at hand, OT analyses may be more adept at 
proving efficacy whereas an ITT analysis produces results indicating effectiveness.  He states 
that ITT analysis answers research questions at the “public health” level, whereas OT 
analysis indicates effect where adherence to treatment may be greater.34 For this evaluation, 
an OT analysis would be favored since we are interested in the effect of pharmacist 
intervention at various levels of adherence, or success.  In the next chapter, I discuss the 
various levels of adherence (success) of interventions and why it is important to measure 
each treatment level in order to make conclusions about the Initiative.  Regardless of the 
chosen method (ITT vs. OT), the researcher must assure baseline comparability to prevent 
biased results.  
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10.1.2 Efficacy versus Effectiveness
Consideration of the term effectiveness as a synonym of efficacy is a regrettably 
common mistake among lay analysts.  These research concepts retain important and 
distinctive differences for both methodological consideration and interpretation of study 
results.  Most of the products and services used in health care differ in their performance in a 
“real world” or “naturalistic” environment versus a well controlled, idyllic environment.  For 
health services in particular, a great disparity exists between the ability of a service to 
produce a desired outcome in a controlled environment (efficacy) and its operation in actual 
practice (effectiveness). This begs the researcher to conduct experiments in “real world” 
settings. 
Yet seeking effectiveness must follow research establishing efficacy.  A service may 
be ineffective, but efficacious.  Thus, establishing efficacy is the primary research goal, with 
establishment of effectiveness to follow.  Foremost is proving efficacy is establishing 
causality, and doing so requires strong internal validity.  Strong internal validity is brought 
about in an RCT through experimentation.  Experimentation is possible through 
randomization, a process that ensures both study and control subjects have equal risk on the 
whole at baseline.  
Two requirements must be maintained throughout the study period to ensure valid 
results following randomization: 
1) Once randomized, the researcher must ensure that control group is not subject 
to any treatment effects
2) Once randomized, the researcher must ensure that the treatment is correctly 
applied to all study patients
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Satisfaction of these requirements is exceptionally challenging for the researcher 
when engaged in intervention or service studies.  First, spillover effects often threaten the 
non-treatment of comparison subjects in “real world” settings.  Second, applying a 
standardized and equi-potent treatment across all study subjects is nearly impossible.  Such is 
the case with pharmacist services studies, where pharmacist action and intensity vary across 
sites.35 Even if both requirements are satisfied and internally valid results emerge, 
randomization still does nothing to ensure external validity.  
External validity is the capacity of the study to mimic results found in the population 
and setting of interest.  Thus an RCT might be completely internally valid, while not 
meaningful at all in practice.  Extraneous factors not present or nor controlled for during the 
study cause treatment effectiveness to be unequal to treatment efficacy.  While some 
extraneous factors enhance efficacy, most detract from it, underscoring the importance of 
measuring effectiveness in parallel with efficacy.
Dallal proposes that the combination of efficacy and adherence produce effectiveness.   
Adherence in this sense is meant to represent all extraneous factors not defined in treatment, 
which presumably has been proved efficacious.  An example using corticosteroid inhalers 
provides an excellent example of his summative statement.  
Inhaled corticosteroids are advantageous in preventing asthma exacerbations due to 
their anti-inflammatory properties.  Reductions of inflammation in the lungs are at least 
partially responsible for increased airflow to patients’ bronchial cavities.  They have been 
proven to be efficacious in producing this effect with repeated administrations, often 
requiring more than one administration per day.   Many factors are at play when considering 
the seemingly simple task of repeated administration.  First and foremost is the consideration 
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of the traditional definition of adherence.  If the patient neglects to administer the drug to 
oneself and fails to follow a pre-defined schedule established through tests of efficacy, 
effectiveness is reduced.  Many human factors bring about self-limiting compliance.  Out-of-
pocket costs, social stigma, and inability to properly activate the inhaler and administer the 
medication properly are only a few.  Yet for Dallal’s statement to hold unequivocally true, 
the consideration of all environmental factors not explicitly defined as treatment in RCT 
trials proving efficacy are required to establish effectiveness. Other factors extraneous to the 
patient that affect efficacy in this example may include dysfunctional or outdated metered 
dose inhaler, co-morbid conditions that vary over time such as seasonal allergies, or other 
factors not considered during the efficacy proving trial.   However, the most likely cause of 
decreased effectiveness with inhaled corticosteroids is self-limiting compliance.   One might 
make the case that this applies generally to all drug products. 
A similar example using the example of an x-ray as a diagnostic tool for a broken leg 
illustrates the added importance of considering adherence beyond that of the patients with 
health services.  Once ordered, the patient must comply with a physicians order to arrive at 
the x-ray machine on time and maintain the proper anatomical position to create the desired 
x-ray image.  Beyond these actions, nothing further is required of the patient to produce the 
image properly.  However, many other factors may influence the quality of the image as well 
as the interpretation of image and subsequent diagnosis.  The quality of the film and the x-ray 
machine itself affect the service.  The x-ray technician, the radiologist, and the ordering 
physician must all perform as prescribed.   Even personnel charged with transporting, 
keeping, and uploading the images into the medical record is crucial to the performance of 
the service.  It is unlikely that all of these factors were considered in an efficacy trial for x-
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rays in diagnosing a broken leg.  That is, if an efficacy trial was ever performed in the first 
place.  To do so with the consideration of all adherence factors would have established 
effectiveness.  Pharmacist services are subject to even greater challenges to adherence due to 
their consulting and augmentive nature.  This fact in combination with multiple practitioners, 
activities and outcomes to consider, create a challenging research environment.
10.1.3 The causal pathway between interventions and outcomes
With ever-evolving technologies and well-informed practitioners, services researchers 
are inevitably asked to assess the outcomes of a new procedure, intervention, or service.  
Often, these advances are complex and multifaceted, intermingling many technologies and 
health care professions.  This evolution places greater pressure on researchers to engage in 
translational or practice-based research.  Demonstration projects are notorious for their 
inability to capture all relevant factors that effect treatment outcomes.  The challenge for this 
proposed study is a familiar one:  how to discern and distinguish the impact of a single 
intervention with multiple stages in the context of many other factors and forces affecting the 
ultimate outcomes of interest.  In this chapter, I briefly describe this challenge by comparing 
it to the relatively simple case of a randomized clinical trial of a drug.   In ensuing chapters, I 
then describe how I will handle these methodological challenges in this study.
Historically, products have been the subject of a great many more RCTs than 
services, especially within the pharmaceutical industry.   Close proximity to the outcome on 
the causal pathway permits researchers of drug products to minimize the numbers of study 
subjects enrolled in efficacy studies because of the high likelihood of adherence in a 
controlled trail.  Small sample sizes require less resource consumption for a study.  This 
proximity also affords the researcher a stronger claim of efficacy.  Yet another advantage for 
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drug products when establishing efficacy is the close proximity of the end point to the 
mechanism. Figure 10.1 illustrates this point. 
Figure 10.1: Hypothetical Causal Pathway for Drug Product Efficacy Trial
Mechanism of Action
Product 
Administration
Intermediate 
Global Outcome
Corticosteroid 
Delivery
Mast cell, 
eosinophil, 
basophil, 
lymphocyte, 
macrophage, 
and neutrophil
inhibition
Increased      
FEV1
Mechanism of 
Action Outcome
Decreased 
Inflammation
Histamine, 
eicosanoid, 
leukotriene, 
and cytokine 
inhibition
Leading to
Mechanism-Based Study for Drug Product
FEV1=Forced Expiratory Volume in 1 Second
Although recently criticized, historical end-points for RCTs of drug products tended 
to be mechanistic or anatomical and not clinical or global with respect to patient functioning.  
This approach aided establishment of efficacy claims for drug products.  Recent calls for 
global measures and increased emphasis on effectiveness may at least partially explain 
increasing sample sizes for RCTs of drug products.  Both product and service studies are 
challenged by the objective of proving effectiveness due to the distal nature of global 
functioning and patient quality of life.  Figure 10.2 illustrates the added complexity and 
burden of effectiveness with global outcomes trials.  
Service trails are at an especially magnified disadvantage. Unlike product trials, 
service trails are distal in the causal pathway prior to and following the mechanism of action 
(Figure 10.3).  This dual disadvantage puts additional burden on the services researcher when 
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establishing both efficacy as well as effectiveness, with severe bias toward the null.  
Pharmacist services trials are especially burdensome as they often maintain more complex 
causal pathways than other health services due to the peripheral nature of ambulatory 
pharmacy practice. 
Figure 10.2  Hypothetical Causal Pathway for Drug Product Efficacy Trial with Global 
Outcomes for Effectiveness
Mechanism of Action
Product 
Administration
Intermediate 
Global Outcome
Corticosteroid 
Delivery
Mast cell, 
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inhibition
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Death
FEV1=Forced Expiratory Volume in 1 Second
QOL=Quality of Life
Mechanism-Based Study for Drug Product with Nested Global Outcomes
In the first part of this chapter of the dissertation I reason that Dallal’s first three 
justifications for ITT analyses are moot with respect to non-randomized, quasi experimental 
approaches required of pharmacist services studies.  With respect to effectiveness, Dallal’s 
final justification, I make the point above that the Initiative is subject to a great many 
extraneous factors both controllable and not controllable effecting the treatment.  To use an 
ITT analyses severely biases the results toward the null.  Furthermore, the treatment itself is 
subjugated to three distinct core activities, as shown later in the chapter, each of which may 
result in differing efficacies.  Thus, showing that Dallal’s justifications for ITT are not valid 
with respect to an analysis of the Initiative, I choose to use an OT method of analysis, using 
only those patients actually receiving treatment and existing throughout the study period.
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Figure 10.3  Hypothetical Causal Pathway for Service Effectiveness Study                   
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10.1.4 Defining the treatment
To establish the causal pathway for the Initiative, I will first define the treatment(s).  
No single treatment may be identified to fully encompass the interventions of the Initiative.  
Multiple activities took place with multiple types of practitioners.  At a minimum, core 
events that are perceived to affect chosen outcome measures to the greatest extent should be 
outlined for empirical testing.  Testing of multiple core events strengthens the external 
validly of the program evaluation while simultaneously informing future PDSA cycles.   
Arguably the first actionable event in the causal pathway of the initiative was the 
download of administrative claims and subsequent screening process.  After screening, 
profiles were generated using pre-determined drug-level algorithms for the presence of alerts.  
Once generated, profiles were sent to pharmacists for review.  
Three main treatments or “core” events remain in the causal pathway and can be 
reasonably defined and empirically tested for causal links following the receipt of profiles for 
review.  The three treatment classifications defined below are the most logical and testable 
treatment nodes since the focus of our analysis is on the effects of pharmacist actions.  Until 
this point in the causal pathway, only fixed costs were incurred by program administrators.  
At the point of pharmacist review, the Initiative began to garner incremental program costs.  
Pharmacists were paid for reviews, and thus increased reviews resulted in increased costs to 
the program sponsor.
Pharmacist Profile/Prospective Review:  Arguably the most important treatment 
classification, pharmacists were paid for this action in the causal pathway and this action 
alone.  This treatment classification is imperative to the establishment of effectiveness, 
program valuation, and ultimately a cost-minimization-ratio.
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Pharmacist Recommendation:  Another compelling treatment classification, 
pharmacist recommendations may be required for billable claims in many pharmacist 
services associated with Medicare Part D.  Furthermore, as a treatment definition, it is the 
first action in the causal pathway that is pharmacist dependent.  That is, the intensity of the 
review and the ability of the reviewer to identify potential drug therapy problems determine 
the frequency and distribution of recommendations among nursing home residents.
Accepted Recommendation/Drug Change:  An accepted recommendation is the 
most proximal event to the Initiative’s mechanism of action (the use of a new drug regimen) 
that can be analyzed given the available data.  As a treatment definition, it is the first action 
in the causal pathway that requires pharmacist interaction with other health care providers.  
Whereas the pharmacist recommendation treatment classification is pharmacist dependent, 
the accepted recommendation treatment classification is both pharmacist and prescriber 
dependent, with prescribers weighing the merit of the pharmacist recommendation.  
These three core treatment classifications encompass the spectrum of causality in the 
initiative from the more distal (Profile Review) to the more proximal (Accepted 
recommendation/Drug Change).  While the more distal treatment definitions better establish 
effectiveness, the more proximal treatment definitions better establish efficacy.  Each of 
these three treatment classifications answers a different research question.  
It is most certainly in the spirit of the PDSA method to analyze efficacy at each 
treatment nodule to aid in the improvement of the entire process.  One of the goals of the 
PDSA process in the context of the Initiative would be to maximize treatment adherence to 
the greatest extent possible once efficacy has been established.  By evaluating treatment 
efficacy and multiple nodes in the treatment process, the researcher can elucidate 
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effectiveness limiting processes and make improvements for future initiatives, interventions, 
and associated activities.  
Arguments certainly exist for other events, actions or intentions to be considered as 
treatment if time, resources, and data allowed.  Profile generation may be considered the best 
category to fit a research objective aimed at public health policy.  Certainly, it was the goal 
of program administrators to have as many profiles reviewed as were generated.   However, 
it is the consultant pharmacist who intended to review profiles to make recommendations.  
What if a profile was generated, but never arrived to the pharmacist to review?  Of what 
significance is the program feature that affords payment only for completed reviews?  
Furthermore, intent may hold an important research question if it is further drilled down to 
“intention to make recommendations”, but not the action of communicating with a physician.   
What about a research objective with consideration of prescribers as the actionable health 
care provider?  Patients may only be treated if a recommendation is accepted, and thus, the 
prescriber’s intention is may dominate the choice of the on treatment-group selection.  
There are more potential treatment nodes in the causal pathway than can be addressed 
in a single dissertation, especially given the limitations of the data with respect to the 
involved health care practitioners.  The above groups seem most relevant to the objective of 
the dissertation and were the motivation for the genesis of Initiative at the outset.  Figure 10.4 
attempts maps the causal pathway for Phase 1 of the Initiative.
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Figure 10.4 Hypothesized Causal Pathway for Outcomes Arising from the North Carolina Polypharmacy Initiative
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The more distal the treatment from the mechanism of action, the more its evaluation 
represents effectiveness over efficacy.  The more proximal the treatment, the more it 
represents efficacy over effectiveness.  Each of the chosen treatments of interest answers a 
different research question:
Treatment Level #1: Profile Review: How effective are adjunct profile reviews
conducted by consultant pharmacists in a nursing home setting at reducing drug costs while 
maintaining health?
Treatment Level #2: Recommendation Made: How effective are recommendations 
made by consultant pharmacists in a nursing home setting at reducing drug costs while 
maintaining health?
Treatment Level #3: Accepted Recommendation: How effective are accepted 
recommendations resulting from consultant pharmacists in a nursing home setting at 
reducing drug costs while maintaining health?
10.2 In Search of a Comparable Group
In this part, I present the concept of the counterfactual ideal.  Then I proceed 
to outline selection biases that may exist at each proposed treatment level in the Initiative.  
Then I explore implications of the resultant baseline differences in risk and the necessary 
cohort strategy to address it.
10.2.1 The counterfactual ideal
For each treatment level, the counterfactual ideal is desired for comparison of post-
treatment outcome measures.  The counterfactual is the theoretical dual existence where 
study subjects can exist in treatment and comparison groups simultaneously, thus ensuring 
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comparability.  Of course, this theoretical dual-existence is quite difficult to arrange, let alone 
measure.  In the absence of divine assistance in the matter, the RCT, through randomization 
approximates the counterfactual by creating a comparable group of study subjects that act as 
a proxy for the experience of the treatment group given no treatment.  Two central concerns 
arise in the absence of randomization and both are manifest in the initiative: 1) Pharmacist 
imposed selection bias (introduced by selection of patients for prospective interventions as 
well as recommendation-based treatment selection) and 2) the presence of baseline 
differences in important risk factors related to the outcomes of interest among some 
treatment groups and their sub-groups unbeknownst to the pharmacist.  To aid in reading 
comprehension, I heretofore refer to pharmacist imposed bias as “active bias” and baseline 
differences as “passive bias”, with passive bias defined as the introduction of bias without the 
knowledge of pharmacists, prescribers, or program administrators, but present nonetheless.  
Both types result in selection bias, despite the action implied term--selection.
10.2.2 Treatment specific selection bias
Unlike randomized clinical trials (RCTs), where experimental and control groups are 
determined prior to experimentation, the Initiative operated under an open enrollment policy 
where new patients could enter respective phases of the project based upon evolving 
screening criteria and/or a consultant pharmacist’s judgment of need.  
Treatment Level #1: Active selection bias is unlikely at this level for residents 
receiving profile reviews since profile generation was guided by the 18 prescription fills in 
90-day criteria and not by pharmacists.  If a nursing home was a participant in the Initiative, 
all residents failing the screening criteria were reviewed.  This prevented active patient 
selection on the part of the pharmacist.  To find a comparable group for these residents at this 
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level of treatment, identical criterion could be applied in non-participating homes to 
determine which residents would have received reviews if residing in participating homes.  
Any bias that does exist at this treatment level does so because of self-selection of 
participating homes.  However, while patients within homes may be different with respect to 
each other, patients between homes are not likely to differ in aggregate with respect to 
participating and non-participating homes.  This point becomes important later as I 
acknowledge a propensity matched group cannot exist for this treatment level among patients 
failing the 18 drug criteria without using replacement matching methods.  This limitation is 
the result of an insufficient number of comparison subjects to match 1:1.
For the 1,743 patients who were introduced to the initiative through prospective 
review and without the generation of a profile, a great deal of selection bias is likely to have 
occurred at this treatment level.  For residents with less than 18 prescription drug fills in 90-
days, pharmacists were able to select out those residents for whom they determined a drug 
therapy problem (DTP) existed.  No pre-determined screening or selection criterion existed 
to apply to the same population of low-utilizers in non-participating homes.
Treatment Level #2: For residents with recommendations resulting from consultant 
reviews, an inherent active selection bias exists that is propagated by the pharmacist 
conducting the reviews.  All residents receiving recommendations were selected out by 
pharmacists for changes to their respective drug regimens.   Any differences in risk for an 
outcome of interest between residents receiving recommendations and residents who did not 
receive recommendations bring about biased results emanating from this selection.  This 
selection prevents comparisons of residents with recommendations in study homes to patients 
in non-participating homes in the absence of a method of adjusting for bias.  Unlike the 
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profile review level, where the screening criteria can be applied to non-participating homes.  
No explicit criterion exists for residents receiving recommendations that can be applied to 
residents in non-participating homes to determine which residents would have received a 
recommendation had their respective homes been participants in the Initiative.  This problem 
holds true for all residents with prospective-only, dual type and retrospective-only recipients 
of recommendations.
Treatment Level #3: For residents with accepted recommendations, an inherent 
selection exists above and beyond that of selection at the recommendation treatment level.  
At the profile review and recommendation received treatment levels, pharmacists play the 
central role in selecting out residents based upon characteristics that put them at risk for 
adverse outcomes. At the accepted recommendation level, prescribers play the central role in 
selecting out patients for change.  They are the gatekeeper to the mechanism of action (drug 
regimen changes).  The same reasons for non-comparability to non-participating homes exist 
in this treatment level as with the recommendation received level, only with greater and 
compounded selection effect since two or more health care providers have now screened 
patients for drug changes and must be in agreement for a change to occur.  This congruence 
is most proximal to the mechanism of action for the service with empirical testing at this 
level best establishing efficacy.   
10.2.3 Baseline differences in risk
Ultimately, selection bias results quite often in maldistributed risk, leading to 
misattribution of effect, and subsequently invalid results.  There are two possible causes of 
maldistributed risk factors resulting from the causal pathway in the Initiative: 1) selection 
(above) and 2) concentric relationships among treatment levels.  The former is inherent to all 
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observational studies and can result from active selection (e.g. pharmacist action) or passive 
selection (e.g. participation of home) with the latter being more unique to this dissertation.  
Each treatment level is a function of the prior treatment level along the causal 
pathway.  Figure 10.5 illustrates this relationship.  If comparisons are made between 
residents having a recommendation accepted and those that did not, only those that did not 
and had a recommendation made can qualify for comparison.  In other words, comparisons 
would stray further from the counterfactual if we allowed those with accepted 
recommendations to be compared with study subjects having a profile review and no 
recommendation.  This unfortunate reality limits the number of eligible comparison subjects 
for each treatment level. Also it prevents the use of research methodologies that could 
attribute effect for each treatment level simultaneously due to lack of independent choice 
among treatment alternatives.  
Figure 10.5 Concentric Relationships among On-Treatment Groups
This limitation has a unique advantage, though.  The conditional nature of the 
concentric circles illustrated above harkens back to the discussion of efficacy versus 
effectiveness.  If the Accepted Recommendation group best establishes efficacy, then 
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differences that exist in successive distal rings may be attributed to adherence.  An accepted 
recommendation is contingent upon a recommendation received.  A recommendation is 
contingent upon a review.  I am not suggesting that, given perfect adherence, every person 
receiving a review should experience a drug regimen change.  However, given perfect 
adherence, all persons that should have drug changes, do have drug changes.   Fortunately, 
predictive models as well as propensity models are now available to model which residents 
should have received drug changes and did not.  These non-adherent residents and the factors 
that led to non-adherence have important ramifications for future PDSA cycles.
Earlier in this chapter, I made the case for an on-treatment (OT) analysis of three 
treatment levels (profile review, recommendation, and accepted recommendation) spanning 
the efficacy-effectiveness spectrum with the goal of parsing out event-specific treatment 
effect.  When combined with the three types of treatment (retrospective-only, prospective-
only, and dual-type) determined earlier, nine possible sub-groupings (3x3) emerge for 
analyses and comparison (Figure 10.6).  Since residents with dual-type and prospective-only 
interventions had at least one recommendations by default (prospective interventions were 
single drug interventions submitted only when a PDTP was identified), no cohorts exist at the 
review level for these treatment types.  
As shown previously, the results of this analysis are only valid if a comparable group 
of study subjects not receiving treatment can be formed to test for differences in effect.  In 
the next chapter I discuss statistical adjustment and matching techniques that increase 
comparability.  Note that residents having Retrospective-Only type interventions are not 
likely to be subject to bias at the review level since all residents were reviewed regardless of 
the presence of a PDTP and all failed the screening criteria.  The only bias that may exist for 
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this cohort may have resulting from selection at the nursing facility level through solicitation 
for Initiative participation.
Figure 10.6 Study Cohort Schematic and Likelihood of Bias
Treatment Level
Treatment Types Prospective-OnlyRetrospective-Only Dual-Type
Profile Review  
(Treatment Level # 1)
Recommendation 
(Treatment Level # 2)
Accepted 
Recommendation 
(Treatment Level # 3)
Bias Unlikely
Bias LikelyBias Likely Bias Likely
Bias LikelyBias Likely Bias Likely
Not 
Applicable*
Not 
Applicable*
*Any resident receiving a prospective intervention has by default received a recommendation and 
thus the Review Level is bypassed
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CHAPTER 11
RESEARCH METHODS THAT ACCOUNT FOR SELECTION BIAS AND 
BASELINE RISK
11.1 Stratification
The most straightforward approach to risk adjustment is simple stratification.  It is 
most appropriately employed when a single important risk factor for the outcome is 
maldistributed between study and comparison groups.  In the Initiative, it is likely that 
residents using more drugs were more likely to receive reviews, with subsequent 
recommendations leading to drug changes than residents with fewer drugs.  Baseline 
differences in drug utilization between study and comparison groups and selection bias 
imposed by providers likely led to a maldistribution of risk with respect to number of drugs 
per month.  If taking more drugs is related to an outcome of interest, than this factor is 
considered confounding and must be accounted for in the analysis.  This factor is not a 
problem in and of itself if the distribution of drug counts per resident is balanced between 
study and comparison groups.  This may not be the case, though, especially as the treatment 
level becomes more proximal to a drug change.  Stratifying both study and comparison 
groups by number of drugs attempts to balance the distributions of this risk factor so that 
study subjects with high utilization are evaluated against comparison subjects with high 
utilization and vice versa (Figure 11.1). 
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Figure 11.1 Stratification Example for Number of Drugs Utilized in One Month
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Kelsey et al. outline hypothesis testing to determine stratum specific effect as well as 
aggregate effect and a method to determine if effect is differential based upon strata.36 The 
foundation of the latter hypothesis test becomes important when discussing propensity 
scoring.
11.2 Simple Linear Regression
Not mentioned above is the number of strata needed to balance subgroups.  The 
greater the effect of the independent variable (number of drugs) on the dependent variable 
with respect to the maldistribution, the more strata required to balance risk appropriately.  
Regression techniques attempt to eliminate the need to stratify altogether.  They utilize a 
hypothesized linear relationship between independent variables (e.g. the number of drugs 
taken) and the outcome of interest.  The linear adjustment for differences in resident-specific 
drug utilization affords a more precise theoretical balance because of the extrapolation of 
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effect.  This is both an advantage of linear regression with its predictive capabilities well as 
an oft-cited disadvantage as shown later when misspecification distorts effect.  
Using drug utilization as a single independent variable, one could regress the number 
of drugs taken on total prescription drug expenditures.  This would allow us to calculate the 
incremental effect of a single additional drug on total prescription drug expenditures (Figure 
11.2). 
Figure 11.2 Regression Example for Number of Drugs Utilized in One Month
Number of Drugs Utilized per Month
T
ot
al
 P
re
sc
rip
tio
n
 D
ru
g
 C
os
ts
X= Study Subject
O= Comparison Subject
X 
X 
X 
X 
X 
X 
X 
X 
O 
O 
O 
O 
O 
O 
X 
X 
X 
X 
X 
X 
O 
O 
O 
O O 
O 
X X 
X 
X 
X X O 
O 
O O 
O 
O 
Incremental 
effect of a single 
additional drug
To estimate the effect of a treatment requires another independent variable, and 
subsequently, multivariate regression.
11.3 Multivariate Regression
Adding a treatment dummy variable allows the model to differentiate study subjects 
from comparison subjects and provides the effect of the treatment on drug costs.  This of 
course assumes that the number of drugs per month used is the only variable affecting drug 
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costs outside of treatment.  Figure 11.3 illustrates the addition of a treatment variable to a 
regression model predicting drug costs with number of drugs used per month.
Figure 11.3 Multivariate Regression Example for Number of Drugs Utilized in One 
Month
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Often, many independent variables have effects on the dependent variable of interest.  
Stark and Mantel present a classic study of confounding introduced by the mixing of effects 
by two independent variables.37 Their study illustrated potential misguided conclusions that 
may be formed by simple associations in the absence of consideration of all relevant risk 
factors.  As presented by Rothman,38 Stark and Mantel considered the mixing of effects of 
birth order and age.  Since birth order and age are highly correlated, the researcher might 
overestimate the effect of birth order on the prevalence of Down Syndrome in the absence of 
age from the model.  If age has a greater effect than birth order, but only birth order is 
factored into the analysis, biased results ensue.  If birth order has no effect at all, then an 
entirely unfounded result is elucidated.  A multivariate regression that includes age would not 
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create the illusion of the dominant effect of birth order since the effects birth order and age 
are partialled out.39 Stark and Mantel ultimately find that birth order has no effect on the 
prevalence of Down Syndrome.  However, if both age and birth order did have and effect, we 
are presented with an entirely different problem: interactive effects.  
Quite frequently co-dependent interactions occur with simultaneous effects on the 
dependent variable of interest.  If birth order and age effects are additive, no bias exists with 
the interpretation of the marginal (incremental) effect estimates resulting from the regression, 
though multicollinearity may exist.  However, if a synergistic effect exists, these estimates 
will be biased, requiring further specification of the model with an interaction term.  Other 
specification problems may result from multivariate regression as well.  Out of sample, or 
outlier observations may unduly affect the estimates of effect due to the presumptive linear 
associations in the absence of specification modifications.  Furthermore, the regression 
example above in Figure 11.3 relies heavily on two study subject observations with low 
utilization and two comparison subjects with high utilization for extrapolations of effect at 
the extremes.  If, in fact, there is relationship between the treatment and the magnitude of 
effect at the extremes, results will be biased with respect to the overall marginal effect 
estimate on treatment.  This suggests a combination of stratification strategies to parse out 
treatment effect in the face of heterogeneous risk factors and regression to maintain precision 
may be most appropriate when the specification of either the dependent or independent 
variables is uncertain.   
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11.4 Co-morbidity Scoring
One challenge associated with studies having global outcome measures is the sheer 
number of risk factors or and/or co-morbidities that must be accounted for when attributing 
effect to global treatments.  For the initiative, the pharmacist service was not limited to a 
single class of drugs, nor a pre-defined disease state.  Any drug treating any condition was 
subject to review at the pharmacist’s discretion.  Furthermore, global outcomes such as total 
prescription drug costs are influenced by a great variety of risk factors, many of which may 
have little to do with pharmacist activities.  
Adjusting for risk factors associated with global outcomes in a regression requires 
many co-morbidity variables, often with required interactions.  Joffe and Rosenbaum give the 
example of a study with 74 covariates that requires 148 tests to verify covariate balance.40 
Assuming a 95% confidence level, at least 7 of these covariates are likely to be significant 
based on chance alone.  Schneeweiss and Maclure identify two overall problems with this 
approach: 1) decreased statistical efficiency (as outline above by Joffe and Rosenbaum) and 
2) increased complexity of variable selection and subsequent decreased comparability to 
other studies.41
Co-morbidity scoring attempts to increase regression efficiency and standardize the 
effect of co-morbidity across studies by condensing all co-morbid conditions into a single 
proxy score.  However, achieving the ideal proxy variable (score) for co-morbid conditions 
has proven to be quite a challenge.  Co-morbidity scoring has shown some usefulness in 
exploratory data analysis, but is plagued by residual confounding and imprecise measurement 
in administrative databases, with age remaining a more desirable proxy.41  Another type of 
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score, propensity to receive treatment or be exposed, has been shown robust in a number of 
health care studies.
11.5 Propensity Scoring
With all the advantages of increased statistical efficiency, interpretability, and 
reliability in combination with the reduced risk of mis-specification, propensity scoring has 
steadily gained popularity among researchers reporting on health care interventions in the 22 
years since Rosenbaum and Rubin first introduced the concept in 1983.42,43 The approach is 
to essentially condense all baseline risk factors into a single probability metric ranging from 
zero to one.  This is done using standard regression techniques that are modeled to predict 
treatment group selection.  The logarithmic function is utilized to constrain the probability 
(score) between zero and one.  
Once an estimated probability of treatment is assigned, study subjects may be 
stratified by probability and subsequently matched with comparison subjects with similar 
likelihoods of receiving treatment.  Those with similar likelihood have “common support” 
(Figure 11.4).  This commonality with respect to the propensity for treatment selection 
allows for non-randomized comparisons.
Once matched, regression is no longer required since risk is presumably equalized, 
though regression after matching is sometimes preferred when attribution of effect is desired 
for risk factors outside of treatment.  This feature affords the researcher greater flexibility 
with respect to the type of statistical test employed upon comparison.  This quality of 
propensity scoring is particularly important for analyses of the Initiative.  For instance, total 
prescription drug costs can be highly variable at or near the end of life, irrespective of 
interventions on the part of health care providers.  More importantly, this effect may be 
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limited to a few residents at a time causing skewness, as seen in the baseline characteristics 
of one initiative subject with nearly $100,000 in drug costs in 90 days.  This single resident 
caused the standard deviation of drug costs to be greater than the average drug cost for all 
study subjects.  Quite frequent in nursing homes, the presence of these outliers, the incidental 
fluctuation in their continuous outcomes, and the ultimate inevitability of the effect beg the 
researcher to use non-parametric testing.  This testing is very convenient once subjects are 
stratified by propensity score.  For this dissertation, the distribution of difference-in-
differences will ultimately determine the chosen test (parametric or otherwise).
Figure 11.4 Common Support Following Logistic Regression on Treatment
Probability of Receiving Treatment
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Also advantageous are the strata-specific comparisons that can be made to measure 
the effect of interventions at various probabilities of receiving an intervention (Figure 11.5).  
It is likely, given more drug use that more treatment effect of a single intervention may 
result.  For instance, persons having more drugs might be more likely to receive more than 
one recommendation or drug change. The potential exists for a threshold that may be 
established as a breakeven point with respect to cost-effectiveness focused interventions such 
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as the Initiative.  Furthermore, because comparison subjects are scored from within a group 
having the access to the intervention, those residents not receiving reviews, 
recommendations, and drug changes at each respective treatment level may be quite 
informative to future PDSA cycles.  Identifying residents that should have received an 
intervention but did not should aid in future targeting algorithms and provider report carding. 
Figure 11.5 Strata Specific Treatment Effects
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Unfortunately, one major limitation exists with propensity scoring methods despite its 
widespread appeal.  Unmeasured risk factors may still bias results.  Propensity scoring does 
nothing in its score assignment to address any factor not taken into consideration in modeling 
the probability of receiving treatment.  
11.6 Instrument Variables
Unlike previously described methods, regression methods using instrument variables 
have the capacity to account for unmeasured baseline risk.   It does so by using a identifying 
a factor that is associated with treatment but has no bearing on the outcome of interest.  
Patient assignment in an RCT is often considered the perfect Instrument variable as it is 
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perfectly correlated with treatment and has absolutely no association with the outcome of 
interest.  While at face value the approach is clearly theoretically superior compared against 
other approaches that do not account for unobserved or unmeasured risk factors, finding a 
reliable and precise instrument is difficult.  Also, the resulting effect estimates are only a 
reflection of variation introduced by the instrument, biasing the approach toward the null.44
11.7 Heckman Two-Step Selection Method
Two-step selection models offer the advantage of including all study subjects, 
regardless of outlying or unmatched subjects.  The first step models treatment, much like 
propensity scoring.  The second incorporates an Inverse Mills Ratio resulting from the first 
step into the second regression.  Choosing between Heckman two-step methods versus 
propensity scoring methods becomes a tradeoff between inclusion of all study subjects (two-
step), but with out-of-sample extrapolations, or the potential exclusion of non-matched study 
subjects (propensity scoring).  Two-step regressions have the added disadvantage of 
estimating potential outcomes, rather than actual outcomes, adding to an already 
cumbersome interpretation of results from the method.
11.8 Difference in Difference Models
Difference in difference models utilize the passage of time to reduce the effects of 
maldistributed risk on treatment differences between study and comparison groups.   Since 
the measure of interest is the before-after difference in the outcome of interest, characteristics 
such as gender that remain fixed over time cannot confound  the pre-period outcome of 
interest.  If the effect of treatment differs for any fixed effect characteristic that is 
maldistributed between groups, confounding by that characteristic remains.  This begs the 
researcher to employ a regression in combination with the difference-in-difference approach 
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to account for maldistributed risk.  The method still suffers from omitted variable bias, 
though any bias is limited to the effect of treatment on fixed effects and not the outcome of 
interest itself.  When used in combination with propensity scoring, the difference-in-
difference approach may be employed without regression since fixed effect characteristics 
have been balanced prior to analyzing differences in before-after differences between study 
and comparison groups.
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CHAPTER 12
PROPOSED METHOD OF EVALUATION FOR PHASE 1 OF THE NORTH 
CAROLINA POLYPHARMACY INITIATIVE
12.1 Proposed Method
Given the constraints of Initiative in its design, data sources, and scope, I propose an 
on-treatment analysis of two different types of interventions, alone and in combination 
(Retrospective, Prospective, Dual-Type) with three core activities (Review, 
Recommendation, Drug Change) performed by consultant pharmacists and attending 
physicians.  This analysis would utilize propensity scoring with difference in difference 
modeling.
12.2 Cohort Assignment and Model Selection
To evaluate overall Initiative success, three primary cohorts will be evaluated against 
propensity matched residents in non-participating nursing facilities.  These cohorts (#1,#2,#3 
below in Figure 12.1) include all intervention types (retrospective-only, dual-type, and 
prospective-only) and will be evaluated at the three levels of treatment (review, 
recommendation, and drug change).  As discussed previously, nine possible sub-groupings 
could be considered separately to determine sub-group effects and also prevent any mixing of 
treatment effects in the event of incomplete balancing from propensity score matching in the 
aggregated groups (#1, #2, and #3).  Evaluation of the sub-groupings separately ensures 
appropriate comparison group matching with homogenous baseline risk by parsing out the 
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type of biased imposed by practitioners involved with the intervention.  Two of these sub-
groupings are not-applicable for this particular initiative since prospective reviews required a 
recommendation as a requirement of submission.  
In Chapter 10.2.4, I discussed the types of bias that are likely for each of the potential 
cohorts.  Of the seven relevant sub-groupings, Cohort #4 (below, retrospective-only profile 
reviews) is the only cohort that is not likely to have active selection bias.  It is also the largest 
Cohort, subsequently outnumbering its potential comparison group approximately 5 to 3, 
preventing 1:1 propensity matching.  It is possible that no baseline differences will be found 
between Cohort #2 and its counterpart comparison group (those with at least 18 drug fills in 
90 days in non-participating homes).  One of the previous analyses published in the Journal 
of Managed Care Pharmacy (Appendix E) using this cohort found that the Initiative was 
successful in reducing drug costs as well as alert rates for PAL List drugs as well as Clinical 
Initiatives List drugs.  Only race was found to maintain a statistically significant mal-
distribution between study and comparison group.  Findings using a propensity scoring 
approach could validate the internal validity of that study in two ways: 1) demonstration of 
similar results and 2) demonstration of co-variate balance prior to matching.  The remaining 
eight cohorts have been shown to have active selection bias and thus require propensity score 
matching prior to difference-in-difference analysis (Figure 12.1).  To be consistent, all 
cohorts in this analysis will be propensity matched regardless of the extent of bias found after 
modeling treatment selection.  
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12.3 Eligibility and Loss to Follow-Up
Residents in participating homes are considered eligible for analysis if they were 
continuously eligible throughout the 90-day pre-intervention period as well as the 90-day 
post-intervention period.  Residents in non-participating homes are considered eligible for 
propensity matching if they satisfied the same 90-day pre and post-intervention eligibility 
criteria.  The 90-day post-period is selected to mimic the 90-day pre-period to allow for a 
difference in difference study design.  The 90-day period was also chosen as a tradeoff 
between a need to minimize drop-out and ensuring a long enough time-period was available 
to assess the effects of the intervention in terms of changes in prescribing and dispensing.  
Figure 12.1 Cohort Schematic and Model Assignment
Treatment Level
Treatment Types Prospective-OnlyRetrospective-Only Dual-Type
Profile Review  
(Treatment Level # 1)
Recommendation 
(Treatment Level # 2)
Accepted 
Recommendation 
(Treatment Level # 3)
All Types
Cohort # 1*
Bias Likely
Cohort # 2
Bias Likely
Cohort # 3
Bias Likely
Cohort # 4       
Bias Unlikely
Cohort # 5       
Bias Likely
Cohort # 6       
Bias Likely
Not 
Applicable
Cohort # 7       
Bias Likely
Cohort # 8       
Bias Likely
Not 
Applicable
Cohort # 9       
Bias Likely
Cohort # 10       
Bias Likely
* Cohort #1 is likely biased because all Intervention Types are included.  This is done to achieve a 
measure of overall programmatic effect.
Roughly 18% of residents were lost to follow-up during the six-month study period.  
This is consistent with a historic rate of discharge and death of 36% annually for the North 
Carolina Medicaid population.  Figure 12.2 illustrates the evolution of study and comparison 
groups throughout the study period.  Loss to follow-up occurred in the six months between 
screens designated with red and green boxes.
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Figure 12.2 Study Design and Cohort Development
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Residents with Reviews 
(<18 Fills)
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Nursing Home Residents with less than 18
prescription fills in 90 days
Residents in comparison 
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Alert Criteria Applied for Viewing By Consultant 
Pharmacist
Alert Criteria Applied for Purposes of Analysis and 
Comparison
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Residents are also required to have at least one prescription fill within the last 35 days 
of the post-period.  This is done to minimize, to the greatest extent possible, including any 
residents in the analysis that may have died during the study or post-periods, subsequently 
preventing a downward utilization bias.  Medicaid had a 34-day supply limit on prescription 
drugs at the time of the study. Dates of death are not recorded in the Medicaid database, and 
can only be inferred if a long period of non-use of services exists up to the month of 
disenrollment.  Since prescriptions are the units of service used most often in a nursing home 
population, prescription use during the last month (35 days) of the study period was thus felt 
to be a reasonable proxy for persistence when used in conjunction with eligibility files stating 
continued eligibility throughout the study period.
I reported descriptive results earlier that included individuals eventually lost to 
follow-up for the empirical analysis.  These descriptive analyses are included in this 
dissertation to depict the total intervention effort, irrespective of drop-out.  A description of 
the overall intervention effort was required to evaluate general intervention activities, 
intensity of interventions, and overall pharmacist intention.  The descriptive analysis in 
chapter 9 presents results based upon the cross-section in time immediately following the 
intervention period.  For the empirical analysis, more strict eligibility criteria are applied and 
a follow-up period is required to screen post-period drug use for utilization and PDTP alert 
prevalence.  
In addition to the previously described eligibility criteria and post-period analysis,  
pre-period exclusion criteria were added to further limit maldistribution of risk emanating 
from differences in disease severity among study and comparison groups that could not 
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otherwise be measured.   Any residents having a hospitalization or an emergency room visit 
in the pre-period were excluded.  Additionally, any resident not having a prescription fill in 
the first 35 days of the pre-period was excluded to restrict the inclusion of any study subjects 
using any third-party payor other than North Carolina Medicaid.  Finally, the presence of a 
“hotelling” charge (claim for the use of a nursing facility bed) was required in all three 
months of the pre-period to ensure subject residency in respective facilities.   Resultant 
sample sizes are shown in Figure 12.3.  Considerable but comparable sample size reductions 
were observed in all groups, both study and comparison.  
Figure 12.3 Study Subjects Remaining After Application of Exclusion Criteria 
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Residents Receiving Reviews
5917
Residents continuously eligible in pre- and post-periods 
and having an Rx fill in last 35 days of post-period
5545
Residents with No Hospitalization in pre-period
5515
Residents with No Emergency Room visit in pre-period
5306
Residents with an Rx fill within first 35 days of pre-period
5255
Residents with a claim for a nursing facility bed 
in each of three months of pre-period
17.1% loss to 
follow-up 
8.2% loss to 
exclusion 
criteria
7298
Residents Continuously Eligible
9.8 % loss to 
eligibility 
Sample size reductions were most evident for Prospective-Only Cohorts, where only 
954 residents were eligible during the entire pre-period.  When followed throughout the post 
period and with application of the exclusion criteria, 5,255 remain for analysis in Treatment 
Level #1 (Review), 3,618 for Treatment Level # 2 (Recommendation) and 2,517 for 
Treatment Level # 3 (Drug Change) as illustrated in Figure 12.4.  Fortunately, all 6,344 
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residents receiving reviews were eligible throughout the entire pre-period.  For 
Retrospective-Only Type interventions, 3,638 remained at the review level, 2,064 at the 
recommendation level, and 1,404 at the drug change level.  For Dual-Type interventions, 986 
remained that had a review and recommendation while 686 remained that also had a drug 
change.  For Prospective-Only Type interventions, 568 remained that had a review and 
recommendation while 427 remained that had also had a drug change.  63 residents had a 
prospective review with no recommendation under a special circumstance, not to be included 
in sub-group analysis.
Figure 12.4 Sub-Group Sample Sizes Following Application of Exclusion Criteria 
12.4 Previous Evaluations
Two evaluations of the Initiative have been conducted prior to this dissertation.  The 
first, published in The American Journal of Geriatric Pharmacotherapy (Appendix D) 
included a portion of the descriptive results found in Chapter 9 of this dissertation.  A cost 
minimization ratio was reported (12:1) as well as a per member per month (PMPM) drug cost 
savings of $30.33.  This study was based solely on pharmacist report and a projection of 
savings based upon the derived result type (Drug Added, Drug Discontinuation, Drug 
5255
Residents remaining after Application of Exclusion Criteria
4624
Residents with Retrospective Reviews
631*
Residents With Prospective-Only Reviews
568
With Recommendations
986
With Recommendations
2064
With Recommendations
427
With Drug Changes
686
With Drug Changes
1404
With Drug Changes
986
With Dual-Type Reviews
3638
With Retro-Only Reviews
568
With Pro-Only Reviews
5255            
Residents with 
Reviews
3618            
Residents with 
Recommendations
2517           
Residents with 
Drug Changes
*63 residents had a prospective review with no recommendation under a special circumstance, not to be included in 
sub-group analysis
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Regimen Change, and Drug Change) and the cost differential between the before reported 
drug and the after reported result.  This study was followed by another published in The 
Journal of Managed Care Pharmacy (Appendix E) analyzing PDTP alert rate reductions and 
drug cost reductions using administrative claims.  PMPM drug savings were found to be 
$19.04.  Study residents were compared against a comparison group in non-participating 
homes to establish before-after difference-in-difference results.  No matching was performed.  
To date, results have not yet been reported for an all intervention types.  All three 
primary comparison groups (All Intervention Types at the Review, Recommendation, and 
Change Levels) are subject to many types of inherent bias resulting from selection as 
discussed in Section 10.2.3. One of the likely drivers of selection bias was the prospective 
intervention, where only residents perceived to have PDTPs where selected for intervention 
by a pharmacist.  The other main driver of bias likely resulted from prescriber selection 
during recommendation acceptance.  As such, at least 9 of the 10 possible cohort-comparison 
groupings were subject to maldistribution of risk resulting from substantial selection 
pressures.  Since the propensity matching method balances this risk, all 10 cohort-
comparison grouping may be evaluated for treatment effects.  Findings from this dissertation 
will be the first to assess the overall effects (All Intervention Types) of the Initiative (Figure 
12.5).
This third planned analysis will allow me to more accurately assess the overall 
(program level) effects, as well as the effects among each sub-group. Since only one of the 
seven relevant sub-groups is likely to be without significant selection bias, propensity scoring 
is needed to match groups based on pre-period risk factors.
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Figure 12.5 Cohort Inclusions of the Three Initiative Evaluations 
Evaluation #1 Evaluation #2 Evaluation #3
AJGP
(n=8,087*)
JMCP
(n=5,917**)
To be Published
(n=5,255)
* 8,087 represents the number of study subjects receiving any intervention without exclusion criteria.       
Since only retrospective reviews were studied in Evaluation #1, n=6334.
* 5917 represents the number of study subjects receiving any intervention with exclusion criteria the first 
inclusion criteria (continuously eligible in pre- and post- period and having an Rx fill in the last 35 days of the 
post period).    Since only retrospective reviews were studied in Evaluation #2, n=5,160.
All subjects
Retrospective
Pro-OnlyDual 
Retro-Pro
Retro-
Only               
(Not studied)
(Not studied)
(-$30.33 PMPM) †
(Not studied)
All subjects
Retrospective
Pro-OnlyDual 
Retro-Pro
Retro-
Only               
(Not studied)
(Not studied)
(-$19.04 PMPM) ‡
(Not studied)(Not studied)
All subjects
Retrospective
Pro-OnlyDual 
Retro-Pro
Retro-
Only               
(Dissertation)
(Dissertation)
(Dissertation)
(Dissertation)(Dissertation)
‡Median drug cost savings resulting from interventions
† Mean drug cost savings resulting from interventions
AJGP = American Journal of Geriatric Pharmacotherapy
JMCP = Journal of Managed Care Pharmacy
(Not studied)
The first evaluation utilized a projected before-after study design.  The second 
applied a before-after design using administrative claims and added a comparison group.  
The third and final evaluation is designed to have the greater amount of internal validity 
based upon study design as a before-after with matched comparison group.  Thus, the final 
analysis as outlined in this dissertation is not only the first to analyze all types of 
interventions, but also to apply strict exclusion criteria and matching based on patient pre-
period characteristics having influence on the outcomes of interest.  
Figure 12.6 illustrates the tradeoff between no and strict exclusion criteria that 
strengthen internal validity versus generalizability and Figure 12.7 illustrates the sample size 
reductions resulting from a longer time horizon.  Evaluation #1 is preferable when 
calculating a cost-minimization ratio since fixed costs are correctly spread over all subjects 
and interventions. Additionally, Evaluation #1 is preferred when stronger external validity 
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(generalizability) is paramount.  Evaluation #3, (more strict criteria with strong study design) 
is preferred when more emphasis is placed upon internal validity. 
Figure 12.6 Study Design, Data Sources, and Exclusion Criteria of Initiative 
Evaluations
Evaluation #1 Evaluation #2 Evaluation #3
Data 
Sources
-Pharmacist Report -Pharmacist Report -Pharmacist Report
-Pharmacy Claims -Pharmacy Claims
-Non-Pharmacy Claims
(n=6,334) (n=5,160) (n=4,624*)
Exclusion 
Criteria
Methods
* 4,624 represents the number of study subjects receiving any retrospective intervention for Evaluation #3.    
It was the first to include subjects with prospective interventions and has a total n=5255.
-None -Absence of Rx Claim in post  
last 35 days of post-period**
-Before-After -Before-After
-With comparison
-Before-After
-With comparison
-And propensity matching
-Absence of Rx Claim in post  
last 35 days of post-period**
-ER Visit in Pre-Period
-Hospitalization in Pre-Period
** Continuous eligibility was required in both pre- and post- periods with this criteria.  For Evaluation #3 an 
Rx fill was required in the first 35 days of the pre-period as well.
-Absence of claim for LTC bed in 
all three months of pre-period
12.5 Comparison Group Assignment
At the outset, Phase # 1 of the Initiative sought to target nursing home residents for 
review that had at least 18 prescription drug fills in 90 days.  During program development, 
the pool of review-eligible residents evolved to include all residents existing in participating 
homes.  Though only residents with 18 or more prescription fills had claims-generated 
profiles sent to pharmacists, reviews could be sought for all residents in participating homes.    
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Figure 12.7 Cohort Developments for the Three Initiative Evaluations
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As stated earlier, treatment selection was brought about by: 1) pharmacist and 
prescriber-specific characteristic(s), where a resident might not have received a review with 
one pharmacist but would have with another (or a drug change from one prescriber and not 
another) as well as 2) resident-specific characteristic(s).  These characteristics, both 
pharmacist and resident, may have caused selection into and out of the group of residents 
receiving reviews and recommendations.  The 20 co-variates outlined are an attempt to 
model treatment selection as accurately and precisely as possible given the available data.  
Endogeneity most certainly remains since there are no available co-variates that describe 
pharmacist or prescriber characteristics, nor do the co-variates completely describe resident-
specific response to drug therapy.   As such, the safer approach is to model treatment 
selection versus residents in non-participating homes, rather than against persons not 
receiving treatment in participating homes.  This approach is illustrated in Figure 12.8.  
Figure 12.8 Propensity Matching Strategy for Study and Comparison Subjects
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Figure 12.9 further illustrates the importance of separate analysis and treatment 
selection modeling for each of the nine proposed cohorts.  Notice that the three cohorts with 
drug changes are a function of the three cohorts of recommendations, which are a function of 
the three cohorts with reviews.  As discussed previously, each of these nine cohorts is subject 
to different selection pressures, both in type of intervention and in health practitioner 
involvement.  At the review level, selection bias may be imposed by program administrators 
through nursing home solicitation for participation.  At the recommendation level, selection 
bias may be introduced by pharmacists as they select out those residents for whom they 
believe to have a PDTP that warrants change.  At the drug change level, prescribers introduce 
selection bias since they ultimately determine which changes are made.  The same holds for 
each of the type of interventions taking place in the initiative.  Each type of intervention 
(Retrospective-Only, Dual-Type, and Prospective Only) are subject to different selection 
pressures based upon the methods and characteristics of each.  For instance, Retrospective-
Only type reviews have profiles for the pharmacist to view with alerts that require the 
reviewer to actively disregard in order to receive payment whereas Prospective-Only reviews 
do not.  This feature alone would has the potential to create large amount of selection bias to 
occur since drugs and their respective types of PDTP alerts on a given residents profile might 
cue a pharmacist towards a recommendation that he/she may not have otherwise been aware 
of without a profile.  
Since the three main cohorts as well as their seven sub-groupings may be subject to 
different selection pressures, all must be subjected to a treatment selection model separately 
when propensity scoring since different co-variates will have differing significance and 
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resultant effects in differing cohorts.  The following illustration depicts the nine proposed 
cohorts.
Figure 12.9 Study Subject Cohorts
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12.6 Propensity Scoring
Perkens et al.45 outline five steps for conducting an evaluation of observational data 
using propensity scoring:
1)  Estimate the propensity score by modeling treatment selection
2)  Stratify Observations
3)  Check the balance achieved by step 1 modeling
4)  If balance not achieved, revisit step one with additional variables or    
interactions
5)  Calculate subclass-specific estimates 
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12.6.1 Step 1: Modeling Pharmacist Response
Estimating the propensity of receiving treatment requires a model that predicts how 
pharmacists respond in terms of resident-specific reviews and subsequent action. Any 
resident characteristics that influence a pharmacist’s inclination to make reviews, 
recommendations, and changes should ideally be included in a logistic regression of 
treatment selection.  If all relevant characteristics are included, a counterfactual match can be 
assigned to every study subject that receives treatment at each respective treatment level 
(Figure 12.10).  For each treatment level (review, recommendation, and change) the 
counterfactual represents those residents that would or should have received treatment had 
they been eligible for treatment.  For treatment level #1 (profile review), the counterfactual is 
represented by residents who should or would have received a review had they been eligible 
for treatment.  For treatment level #2 (recommendation), the counterfactual is represented by 
residents who would have received a recommendation.  For treatment level #3 (drug change), 
the counterfactual is represented by residents who would have received a drug change had 
they been eligible for treatment.
Figure 12.10 Comparison Subject Modeling
Treatment Level
Profile Review  
(Treatment Level # 1)
Recommendation 
(Treatment Level # 2)
Accepted 
Recommendation 
(Treatment Level # 3)
Comparison Subjects
Residents that 
should/would have
received reviews
Residents that should/would 
have received 
recommendations
Residents that should/would 
have had accepted 
recommendations
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Potential matches are not mutually exclusive among treatment levels.  A comparison 
subject may be a potential match for any or all treatment levels.   Because the model is 
performed at respective treatment levels (review, recommendation, and drug change) and 
treatment types (prospective-only, retrospective-only and dual-type), different sets of patient, 
pharmacist or physician characteristics may be in play as potential sources of bias  and every 
potential comparison subject is likely to have a slightly different propensity score for each of 
the seven sub-cohorts.
All variables related to both treatment and response will be included in the propensity 
scoring model estimating treatment selection.45 Post-treatment variables were not be 
included, as bias would result from over matching.46  As discussed earlier, both active and 
passive selection occurred during the deployment of the Initiative.  Using both primary (data 
entry from hard-copy profiles) and secondary (administrative claims data) sources, the 
following variables were chosen to estimate treatment selection:
Passive Treatment Selection: Age, Race, Gender
Active Treatment Selection: Number of Potential Drug Therapy Alerts (PDTPs), 
Number of Drugs Filled in 90-days, 
Total Cost of Drugs in 90-days
In addition to the total number of PDTP alerts, a separate explanatory variable is used 
for each type of PDTP since each PDTP has different origins and meanings as an alert.  
Pharmacist interpretation of these alerts is likely to vary considerably among PTDPs, and 
thus each PDTP must be modeled separately:  
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Potential Drug Therapy Alerts:Number of: Therapeutic Duplications
Beers List Drugs
Consider Length of Therapy
PAL List Drugs
Clinical Initiatives Drugs
Further specification using interaction terms, squared terms, and potentially cubed 
terms should be employed when treatment selection is not fully understood.47 Thus, I added a 
squared term for age to model the potential effects of exponential treatment selection with 
respect to age.  Additionally, since I chose to model number of alerts linearly rather than 
categorically, I included squared terms for each of the PDTP alert categories.  It is possible 
that an exponential relationship exists between pharmacist response and the number and type 
of alerts presented to them.  This effect is illustrated below in Figure 12.11.  
Figure 12.11 Relationships between Number of Alerts and Number of Drug Interactions
Drug A Drug B
Drug A Drug B
Drug C
Drug A Drug B
Drug C Drug D
Drug A
Drug B
Drug D Drug E
Drug C
1 or more Potential 
Drug Interactions
3 or more Potential 
Drug Interactions
6 or more Potential 
Drug Interactions
10 or more Potential 
Drug Interactions
1...3…6...10….exponential gain with each additional drug
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Interactive effects may exist between PDTPS, Number of Drugs, and Total drug cost 
as well.  If interactive effects do occur among these variables, construction of a co-variate of 
interacting terms assures appropriate treatment selection modeling.   If no interactive effect is 
observed, little is lost, since one of the advantages of propensity scoring is the diminished 
concern for overspecification, given large sample sizes.48    
Squared terms: Age2, (No. of Therapeutic Duplications) 2,
No. of Beers list) 2, (No. of Consider Length) 2, 
(No. of PAL List) 2, (No. of Clinical Initiatives) 2
Interacted terms: No. of Drugs x No. of PDTP Alerts,
No. of Drugs x Total Cost of Drugs,
No. of PDTP alerts x Total Cost of Drugs
In summation, the fully specified, fully interacted model is as follows:
Treatment selection = Age + Age2 +Race + Sex + Number of Drugs + Cost of Drugs+ 
Number of Alerts + No. of Duplications + No. of Beers +
No. of Consider Length + No. of PAL + No. of Clinical Initiatives +
(No. of Duplications) 2 + (No. of Beers) 2 +(No. of Length) 2 +
(No. of PAL) 2 + (No. of Clinical Initiatives) 2 + (No. of Drugs x No. of Alerts) +
(No. of Drugs x Cost of Drugs) + (No. of alerts x Cost of Drugs) + error term
Rubin et al.49 found that it is more important to include unimportant co-variates than 
to exclude important co-variates.  Wang et al. notes that the goal of treatment selection 
modeling is to try to over-fit the model by including as many potential confounding co-
variates as possible.50 Additionally, Drake found no additional bias imposition from 
misspecification of co-variates.48 Indeed, propensity scores are most useful when the 
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relationship between baseline risk factors and treatment selection are not fully understood.51  
To date, there are no established or recommended criteria for propensity score model
development available,52 though consensus dictates that I include all potentially relevant co-
variates with higher order terms as well as interacted terms. 
12.6.2 Step 2: Stratify (Match) Observations
Once scored, both study and potential comparison subjects must be matched to 
achieve balance among baseline characteristics.  A multitude of matching techniques are 
available to the researcher employing a propensity scoring approach.  Generally, six types of 
matching are available to researchers (Stratification, Nearest Neighbor, Caliper, 
Mahalanobis, Kernel, and Radius).53  
Stratification methods assign study and comparison observations to strata based 
proximity of propensity score.  Once stratified, treatment effect is determined by weighting 
the outcome measure by sample sizes of the strata. 
Nearest neighbor matching simply matches study and comparison subject scores that 
are most closely aligned in value.  Different matching types can take place (1:1, 2:1, with or 
without replacement), but all matching is at the subject level.  Nearest match without 
replacement works as well as replacement methods when a sufficient number of “relevant 
comparison units” are available.47
Caliper matching utilizes the propensity score variance to limit the distance between 
the propensity scores for potential study and comparison matches.  A pre-defined fraction of 
the variance is set, whereby a match must fall within this distance to be eligible for 
comparison.  Doing this ensures that propensity scores are not matched that are “out of 
sample”.  
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Radius matching employs a predefined distance requirement rather than a variance 
fraction.  It also ensures matches are not “out of sample”, but has the additional limitation of 
a fixed distance restraint.  Thus, unlike caliper matching, the potential for making an “out of 
sample” match is further reduced if variation in propensity scores is high.
Kernel matching uses weighting to adjust for the distance between matches.  Thus, 
matches that have fewer distance between them are more influential in the resultant analysis, 
whereas matches with greater distance between them have less influence on the results.
Mahalanobis metric matching uses matrices to find the smallest difference between a 
study subjects and all eligible comparison subjects based upon the distribution of all co-
variates for each comparison subject.  It is essentially a more sophisticated manner in which 
to match with the true nearest neighbor based on the treatment selection model.  It may be 
combined with Radius or Kernal techniques to ensure study subjects are not matched to any 
comparison subject that is “out of sample”.  It may be performed with or without 
replacement.  
Mahalanobis matching provides for the most comprehensive and precise matching 
based upon the chosen co-variates in the selection model.  Another convenient feature is its 
ability to use with or without replacement matching once a Mahalanobis metric has been 
established to which comparison subjects are matched.  The method is robust at determining 
the closest matches since it determines simultaneously considers all co-variates when 
determining distance to nearest neighbor.  Additionally, as shown previously, cohorts #4, and 
#5 have study sample sizes that are greater than the number eligible comparison subjects, 
necessitating a matching technique that allows for with replacement matching.   Radius and 
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caliper restrictions are not placed upon the matching method since analysis of all study 
subjects is desired. 
One of the caveats when utilizing any propensity matching procedure with 
replacement is the replication of comparison observations when evaluating outcomes.   The 
method simply matches study subjects with its nearest neighbor regardless of the frequency 
with which it has been replaced.  The number of times a particular observation may be 
replaced is referred to as its weight.  To date, no consensus or thorough review of matching 
techniques exist, though most researchers imply that choice of method depends on a variety 
of factors specific to each particular study.54,55
Regardless of the particular advantages or disadvantages of replacement methods, 
they have been shown to be robust in practice,47,53 especially when evaluating 
interventions,56,57 and when the degree of overlap between treatment and comparison groups 
in large.47 Unlike drug products, which are standardized so that each patient receives nearly 
identical treatment upon administration, services such as those that pharmacists provide 
differ depending on the pharmacist providing the service and as well as the patient-specific 
needs of the person receiving the service.  Thus, when possible, all subjects in intervention 
studies should be included in the analysis when possible unless these inherent differences are 
accounted for in the analysis, a difficult proposition at best given the nuance in the delivery 
of a service.  In this investigation, matching with replacement is preferred, since treatment 
selection may predict subsequent treatment levels.  For example, in the case of matching at 
the review level, it is quite possible that more of persons not having a recommendation will 
have nearest neighbor matches, as opposed to persons with recommendations by pharmacists.  
This maldistribution of propensity to receive a recommendation may bias the estimate for 
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effect at the review level.  The same holds at the recommendation level, were a 
disproportionate number of persons not having drug changes will have a nearest neighbor 
match, since the overall propensity of receiving treatment is likely higher in the study group 
than in the comparison group.  Figure 12.12 illustrates this phenomenon.
Figure 12.12 Potential Bias Imposed by Matching without Replacement
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12.6.3 Step 3: Check the Balance Achieved by Step 1 Modeling
Once matched, I will check to assure successful balancing by statistically testing for 
differences in baseline risk.   For categorical variables, I will use chi-square testing and 
Student T-testing for continuous variables.  Despite multiple comparisons, I do not plan to 
use a Bonferroni-type adjustment.  Joffe and Rosenbaum support this decision, arguing that 
randomization (the gold standard) tends to elicit at least one significant difference for every 
20 co-variates40, so that we should expect some random associations to prove statistically 
significant at a 95% confidence level given enough comparisons.   Using a Bonferroni type 
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adjustment makes the balancing test less conservative, not more conservative (As the 
adjustment intends) since the null hypothesis is no balance in co-variate distributions.  
12.6.4 Step 4: If Balance Not Achieved, Revisit Step 1 and Remodel
If balance is not achieved (p<=0.05) for each of the covariates, I will revisit the 
treatment selection model and adjust variables or include additional variables such as co-
morbid conditions.  If multiple iterations of the treatment selection model do not achieve 
balance among all co-variates, I will relax the requirement of a fully balanced set of baseline 
characteristics so as not to limit the inclusion of all study subjects in the analyses.
12.6.5 Step 5: Calculate Subclass-Specific Estimates
Since I am using the Mahalanobis method of matching, I will not use pre-determined 
strata following propensity scoring.  Instead, I will form quintiles for sub-class analysis 
following successful matching as described in Chapter 11. (Figure 11.5 Strata Specific 
Treatment Effects).  
12.7 Outcome Measures
I have selected outcome measures for their relevance to the previously stated 
dissertation objective:
Determine if the Initiative was effective in reducing drug 
expenditures while simultaneously maintaining or improving the quality 
of care received by nursing home patients.
The required measures are conveniently found in the treatment selection 
model.  The before-after with comparison study design allows for both: 1) a 
difference in difference calculation as well as 2) a measurement of effect using the 
same co-variates that described baseline risk.  In addition to the selected co-variates, a 
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categorical measurement (hospitalization) is added as an event (Medicare crossover 
payments precluded the used of this variable in the selection model).  
Proposed Outcome Measures
Intermediate Quality: Prevalence of Beers List Drug Alerts
Prevalence of Consider Length of Therapy Alerts
Prevalence of Therapeutic Duplication Drug Alerts
Intermediate Cost: Prevalence of PAL List Drug Alerts
Intermediate Cost /Quality: Prevalence of Clinical Initiatives List Drug Alerts
Global Utilization: Number of Prescription Drug Fills
Global Cost: Total Prescription Drug Cost
Global Quality: Prevalence of Hospitalizations in Post Period
With a balanced sample, post treatment differences in co-variates may be 
attributed to treatment alone, assuming no relevant variables were omitted when 
modeling treatment selection.  This assumption is never satisfied fully in practice, but 
a well-developed treatment selection model limits any bias that may occur.  Figure 
12.13 illustrates pre and post period screenings that occurred.  These screenings 
served two functions: 1) to populate alert categories on patient profiles for those 
failing the 18 drug in 90 day criteria and 2) to measure drug utilization with total drug 
use, cost, and prevalence of PDTP alerts.  Notice that six of the nine proposed cohorts 
used pre-period screens to populate resident profiles, while three categories received 
screens for the purposes of the analysis, but were never used to inform consultant 
pharmacists of PDTP alerts.  All nine cohorts were subjected to post-period screens to 
compare to pre-period screens to determine the before after difference in drug 
utilization.  Similarly, comparison groups from non-participating homes are subjected 
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to the same alert criteria and screen, though profiles never became available to their 
consultant pharmacists or their prescribers (Figure 12.13).
Figure 12.13 Before-After Screening by Cohort
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Noticeably absent from the proposed outcomes are qualitative measures.   One such 
measure is the Medication Appropriateness Index (MAI).  Like other qualitative or subjective 
measures, this index is not particularly useful for an evaluation of this Initiative.  The 
consultant pharmacists were charged with deciding the appropriateness of the drug regimens.  
The MAI, like pharmacist action, requires a subjective evaluation of medications and uses 10 
criteria quite similar to the criteria employed in this study as part of the possible problems 
identified on the drug profile (e.g. dose problems, therapeutic duplications, duration), thus 
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rendering the MAI is impractical for use in this study.  Furthermore, recent evidence has 
shown only moderate inter-group agreement is found using the MAI when multiple raters are 
used.58 While the MAI has been validated in circumstances where no prior review had taken 
place,59 no meaningful validation has been performed in a circumstance such as the Initiative, 
were consultant pharmacists would be rating other consultant pharmacists; as it would be a 
redundant exercise.  
12.8 Statistical Testing
If difference-in-difference results are generally not skewed by outliers, t-testing will 
be used to determine statistical significance.  If evidence of skewed distributions exist, I will 
use non-parametric testing.  Specifically the Wilcoxin two-sample test for changes in alert 
rates, number of drug fills, and total cost of drugs between study and comparison groups.  
Relative risk estimates will be determined for hospitalization events and between groups
testing performed using the Chi Square Distribution.  Though McNemar’s Chi Square is a 
popular test to apply for before-after studies, it is infeasible for the evaluation of 
hospitalization risk since persons having hospitalizations in the pre-period were excluded 
from the analysis.  STATA (StataCorp. 2005. Stata Statistical Software: Release 9. College 
Station, TX: StataCorp LP) statistical software version 9.0 was utilized for all statistical 
testing.  Mahalanobis matching was performed using the PSMATCH2 file available at 
http://ideas.repec.org/c/boc/bocode/s432001.html.60  
This evaluation and its predecessors received Institutional Review Board approval 
from The University of North Carolina at Chapel Hill.
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CHAPTER 13
PHASE 1 RESULTS, INTERPRETATION, AND STUDY LIMITATIONS
13.1 Co-variate Balance
Ultimately, the goal of propensity scoring with subsequent matching is to match study 
subjects with comparison subjects based upon relevant co-variates as closely as possible 
given a choice of matching methods.  For this analysis, participant behavior was modeled 
using 20 variables presumed to influence treatment selection at all three levels (Review, 
Recommendation, and Change) as well as all three types (Retrospective-Only, Dual-Type 
and Prospective-Only) of intervention. 
The Mahalanobis method of matching produced substantial reductions in bias for 
most cohort-comparison groups.  Table 13.1 displays the percentage of absolute bias that was 
present in both unmatched as well as matched cohort-comparison groups for Comparison #1 
(Review Level, All Intervention Types).  
Absolute bias was introduced to propensity scoring methods by Rosenbaum and 
Rubin61 in 1985 using the following calculation in Figure 13.1:
Figure 13.1 Formula to Calculate Absolute Bias Percentage
( )%Absolute Bias =100 µt µcVart Varc
2
Where: µt
µc
Vart
Varc
= Mean of the Treatment Group
= Mean of the Comparison Group
= Variance of the Treatment Group
= Variance of the Comparison Group
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This calculation standardizes the magnitude of difference in means across treatment 
and comparison groups to enable bias comparisons between co-variates as well as 
comparisons among and between treatment selection models.  While offering no easily 
interpretable result, the effect of standardization of distance between groups provides a 
convenient manner in which to identify quickly and readily variables that remain 
problematic.  Table 13.1 lists the percentage of absolute bias by co-variate both before and 
after matching as well as the percentage reduction in bias achieved by propensity scored 
matching using the Mahalanobis with replacement method.  
The magnitude of the difference in means between study and comparison groups is 
directly related to the bias measurement, while the variance is inversely related.  This point is 
important when considering a co-variant such as Total Amount Paid since its standard 
deviation is greater than its magnitude, correctly suppressing the reported bias.  Conversely, 
if the variance around a measurement is small, such as the case with age where less than a 
2% absolute difference exists between groups but the variance in age is small, pre-matching 
bias is much higher (14.1%).
Table 13.1 also reports the average percentage bias for both matched and unmatched 
comparisons as well as the Pseudo R2, a measure of goodness of fit.   This measure is similar 
to R2, in that it approximates the amount of variance explained by the model.   The 
unmatched cohort-comparison group shown above has bias that explains 10.5% of treatment 
selection, whereas the matched group has only 0.8%.
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Table 13.1 Bias Measurements, Reductions and Significance for Comparison #1
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.6 79.4 -14.1 -6.62 0.000
Matched 77.6 78.5 -7.1 50% -3.83 0.000
(Age)2 Unmatched 6,175 6,455 -15.7 -7.38 0.000
Matched 6,175 6,286 -6.2 61% -3.35 0.001
Race Unmatched 32.2% 24.9% 16 7.48 0.000
(Non-White) Matched 32.2% 30.5% 3.6 78% 1.79 0.074
Sex Unmatched 75.1% 78.8% -8.7 -4.05 0.000
(Female) Matched 75.1% 76.2% -2.6 70% -1.3 0.195
Total Number of Drugs Unmatched 26.9 20.4 57.5 27.22 0.000
Matched 26.9 25.6 11 81% 6.11 0.000
Total Amount Paid Unmatched $1,442 $1,088 27.1 12.19 0.000
Matched $1,442 $1,340 7.8 71% 4.04 0.000
Total Number of Alerts Unmatched 9.37 6.73 48.1 22.57 0.000
Matched 9.37 8.86 9.4 81% 4.98 0.000
Number of Duplication Alerts Unmatched 4.47 3.04 41.9 19.55 0.000
Matched 4.47 4.14 9.8 77% 5.1 0.000
Number of Beers List Alerts Unmatched 0.686 0.522 18.4 8.55 0.000
Matched 0.686 0.645 4.6 75% 2.29 0.022
Number of PAL List Alerts Unmatched 1.47 1.14 27.9 13.03 0.000
Matched 1.47 1.42 3.5 87% 1.82 0.069
Number of  Clinical Initiatives Alerts Unmatched 2.60 1.89 42.1 19.72 0.000
Matched 2.60 2.51 5.5 87% 2.87 0.004
Number of Consider Length Alerts Unmatched 0.150 0.135 3.3 1.55 0.121
Matched 0.150 0.143 1.6 51% 0.8 0.423
(Number of Duplication Alerts)2 Unmatched 32.4 20.1 25.4 11.82 0.000
Matched 32.4 27.3 10.6 58% 5.57 0.000
(Number of Beers List Alerts)2 Unmatched 1.35 0.98 12.5 5.78 0.000
Matched 1.35 1.20 5.1 59% 2.53 0.012
(Number of PAL List Alerts)2 Unmatched 3.63 2.60 20.6 9.53 0.000
Matched 3.63 3.31 6.4 69% 3.19 0.001
(Number of Clinical Initiatives Alerts)2 Unmatched 9.62 6.33 29.7 13.75 0.000
Matched 9.62 8.76 7.8 74% 3.87 0.000
(Number of Consider Length Alerts)2 Unmatched 0.230 0.187 4.7 2.17 0.030
Matched 0.230 0.218 1.4 71% 0.66 0.511
Total Number of Alerts x Total Number of Drugs Unmatched 293.7 187.8 37.7 17.54 0.000
Matched 293.7 264.3 10.5 72% 5.45 0.000
Total Amount Paid x Total Number of Drugs Unmatched 44,936 29,281 22.5 10.05 0.000
Matched 44,936 39,467 7.9 65% 4.04 0.000
Total Amount Paid x Total Number of Alerts Unmatched 16,183 10,170 23.9 10.69 0.000
Matched 16,183 14,049 8.5 65% 4.33 0.000
Average Bias Unmatched 24.89
Matched 6.53 74%
  Pseudo R2 Unmatched 0.105
Matched 0.008
Comparison #1 (All Residents with any Type of Review)
Sample Sizes:  Study Group n=5,255                                                                                                                                                                                               
Unmatched Comparison Group n=3
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Also reported in Table 13.1, is the statistical significance of the difference in means 
between treatment and comparison groups using between groups t-testing, as well as the 
reduction in percentage absolute bias.  Results of the T test determine whether or not the 
reductions in bias between the matched and unmatched samples were sufficient to balance 
co-variates.  Significant differences (p<0.05) indicate that the co-variate remains unbalanced.  
Despite Mahalanobis matching, 15 of the 20 co-variates remain unbalanced using the 
between groups t-testing at a p-value < 0.05.  While the number of covariates with 
statistically significant differences remained high, the magnitude of the unbalance/difference 
is not great.  The percentage bias remaining post-match ranged from 1.4% for the co-variate 
(Number of Consider Length Alerts) to 11.0% for the (Number of Drugs) co-variate.   On the 
whole, balancing was improved with a 6.53% post-match bias, compared with 24.89% pre-
matching bias.   This represented a 74% reduction in overall bias.
This remaining imbalance must be viewed in context.  It is not uncommon for many 
co-variates to remain unbalanced following matching.  Further, with such large sample sizes 
employed (N>10,000), even small differences become statistical significant and may not 
result in much bias in effect estimates. Of note, the matched cohort-comparison for 
Comparison #12 (Prospective-Only, Drug Change) has no statistically significant differences 
between study and comparison subjects for any of the 20 co-variates, yet its average 
percentage bias was 6.67%, greater than matched subjects for Comparison #1 (6.53%).  This 
effect may be due in large part from the smaller sample size (n<3000).  Replications of Table 
12.1 for all comparison groups maybe found in Appendix A.
Table 13.2 displays the mean percentage bias existing in the unmatched comparison 
groups for all 10 comparisons.  As expected, bias exists to the greatest extent when 
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considering all types of Interventions.  The greatest existence of bias is found in the group 
receiving drug changes for all types of interventions with a percentage bias of 30.18%.  Also 
as expected, the group with the least amount of percentage bias was for Comparison #4 
(Review Level, Retrospective-Only).  Since reviews were performed on all residents in 
participating homes failing the screening criteria, program administrators were the only likely 
source of selection bias.  
Table 13.2 Mean Percentage Bias among Comparison Groups (Pre-Match)
All Types Retrospective Dual-Type Prospective
Review 24.89 4.92 N/A N/A
Review and 
Reccommendation
28.90 6.55 12.75 17.66
Review, 
Recommendation, and 
Drug Change
30.18 8.61 16.36 18.93
Pre-Matching Bias           
( Mean % )
Intervention Type
It is apparent from Table 13.2 that prospective interventions imposed the greatest selection 
pressures.  This finding is consistent with the nature of prospective interventions as 
conducted in the Initiative, where pharmacists initiated treatment only when a problem was 
discovered.
Table 13.3 shows the extent of percentage bias among all comparison groups 
following matching.  Following successful Mahalanobis matching, the extent of remaining 
bias is remarkably similar across comparison groups.   
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Table 13.3 Mean Percentage Bias among Comparison Groups (Post-Match)
All Types Retrospective Dual-Type Prospective
Review 6.53 5.06 N/A N/A
Review and 
Reccommendation
7.83 6.97 7.48 5.78
Review, 
Recommendation, and 
Drug Change
7.97 6.80 7.64 6.67
Post-Matching Bias           
( Mean% )
Intervention Type
Percentage bias ranges from 5.06% in Comparison #4 (Review Level, Retrospective-
Only) to 7.97% in Comparison #3 (Drug Change Level, All Intervention Types).  Just as with 
the unmatched comparison groupings, bias increased slightly across Intervention Types as 
the Intervention Level became more proximal to the mechanism of action (changed drug 
utilization). This finding is consistent with the notion that additional selection bias occurs as 
one nears the drug change event on the causal pathway.  The exception to this rule was found 
at the Recommendation Level in the Retrospective-Only intervention group, which 
maintained a higher level of bias than its Drug Change Level counterpart.
Table 13.4 shows reductions in mean percentage bias among all comparison groups 
following matching.  
Table 13.4 Reduction in Mean Percentage Bias among Comparison Groups 
All Types Retrospective Dual-Type Prospective
Review 73.76 -2.95 N/A N/A
Review and 
Reccommendation
72.90 -6.37 41.33 67.29
Review, 
Recommendation, and 
Drug Change
73.59 21.06 53.32 64.76
Pre-Post Bias 
Difference                 
(Mean % Reduction )
Intervention Type
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Large bias reductions were observed in all comparison groups.  Though none 
approached the desired 100% reduction, 6 of 10 comparison groups experience reductions of 
greater than 50%.  Interestingly, the Review and Recommendation Levels for the 
Retrospective-Only Intervention Type experienced greater levels of bias after matching.  This 
is possible, as Rosenbaum and Rubin have stated,61 if the pre-matching bias is substantially 
less than 20%.   
13.2 Distribution of Propensity Scores
Mahalanobis matching is preferred when treatment selection may be non-linearly 
related to many co-variates.62 It is also the method of choice for multiple treatments63 and 
multi-level treatments.  Its advantage is drawn from its inclusion of all co-variates as well as 
the propensity score when calculating distances between study and comparison subjects.  
While this strategy ensures substantial bias reduction on all co-variates, it may do so at the 
cost of increased distance between propensity scores for study and comparison subjects 
compared to other methods of matching that only consider the propensity score itself.61 In
practice, it is possible to employ a method of nearest propensity scored neighbor as a first 
method of matching to ensure equal propensity to receive treatment, followed the 
Mahalanobis method.61  
When Mahalanobis matching is applied alone, a check on the distributions of 
propensity scores between study and comparison groups is prudent to ensure that the distance 
between study and comparison subjects  is minimal for both: 1) co-variates as well as the 2) 
the propensity to receive treatment.   Propensity score distributions both pre and post 
matching for both study and comparison groups in all 10 comparisons are shown below.    
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Figure 13.2 contains graphical representations of the distributions of propensity to receive 
treatment prior to Mahalanobis matching.
Figure 13.2 Distributions of Propensity Scores between Study and Comparison Subjects 
(Pre-Match)
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Upon visual inspection, the greatest differences in the distribution of propensity to 
receive treatment between study and comparison groups are found in the three primary 
comparisons (All Levels, All intervention Types).  This is not surprising since these cohort-
comparison groups contained all study participants, regardless of the result if the 18 drug fill 
in 90 day criteria.  Similarly, the pool of comparisons for these cohort-comparison groupings 
contained all residents in non-participating homes meeting the inclusion criteria, regardless 
of the number of drugs filled in the 90 day pre-period.  
Substantial distributional differences also exist for the Prospective-Only treatment 
sub-groups and are likely the result of increased selection pressures for that type of 
intervention.  Interestingly, the Dual-Type interventions do seem to have some distributional 
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differences on propensity score, though this is likely a result of selection from prospective 
selection rather than retrospective selection since the Retrospective-Only sub-groupings have 
little distributional differences, especially at the review and recommendation levels.  
Figure 13.3 contains graphical representations of the distributions of propensity to 
receive treatment following Mahalanobis matching.
Figure 13.3 Distributions of Propensity Scores between Study and Comparison Subjects 
(Post-Match)
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From visual inspection of Figure 13.3, it is apparent that the Mahalanobis provided a 
close match on propensity scores in addition to the 20 co-variates of interest.  
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13.3 Frequency of Re-Sampling
With replacement methods are not bounded by the number of instances in which a 
potential match may be used to make comparisons against a study group.  Figure 13.4 shows 
the frequency of re-sampling of comparison subjects across all 10 comparison groups.
Figure 13.4 Frequency of Re-Sampling from Pool of Comparison Subjects (Post-Match)
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The x-axis represents the frequency of re-sampling on a given comparison subject.  
The y-axis represents the number of comparison subjects having the re-sampling frequency. 
The smoothed line represents the cumulative frequency with 100% representing cumulative 
number of matched comparison subjects, or nM.  This sample size (nM) represents the number 
of unique comparison observations without the inclusion of re-sampling observations.  The 
denotation nS represents the number of study subjects for each cohort-comparison grouping.  
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The denotation nC represents total number of comparison subjects eligible for matching that 
meets all of the inclusion criteria.  
The maximum number of instances in which a comparison subject was re-sampled 
was 14 in Comparison #1 (Review Level, All Intervention Types).  Comparison #1 (Review 
Level, All Intervention Types) had the greatest frequency of re-sampling as well as the 
lowest cumulative frequency throughout.  This is largely due to the ratio between study 
subjects and possible comparison subjects at 5,255:3,801. Where the ratio of study subjects 
to comparison subjects is greater, a greater required frequency of replacement occurs.  The 
sparse number of eligible comparison subjects from non-participating nursing homes further 
supports the use of replacement method matching since we are interested in comparing 
possible study subjects due to heterogeneous intervention effects.  While the study subject to 
comparison pool ratio largely determined the frequency of re-sampling, it was also 
necessitated to some extent by the amount of common support available from which to draw 
comparison subjects.  The farther the inter-subject distances resulting from the 20 co-variates 
of interest and the propensity score, the greater the required frequency of replacement to 
maximize balance. 
13.4 Results from Comparison #1 (Review Level, All Intervention Types)
Comparison #1 (Review Level, All Intervention Types) is an important cohort-
comparison grouping for evaluation of overall intervention effect.  Since all study subjects 
meeting the inclusion criteria are evaluated regardless of intervention type, this comparison 
may be viewed as a “main effect”.  The remaining primary comparisons (Comparison #2 and 
#3, Recommendation and Drug Change levels for all Intervention Types) test overall effect 
as well, yet not at the level of initiation of treatment.  The thrust of the Initiative was to have 
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pharmacists review computer generated profiles, with payment for services at the Review 
Level of Treatment.  Thus, programmatically this comparison is best used for any cost-
minimization analyses subsequent to this dissertation (For prospective interventions, the 
review and recommendation levels were co-incidental with this particular program since 
payment for services was conducted at the recommendation level).
A statistically significant difference-in-difference three month prescription cost 
reduction of $64.09 was found, equal to a 4.4% reduction in overall expenditures for 
pharmaceuticals.  This translates to a per member per month (PMPM) drug cost savings of 
$21.36.  Difference-in-difference reductions were also found for three of five alert types.  
PAL list alerts experienced at 19.2% reduction, while Clinical Initiative Alerts were reduced 
by 9.6%.  A small, but statistically significant reduction in Duplication Alerts was observed 
(3.8%) as well.
Table 13.5 underscores the importance of using a difference-in-difference approach 
for intervention studies.  Note that the within-group drug cost reduction was only 0.7% for 
the study group, while it increased in the comparison group (4.7%).  This seems intuitively 
feasible since we would expect the number of drugs and their aggregate costs to increase 
given the progression of time, especially at a late stage in life.  This result also highlights the 
imperative need for a comparison group.
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Table 13.5 Comparison #1 Treatment Effects (Review Level, All Intervention Types) 
Variable Group p-value
Total amount paid Review $1,442 -9.60 -0.7%
Comparison $1,341 54.49 4.1% -64.09 -4.4% 0.000
Total number of drugs Review 26.9 -0.33 -1.2%
Comparison 25.6 -0.38 -1.5% 0.05 0.2% 0.781
Number of PAL list alerts Review 1.47 -0.42 -28.7%
Comparison 1.42 -0.14 -9.8% -0.28 -19.2% 0.000
Number of  Clinical Initiatives alerts Review 2.60 -0.25 -9.6%
Comparison 2.51 0.001 0.1% -0.25 -9.6% 0.000
Number of Beers List alerts Review 0.69 -0.05 -8.0%
Comparison 0.64 -0.04 -6.7% -0.01 -1.7% 0.488
Number of duplication alerts Review 4.47 -0.30 -6.6%
Comparison 4.14 -0.13 -3.1% -0.17 -3.8% 0.013
Number of Consider Length alerts Review 0.15 -0.01 -5.5%
Comparison 0.14 0.001 0.9% -0.01 -6.3% 0.363
Sample Sizes:  Study Group n=5,255                                                                                                                                                                                               
Unmatched Comparison Group n=3
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #1 (All Residents with any Type of Review)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
11
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Note also that PAL list alerts declined by 9.8% in the comparison group. This decline 
is likely a result of a concerted statewide effort to encourage all physicians serving Medicaid 
recipients to prescribe preferred drugs on the PAL list. Comparison group prescribers and 
pharmacists were not isolated from these effects.   Had a difference-in-difference approach 
not been employed, an overestimation of PAL List Alert reductions may have been 
erroneously reported.
One concern addressed in this dissertation is whether or not interventions that resulted 
in drug changes had the undesired effect of adversely affecting health consequences.  As 
explained earlier, I chose the occurrence of one or more hospitalization events per person 
over the 3 month post period was the most tangible (and easily obtained) measure.  The 
resulting in a 2x2 contingency table and Chi-Square testing are shown in table 13.6.  
Table 13.6 Hospitalization Events, Comparison #1                                                           
(Review Level, All Intervention Types)
Hospitalization Event 311            358             669     
No Event 4,944         4,897          9,841  
Total 5,255         5,255          10,510
Relative Risk
chi2(1)
p-value
95% Confidence Interval
Fisher's Exact (p-value)
Notes: Events are person level.  Repeat hospitalizations are 
not reflected in the 2x2 contingency table.  Person time is 
equal 3-month post-period intervals.
0.066
3.53
0.06
(0.75 - 1.01)
Treatment 
Group
Comparison 
Group
0.87
Comparison #1 (All Residents with any Type of Review)
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The estimate of relative risk of having a hospitalization, given the treatment 
(Pharmacist Review) was 0.87 with a 95 % confidence interval of (0.75-1.01) and a p-value 
of 0.060.  Fisher’s exact test produced a p-value of 0.066.  This result indicates that there 
may be an association between intervention activities and a reduction in the risk of a 
hospitalization event, though not statistically significant with 95% confidence.
13.5 Evaluation of Treatment Effects Using Multiple Testing Methods 
Matching with replacement, while justified as a techique to achieve balance between 
comparison and study groups, does create a statistical inference dilemma.  The assumption of 
independence with standard statistical testing techniques is violated.  For instance, in 
Comparison #1 (Review Level, All Intervention Types), the study subject sample size was 
5,255, with a resultant unweighted comparison sample of 2,178 after matching.  For between 
groups t-testing, the STATA function PSTEST (a command designed to test balance and 
outcome measures) uses standard, equal variance testing with 10,508 reported degrees of 
freedom (the study sample size plus the weighted sample size minus two [5,255 + 5,255 -2]).  
Intuitively, it would seem the number of unique observations (7,433) should determine the 
degrees of freedom since there are, in fact, 7,431 observations free to vary [5,255 + 2,178 -2].  
Similarly, weighting or over-sampling in survey analysis causes similar inferential 
challenges, and often a primary sampling unit (PSU) adjustment is made to the variance of 
estimates.  The situation arising with replacement matching methods may be distinctly 
different in one important feature; the repeated observation when matching is meant to 
represent more than one occurrence of the risk factor, outcome, or event.  In other words, 
surveys that leave sub-populations under or over represented are sampled from an existing 
population with unknown parameters.  In the case of the initiative, the population parameters 
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are known and the repeated observations are in essence drawn from a non-existent 
population, thus violating the assumption of independence. 
Indeed, this issue is yet to be resolved, especially with difference in difference 
models,64 though some have suggested bootstrapping effect estimates.47,65 Mention of this 
particular problem is remarkably sparse in the literature to date, possibly due to lack of 
statistical programming that specifically deals with difference-in-difference estimates of 
effect.64 As disease management programs evolve from a predominately pilot project 
existence to widespread, more all-inclusive programs, a limited number of potential 
comparison subjects will necessitate the use of with replacement methods of evaluation.66
I chose to address this issue by re-testing the results for Comparison #1 (Review 
Level, All Intervention Types) using additional statistical evaluations to validate the 
statistical significance of reported treatment effects for the remaining nine comparisons using 
the standard t-testing method.  I used a threefold approach in addition to the standard 
approach: 1) I report p-values using the degrees of freedom from unique observations, 2) I 
report p-values based upon an unequal variance assumption that determines the degrees of 
freedom based upon distributional variance and 3) I show that bootstrapped standard errors 
are not dissimilar to standard errors reported from t-testing, rendering bootstrapping 
redundant.  Table 13.7 displays the results from this threefold approach.
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Table 13.7 Comparison of Statistical Testing (Review Level, All Intervention Types)
Variable
Total amount paid -$64.09 0.000 0.001 0.001 -$92.27 -$98.62 -$35.91 -$28.47
Total number of drugs 0.045 0.781 0.830 0.833 -0.28 -0.33 0.37 0.55
Number of PAL list alerts -0.28 0.000 0.000 0.000 -0.33 -0.33 -0.24 -0.20
Number of  Clinical Initiatives alerts -0.25 0.000 0.000 0.000 -0.30 -0.29 -0.20 -0.15
Number of Beers List alerts -0.012 0.488 0.594 0.597 -0.044 -0.042 0.021 0.028
Number of Duplication alerts -0.17 0.013 0.055 0.059 -0.30 -0.36 -0.036 0.014
Number of Consider Length alerts -0.010 0.363 0.482 0.490 -0.030 -0.033 0.011 0.016
Risk of Hospitalization -0.0089 0.06**** n/a n/a -0.0183 -0.0217 0.0004 0.0044
p-value                
(unequal 
variance)*
Comparison #1 (All Residents with any Type of Review)
determination of degrees of freedom
* p-value reported for t-test with unequal variance imposes a separate number of degrees of freedom for each outcome measure                                                                                                                   
** t-test applie
Bootstrap                             
Lower Bound                                       
(2.5%)*** 
t-test                                   
Upper Bound                                       
(2.5%)** 
p-value                
(df=10,508)
p-value                
(df=7,431)
DID 
Estimate
t-test                             
Lower Bound                                       
(2.5%)** 
Bootstrap                             
Upper Bound                                       
(2.5%)***
11
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For outcome metrics Total Amount Paid, Number of PAL List Alerts, and Number of 
Clinical Initiatives Alerts, none of the three additional statistical tests provided a different 
conclusion from hypotheses tests, and had very minimal effects on the p-value.  Bootstrapped 
confidence intervals were remarkably similar to those resulting from two-tailed t-testing with 
unequal variance assumptions in all cases, though the 95% confidence interval was slightly 
larger in all cases.  For Total Amount Paid, the confidence interval using t-testing was (-
$92.27 to -$35.91) while bootstrapping replicates produced a confidence interval of (-$98.62 
to -$28.74).  
Testing using the three additional methods did produce a different hypothetical result 
using a standard of 95% confidence for reductions in Consider Length Alerts.  Using the 
standard method, the resultant p-value was p=0.013.  Using the reduced degrees of freedom 
representing unique observations, the resultant p-value was p=0.055, scarcely outside the 
popular range for rejecting the null hypothesis.  Using the unequal variance assumption, the 
resultant p-value was p=0.059, also just outside the 95% confidence interval.  Interestingly, 
bootstrapping produced a similar finding to the previous two supplementary methods of 
statistical testing with an upper bound estimate of 0.014, also remarkably close to rejecting 
the null hypothesis of no effect.  
13.6 Sub-Group Results
Difference-in-difference drug cost reductions were found in all ten comparisons of 
interest (Table 13.8).  As expected, drug cost reductions increased in magnitude at 
subsequent levels of treatment. Comparison #2 (Recommendation Level, All Intervention 
Types) produced a drug cost reduction of -$91.94, or 30.64 PMPM.  Residents having a 
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review, recommendation and ultimately a drug change (Comparison #3, Drug Change Level, 
All Intervention Types) had three-month difference-in-difference reduction of -$114.15, or -
$38.05 PMPM.  Results were similar for Retrospective-Only Type Interventions at all 
treatment levels (Comparisons #4, #5, and #6) with PMPM reductions of -$20.80, -$30.52, 
and -$41.96 respectively.  Prospective-Only Type Interventions also produced similar results 
with PMPM reductions of -$36.94 for Recommendation Level (Comparison #9) and -$40.05 
for Drug Change Level (Comparison #10).  Interestingly, Dual-Type Interventions produced 
the least drug cost savings.  Using a two-tailed t-test, Comparison #7 (Recommendation 
Level, Dual-Type Intervention) produced a difference-in-difference estimate of -$37.18, or 
$12.39 PMPM at a p-value of 0.28, though the Drug Change Level comparison resulted in an 
estimate of -$83.34, or $27.95 PMPM.  This intervention type (Dual-Type) produced, 
somewhat paradoxically, the greatest number of recommendations per reviewed person while 
producing the least amount of drug cost savings.  Detailed results tables for each sub-group 
may be found in Appendix B.
Table 13.8 Drug Cost Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-64.09*                             
(-4.4%)
-62.39*                                                        
(-4.1%)
N/A N/A
Review and 
Recommendation
-91.94*                                              
(-6.3%)
-91.58*                                                              
(-5.9%)
-37.18                                                              
(-2.3%)
-110.83*             
(-15.0%)
Review, Recommendation, 
and Drug Change
-114.15*                                                    
(-7.8%)
-125.89*                                             
(-8.0%)
-83.84*                                                                
(-5.0%)
-120.15*
(-16.4%)
Drug Cost                              
DID Mean $, (%)
Intervention Type
Notes: DID=Difference in Difference
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
Drug Costs measurements were obtained from a 90-day post-period
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On average, a retrospective review produced a drug cost savings of 4.4%.  Among all 
comparisons, the greatest percentage reduction in drug costs was found for residents having a 
drug change in the Prospective-Only intervention group, with a reduction of 16.4%.  This 
makes intuitive sense since these residents, on average, had baseline drug costs substantially 
smaller than there Retrospective Intervention counterparts (~$250 PMPM vs ~$500 PMPM) 
due to the 18 drug fill screening criteria.
With the exception of Dual-Type Interventions at the Review Level (Comparison #7), 
no difference-in-differences were found in the number of drugs used in the 90-day post 
period (Table 13.9).  A 2.62% difference or an increase of 0.81 drug fills in 90-days was 
found in Comparison #7.   This result is similarly paradoxical to drug cost savings for Dual-
Type Interventions in that the expected result was the reverse.  It may indicate incomplete 
matching for Dual-Type study subjects, or more likely, the presence of some unmeasured 
endogenous factor not included as a co-variate in the treatment selection model.  
Table 13.9 Number of Drug Fill Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
0.045                                                                
(0.17%)
-0.035                                                           
(-0.12%)
N/A N/A
Review and 
Recommendation
0.19                                        
( 0.70%)
0.047                                     
(0.16%)
0.81*                    
(2.6%)
0.16                         
(1.3%)
Review, Recommendation, 
and Drug Change
-0.092                                                                  
(-0.34%)
-0.46                
(-1.6%)
0.41                                          
(1.3%)
0.15
(1.2%)
Notes: DID=Difference in Difference
Number of Drugs                              
DID Mean, (%)
Intervention Type
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
Number of Drug fill measurements were obtained from a 90-day post-period
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Substantial and significant percentage reductions in the incidence of PAL List alerts 
were found in all 10 comparison groups (Table 13.10).  Percentage reductions ranged from 
18.1% in the Review Level, All Intervention Types (Comparison#1) grouping 37.7% 
reduction at the Drug Change Level of the Prospective-Only Intervention Group 
(Comparison #10).  Absolute reductions in PAL List Alerts were similar at respective 
intervention levels with the Recommendation Level producing reductions of  -0.36, -0.36 and 
-0.30 for Retrospective-Only, Dual-Type, and Prospective-Only interventions respectively.  
The Drug Change Level produced reductions of 0.49, 0.47 and 0.38 respectively.   These 
results indicate that, on average approximately one PAL List drug was dropped from a 
resident’s drug regimen for every two residents having a successful review, recommendation 
and drug change.   At the review level, approximately one of every three residents with a 
review had a PAL List drug removed, on average.  As observed with drug cost reductions, 
the percentage reductions in PAL list alerts becomes more pronounced moving closer to the 
mechanism of action (changed drug consumption).  
Table 13.10 PAL List Alert Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-0.28*                                                               
(-19.2%)
-0.27*         
(-18.1%)
N/A N/A
Review and 
Recommendation
-0.35*                                                                
(-21.7%)
-0.36*                   
(-21.3%)
-0.36*                                   
(-20.3%)
-0.30*                                
(-30.6%)
Review, Recommendation, 
and Drug Change
-0.44*                                                      
(-26.6%)
-0.49*                                     
(-27.9%)
-0.47*                          
(-25.6%)
-0.38*                        
(-37.7%)
PAL List Alert                           
DID Mean, (%)
Intervention Type
Notes: DID=Difference in Difference
Number of PAL List Alert measurements were obtained from a 90-day post-period
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
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Patterns for percentage of Clinical Initiatives Alert reductions also mimicked drug 
cost reductions findings and findings of PAL List reductions. Cohort-comparison groupings 
experienced proportionally similar reductions (Table 13.11).  The smallest percentage 
reduction was found at the Review Level for All Intervention Types (9.6%) and the largest at 
the Drug Change Level for Prospective-Only Type (13.9%).   In absolute terms, the number 
of reductions in Clinical Initiative Alerts was 0.25, 0.25, and 0.31 for the Review, 
Recommendation, and Drug Change Levels for all intervention types.  Approximately one-
third of all residents having a successful review, recommendation and drug change, had a 
Clinical Initiatives List drug removed from their regimen, on average.   
Table 13.11 Clinical Initiative Alert Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-0.25*                                                      
(-9.6%)
-0.30*                   
(-11.6%)
N/A N/A
Review and 
Recommendation
-0.25*                                                         
(-8.9%)
-0.30*                  
(-10.4%)
-0.22*                             
(-7.0%)
-0.17*                        
(-10.3%)
Review, Recommendation, 
and Drug Change
-0.31*                                              
(-10.9%)
-0.37*             
(-12.3%)
-0.31*                     
(-9.6%)
-0.24*                            
(-13.9%)
Notes: DID=Difference in Difference
Number of Clinical Initiatives Alert measurements were obtained from a 90-day post-period
Intervention TypeClinical Initiatives Alert                
DID  Mean, (%)
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
No statistically significant reductions were found for Beers List Alerts (Table 13.12) 
for any of the ten comparisons of interest, nor for Consider Length Alerts (Table 13.13).
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Table 13.12 Beers List Alert Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-0.012                                         
(-1.7%)
-0.030                  
(-4.2%)
N/A N/A
Review and 
Recommendation
-0.018                                          
(-2.6%)
-0.021              
(-2.8%)
-0.028                         
(-3.3%)
-0.042                  
(-16.4%)
Review, Recommendation, 
and Drug Change
-0.030                                                  
(-4.2%)
-0.033                
(-4.5%)
-0.41                                        
(-4.4%)
-0.037            
(-14.3%)
Number of Beers List Alert measurements were obtained from a 90-day post-period
Notes: DID=Difference in Difference
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
Beers List Alert                          
DID Mean, (%)
Intervention Type
Table 13.13 Consider Length Alert Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-0.010                                                 
(-6.4%)
-0.008     
(5.2%)
N/A N/A
Review and 
Recommendation
-0.007                                  
(5.2%)
0.00                       
(0.0%)
-0.016                             
(-10.5%)
-0.030                                 
(-36.2%)
Review, Recommendation, 
and Drug Change
-0.010                       
(7.9%)
-0.009                          
(-6.6%)
-0.022                             
(-15.5%)
-0.023                      
(-27.8%)
Consider Length Alert          
DID Mean, (%)
Intervention Type
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
Number of Consider Length Alert measurements were obtained from a 90-day post-period
Notes: DID=Difference in Difference
 Statistically significant reductions in Duplication alerts were found at the Review 
Level for All Intervention Types and Retrospective-Only Type interventions produced 
statistically significant reductions of 3.8% and 6.9% respectively (Table 13.14).  However, 
this finding should be taken with some caution since these reductions are inconsistent with 
subsequent intervention levels.  Each subsequent level of treatment should produce 
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progressively greater effects.  The lack of this hypothesized effect suggests serendipity may 
be at play, owing possibly to multiple comparisons or incomplete matching.  
Table 13.14 Duplication Alert Reductions Resulting from Initiative Activities
All Types Retrospective Dual-Type Prospective
Review
-0.17*                                     
(-3.8%)
-0.333*                         
(-6.9%)
N/A N/A
Review and 
Recommendation
-0.067                                       
(-1.5%)
-0.167                       
(-3.5%)
0.116                         
(2.3%)
-0.035                    
(-2.3%)
Review, Recommendation, 
and Drug Change
-0.104                                      
(-2.4%)
-0.193                    
(-3.9%)
0.016                            
(0.3%)
-0.087                               
(-5.6%)
Intervention TypeDuplication Alert                     
DID Mean, (%)
Number of Duplication Alert measurements were obtained from a 90-day post-period
Notes: DID=Difference in Difference
 * statistically significant at p<0.05 using a two tailed t-test with equal variance assumption 
As a qualitative measure of downstream impact of interventions, hospitalization 
events were obtained for the 90-day post intervention period.  All point estimates of relative 
risk were less than one, though only one cohort-comparison grouping elicited a significant 
reduction in risk using Fisher’s Exact Test (Comparison #4, Review Level, Retrospective-
Only).  More comparisons may have elicited statistically significant results with sufficient 
sample size.  Figure 12.5 shows point estimates of relative risk of a hospitalization event in 
the post period with upper and lower boundaries for a 95% confidence interval.
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Figure 13.5 Relative Risk of Having a Hospitalization Resulting from Intervention
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13.7 Sub-Strata Results from Comparison #1
One of the many advantages of propensity scoring is the ability to parse out effect by 
level of treatment selection.  Figure 13.6 shows the drug cost difference-in-difference by 
propensity score quintile for Comparison #1 (Review Level, All Treatment Types).  
Statistically significant reductions in 90-day drug costs were found for Quintiles #3, #4, and 
#5.  Mean difference-in-difference reductions increased proportionally with treatment 
selection.  This finding is logical since program administrators, pharmacists and prescribers 
are likely to select out those residents most in need of a drug therapy change.  
Figure 13.6 Drug Cost Savings by Propensity Score Quintile
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13.8 Limitations
This dissertation went to great lengths to address major threats to validity in the 
assessment of this intervention.  Nevertheless, there were several limitations that must be 
recognized.
Regression to the Mean:  As with any non-randomized, observational study, 
regression toward the mean must be considered.  The comparison groups for Evaluations #2 
and #3 were selected in the same manner as study group patients, hence both should have 
equally incurred this regression effect and it is, in essence, neutralized for purposes of 
differential analysis.  
Especially challenging in the evaluation of this particular pharmacist service is the 
presence of a mandated existing monthly review.  The aim of this dissertation was to assess 
the marginal effect of this review above and beyond pre-existing OBRA-87-mandated 
monthly reviews (baseline effects).  It was not possible to assess, nor infer, the impact of this 
intervention in the absence of OBRA-87 mandated monthly reviews. 
Using a payor perspective, I assessed the impact of all drug claims for recipients, not 
just those just those drugs flagged in patient profiles from pre-intervention screening.  It is 
likely that our broader focus diluted our findings toward the null.  Yet we found important 
drug cost differences on a PMPM basis in all three evaluations. 
Use of Administrative Claims Data:  Using administrative claims data to measure 
differences in drug costs is not without limitations.  Drugs may have been filled without 
submission of a claim or nursing homes may have paid for products such as over-the-counter 
medications out of a separate budget, though there is no evidence that this may have occurred 
differentially between study and comparison subjects.  Further, this study takes a payor 
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perspective and paid claims are the most meaningful measurement from this perspective.  
Administrative claims are poor stand-alone proxies for measuring changes in quality, 
particularly in such areas as adverse effects or health status.  On the other hand, claims 
databases were the only data source with which to measure impact on heath care or economic 
impact from a payer perspective.  The large sample sizes involved in our study suggest that 
our findings are real and replicable.
Loss to Follow-Up:  Resident attrition in North Carolina Nursing Homes remained 
steady at 36% over the four year study period, making an evaluation of the persistence of 
intervention effects quite difficult.  At a minimum, at least three one-month follow-up 
periods were required to assure that drug therapy changes were reflected in claims data and 
persisted for Evaluations #2 and #3.  On the other hand, a longer follow-up period of 6-12 
months would have incurred problems of patient attrition within the nursing homes, 
subjecting the study to additional bias resulting from unknown factors associated with 
attrition. During this study period, attrition rates closely approximated statewide averages, 
and there was some comfort in the finding that attrition rates were not significantly different 
between study and comparison groups. 
Unknown Intervention Persistence:  Despite a robust study design, the downstream 
effects of repeated interventions, the effects of continually evolving PDTP alerts criteria, and 
intervention persistence beyond the three month post-period are unknown.  The long term 
impact of these interventions in both cost and quality dimensions remains unknown.   
Extrapolation of findings beyond the 3 month follow-up window must be done with caution, 
though patients in long-term care facilities are known to have relatively stable drug therapy 
regimens over time in the absence of interventions of the type employed in this study.
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Internal Validity versus External Validity Tradeoff:   This investigation went to 
great lengths to equalize study and comparison groups for purposes of analyzing the impact 
of different forms of interventions.  In doing so, there is always a tradeoff between internal 
and external validity.  The selection criteria I employed limited my ability to generalize to 
Medicaid nursing home residents who did not share the same characteristics.  
Endogeneity and Omitted Variable Bias:  As with nearly all other practice based 
interventions studies, it was not possible to draw a true random sample of patients across
nursing homes or pharmacist consultants due to the intermingling of providers and the need 
of program administrators to elicit as many participants as possible in the shortest amount of 
time possible.  A randomized controlled trial of a “real world” program such as this is simply 
not feasible nor practical.  Any randomization that would have been employed would have 
had to account for all clustering effects and interactions between providers common to the 
long-term-care arena.  It would have been difficult, if not impossible, to construct a truly 
randomized patient-level sample within a nursing home since physicians often provide care 
to patients in more than one nursing home.  Additionally, groups of pharmacists are often
clustered through consulting organizations serving multiple nursing homes and multiple 
nursing homes often operate under a common ownership structure.   
 Thus, our comparison group was not, by design, a randomized sample of patients.  
However, propensity scoring approaches are powerful in their ability to reduce bias, and have 
been shown to perform better than randomization in some circumstances.42  This quasi-
experimentation is only valid, however, if the researcher ensures that all relevant aspects of 
treatment selection and baseline risk are contained in the propensity scoring model, 
regardless of balance of observed co-variates.  It is always possible that an important 
132
treatment selection variable may have been omitted in this claims data analysis, causing 
potentially biased results to emerge.   Yet I believe the 20 co-variate treatment selection 
model used in Evaluation #3 to be robust and complete.  
Inexact Treatment Selection Modeling: Aside from the problem of unobserved, or 
omitted variable bias, inexact matching remains a challenge in this and other propensity 
matching studies.  Matching on observed variables rarely produces complete balance using 
inferential significance testing, especially with large numbers of covariates in the treatment 
selection model and strong statistical power emanating from sample sizes in the thousands.  
To the extent that the possibility of bias remains after matching, that bias would be reflected 
in the results.  Generally, this problem is exacerbated when a few comparison observations 
are available to minimize distance between study and comparison subjects.  The propensity 
matching method in this study has been shown to be robust when large sample sizes exist,42
and while the method used herein is often employed with far fewer subjects, it is fortunate in 
this study that sample sizes were relatively large in this evaluation. 
Generalizability:  The findings of this study must be viewed in the context of the 
setting, time, and environment in which it was conducted.  In NC, Medicaid programs were 
under considerable pressure to reduce overall costs.  There were few options to do so under 
federal statutes (e.g., prior authorizations and preferred drug lists).  One option was certainly 
to reduce fees to providers, including fees to pharmacist consultants.  The threat of reduced 
fees to providers may have been a motivator for the success of the Initiative.  The incentive 
to participate in earnest may not be present in other environments, decreasing the external 
validity of the findings herein. However, cost containment pressures and medication safety 
issues have been paramount in most state Medicaid programs and other federal programs in 
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most states for quite some time with no sign of abatement.  Yet any service study, regardless 
of research method, control or design is subject to substantial threats to external validity.  
Pharmaceutical care services in particular, tend to be rather unique to specific geographic 
regions, settings and patient populations.  Foremost among unique qualities are the 
predispositions of the pharmacists themselves and their disparate abilities to impact patient 
care in given situations.
Lack of Consideration of Nursing Home, Pharmacist and Prescriber 
Characteristics:  This study did not explicitly examine the decision-making processes of 
participant pharmacists or physicians regarding drug therapy changes.  This was because 
claims data and pharmacist problem encounter documents were the only data source 
available for analyses.  This lack of consideration has a twofold limitation.  First, evaluation 
of these characteristics could prove valuable to future Initiative phases as well as other 
fledgling pharmaceutical care programs across the country.  Identification of the traits among 
homes, pharmacists and prescribers that are associated with positive outcomes could lead to 
better program development.  Second, these characteristics may act as confounders of the 
evaluations herein if they are predictive of intervention success and a maldistribution exists 
among study and comparison groups with respect to home, pharmacist, and prescriber 
characteristics and practice patterns.  In essence, these characteristics may have served as 
omitted variables that ultimately imposed bias upon the results.  While this possibility exists, 
there is no apparent rationale that suggests a maldistribution of characteristics exists.  To the 
extent that groups of homes, pharmacists and prescribers behaved similarly by association, 
some unobserved clustering effects may also have been present.
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Unknown or Unrealized Incentives:  The amount of compensation to providers may 
or may not have affected the results.  It may have had a positive effect since it was the first 
explicit recognition, through direct compensation, of drug therapy review services in a 
Medicaid program.  However, since payments were relatively low as compared to rates for 
service delivery among other health care providers, compensation may have also negatively 
impacted Initiative response.
Service variability:  In all three evaluations undertaken as part of this Initiative, there 
was an implicit assumption that all pharmacist activities were equipotent.  As I stated in 
Chapter 10 (Methodological Considerations), service studies are subject to much greater 
variability in practitioner and study subject activities.  Unlike drug products which are very 
standardized, pharmacist services are more heterogeneous in their effects (as are most other 
professional service interventions).  I did not examine differences in individual pharmacist
behavior, nor did I address effect differences across pharmacy provider organizations, though 
some researchers have successfully done so.67,68  Future work warrants this type of 
consideration.
Effect Attribution:  None of the three Initiative evaluations were designed to 
distinguish the relative contribution of intervention components (e.g., profile, toolkit, 
financial reward, pharmacist motivations).  Therefore, results must be observed in aggregate.
The Problem of Multiple Comparisons:  Evaluation #3 makes multiple 
comparisons (eight outcome metrics) across ten cohort-comparison groupings.   Standard 
statically inference approaches suggest that one of every twenty comparisons should have a 
statistically significant and serendipitous relationship with the independent variable of 
interest using a 95% confidence interval.  It is unclear weather a Bonferroni-type adjustment 
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is warranted or should be applied in this circumstance since all ten comparisons were 
modeled separately.  The safer option seems to be to take the p-values at face value and avoid 
hypothesis testing conclusions. In this dissertation, I have presented p values of tests 
unadjusted for multiple comparisons.  The reader may wish to apply Bonferroni corrections 
to observed p values in rendering their own interpretation of these findings.  By simply using 
critical value of p<0.01 when hypothesis testing, one effectively reduces the occurrence of an 
erroneous conclusion resulting from the multiple comparisons problem to 1 in 100.  If a 
critical p value of <0.01 were used, drug cost savings in Comparison # 11 (Recommendation 
Level, Prospective-Only Type Intervention) would not be statistically significant.  
Reductions in PAL list alerts and Clinical Initiatives Alerts would remain statistically 
significant in all comparisons.  While I reiterate my belief that the drug cost savings and alert 
reductions were demonstrated in this project are real, statistically significant, and meaningful.  
I leave to the reader their own interpretation of statistical significance of reported p values.
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CHAPTER 14
PHASE 2 AND 3 DESCRIPTIVE RESULTS
14.1 Phase 2 Descriptive Results
Phase 2 of the North Carolina Nursing Home Polypharmacy Initiative was conducted 
over a three month period from March-June of 2003.  Preliminary results from Phase 1 of the 
initiative created a desire among administrators to expand the program even further to touch 
as many Medicaid enrollees residing in North Carolina Nursing Homes as possible.  
Additional nursing homes and their pharmacist consultant organizations were invited to 
participate in Phase 2.  An additional 12 homes ultimately agreed to participate.  Screening 
criteria were also expanded to allow any resident having any type of drug therapy problem 
alert to receive comprehensive reviews.  Thus, nearly all residents residing in participating 
nursing homes became eligible for profile reviews in Phase 2.  
Results were similar to those found in Phase 1 of the Initiative.  An additional 4,123 
residents received reviews with 2,639 recommendations, or 0.62 recommendations per 
resident reviewed.  Interestingly, this rate was roughly half that of the 1.21 recommendations 
per resident reviewed in Phase 1.  This reduction was likely the result of a fewer number of 
drugs to be reviewed since the 18 fill in 90-day screening criteria was lifted for Phase 2.  On 
average, residents receiving reviews in Phase 2 had 4.6 drug fills per month in contrast to the 
9.0 per month in Phase 1.   
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In Phase 2, changes to a more cost-effective drug were again the dominant result type, 
responsible for 62.5% of all drug regimen changes resulting from intervention activities 
(Table 14.1).  The distribution of result types were remarkably similar to that found in Phase 
1.  However the number of drug changes per 100 reviewed residents dropped from 75.6 in 
Phase 1 to 44.7 per 100 in Phase 2, likely owning to less sick residents with fewer drugs 
being reviewed. 
Table 14.1  Resultant Changes in Therapy by Type (N=4,123 residents)
Frequency (%)             Average Number per 100 Residents*
Dose/Delivery Changed   243 (13.2) 5.9
-Dose or administration was changed
Drug Added      38 (2.1)  0.9
-Drug added for untreated indication
Drug Change 1,154 (62.5) 28.0
-Drug was changed from one to another
Drug Discontinued    410 (22.2) 9.9
-Drug was discontinued or changed to PRN
Total**  1,845 (100) 44.7
*  Denominator is the total number of residents receiving a completed review by consultant pharmacists
** A result type of  “Other-Any result not listed above” occurred in 325 instances but was not considered to be verified drug changes.
Note: Pharmacist report used as a data source.
14.2 Phase 3 Descriptive Results
Phase 3 of the North Carolina Nursing Home Polypharmacy Initiative was conducted 
from March of 2004 through December of 2005.  Unlike the previous two phases, patient 
profiles were not generated, nor were screening criteria applied.  Any resident in any 
participating Nursing Facility was eligible for any type of intervention at any time.  
Phase 3 of the Initiative produced an additional 5,813 residents not previously 
reviewed by consultant pharmacists as part of the Initiative.  Phase 3 reviews produced 5,023 
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additional recommendations by pharmacist, many times for residents reviewed in previous 
phases. 
139
CHAPTER 15
CONCLUSIONS AND LESSONS LEARNED FROM THE NORTH CAROLINA 
POLYPHARMACY INITIATIVE 
(PHASES 1, 2 AND 3)
This initiative, spanning from the pilot study through Phase III, has contributed to my 
summary conclusions and lessons learned, outlined below:  
1.  Plan-Do-Study-Act (PDSA) strategies are valuable for both evaluations as 
well as for use with programmatic improvements:  Real world Initiatives are ever 
evolving and necessarily responsive to changes in practice, environment and resource 
demands.  Using a PDSA approach enables the program administrator and researcher to find 
common ground on which to proceed and improve Initiative features.
2.  Collaboration is essential among principals involved in any large 
intervention, and requires administrative support:  Having a figure-head, spokesperson, 
or sponsoring entity is crucial to engendering health care practitioners.  In this Initiative, 
AccessCare provided this role by fostering support from across the state, both geographically 
as well as across disciplines.  AccessCare believed that organizational buy-in was the most 
effective element in Initiative success.
3.  A targeted program using pharmacists to review patient profiles may be 
quickly launched and expeditiously performed across large numbers of patients, at least 
in long-term-care settings:  The ability of the initiative to be expeditiously executed from 
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conception to evaluation was essential in this “real world” setting.  Each of Phases 1, 2 and 
the pilot project required less than six months from conception to implementation to 
evaluation for the next phase.  What’s more, this program touched 98 of North Carolina’s 
100 counties and involved roughly two-thirds of all Medicaid enrollees residing in nursing 
homes during the study period.  Most interventions occurred within one month of each 
respective phase.
4.  An expansion of the role of the geriatric consultant pharmacist specialist may 
help contain drug related health care expenditures in the elderly without adversely 
affecting total health care costs or quality:  The current role for nursing home consulting 
pharmacists is based on OBRA- 87 and other federal regulations requiring drug regimen 
reviews to be conducted at least monthly by consultant pharmacists.  The Initiative sought to 
provide an enhanced version of Drug Regimen Reviews (DRRs). This model incorporated a 
pharmaceutical care plan. Within a pharmaceutical care plan, the pharmacist works with 
other members of the health care team to implement and monitor patient drug therapy.    The 
results from all three evaluations of the initiative suggest that the addition of PDTP alerts to 
usual-care DRR reviews was associated with more changes in drug therapy and a reduction 
in computer-generated drug therapy alerts during the follow-up period.
5.  A computerized alerting system can be successful in reducing potential drug 
therapy problems if an emphasis is placed on specific alerts with pharmacist and 
prescriber acceptance and collaboration (i.e., “buy-in”) to address problem alerts and 
prudently dismiss false positive alerts:  Evaluations #2 and #3 measured PDTP alert 
reductions among study participants.  Two of five alert categories were found to have 
substantial and statistically significant reductions following interventions using profiles 
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outlining these alerts (Clinical Initiatives and PAL List Drugs).  These two categories were 
constructed by physician and pharmacist leaders, suggesting that practitioner involvement 
with a centralized DUR process aids in program response.  Beers list and therapeutic 
duplication alerts decreased in all study groups and in the comparison group in both 
Evaluations #2 and #3, yet these reductions were not statistically different between study and 
comparison groups. This finding is consistent with the role of DRRs as outlined in OBRA 87.  
These types of drugs and drug problems are explicitly mentioned as part of the guidelines for 
conducting customary mandated DRR reviews.  Although residents in comparison homes 
were not subject to claims-generated drug profile reviews with potential drug therapy 
problem (PDTP) alerts as part of the Initiative, residents in both study and comparison homes 
were subject to OBRA-87-based requirements and screening guidelines for the overuse of 
particular prescription drugs.  This may explain the reduction in both groups.  
6.  Propensity scoring is both an effective evaluation tool as well as prognostic 
indicator of which patients should receive supplemental services:  The advantage of 
propensity scoring as it relates to these findings lie with its ability to determine a cost-
minimization threshold.  Given a $12.50 payment for review services, any resident in 
comparison homes having a propensity score greater than 0.63 should receive a targeted 
intervention, according to sub-strata results.  The treatment selection model suggests that the 
reviews would be cost-beneficial within the first three months following the intervention 
alone, with the potential for accruing greater benefits over time.  Using a propensity score as 
a targeting strategy could have major implications for the expansion of pilot projects 
currently underway in Medicare Part D.  Once a pilot project has been conducted, the 
resulting propensity score match could identify both those in need as well as those likely to 
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benefit from supplemental services.  This strategy harkens back to the Plan-Do-Study-Act 
philosophy.
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CHAPTER 16
POLICY IMPLICATIONS FOR PHARMACIST SERVICES
The North Carolina Nursing Home Polypharmacy Initiative was a success.  
Overall, Phases 1, 2 and 3 of the initiative produced 17,545 recommendations for 19,144 
nursing home residents in the state of North Carolina.  These recommendations generated 
greater than 10,000 changes in drug therapy over a three year span of time, with an estimated 
$9-12 million dollars in accrued drug cost savings through December 2005.69 Results from 
the pilot project together with Phase 1 results published in a peer reviewed journal suggest 
annualized cost-minimization ratios of 13:1 and 12:1 respectively.70,71,72  
This initiative serves as a viable example of a Medication Therapy 
Management Program (MTMP) called for under Part D of the Medicare 
Modernization Act of 2003.  The Initiative combined a population level, computer-based 
retrospective drug use review (DUR) profiling system with a comprehensive and patient-
specific drug regimen review (DRR) system. Alerts were generated by the payor, in this case 
NC Medicaid, and were provided to consultant pharmacists for review and recommendation.  
While the strategy of targeting drugs and drug classes at the population level is far from 
novel given over 25 years of experience with DUR in dispensing systems, doing so in concert 
with a comprehensive review of the entire drug regimen at the point of care (the nursing 
home) has not been done on this scale.  In line with usual-care in long term care settings, 
pharmacists were free to review and recommend therapy changes for any drug in a patient’s 
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profile for any problem they discovered, regardless of any alerts provided on claims-
generated resident profiles.  Administrative claims alone may only be 65% sensitive and 88% 
specific when tested against manual review,73 suggesting a need for combined computerized 
and manual review of drug use.  The Initiative successfully demonstrated that this combined 
DUR-DRR intervention is feasible and valuable.
Beginning in 2006, PDP and MA-PD sponsors took on this DUR role as required 
under the Medicare Modernization Act of 2003.  Standard DUR approaches have offered 
little evidence to date of effectively improving patient outcomes for state Medicaid enrollees 
despite the large budget outlays to these programs,74-77 yet population specific (targeted) 
interventions such as the Initiative have shown some success.78-80Use of continuous quality 
improvement strategies such as the PDSA approach in DUR programs may improve both 
their success and appeal.81 Designing studies to determine both what works and what does 
not work promotes programmatic and operational improvements.  To date, evidence of DUR 
non-success has been offered at highly aggregated levels, without emphasis on specific 
actions and non-action, subjecting studies to washout effects.81 DUR activities, as well as 
their evaluations, lack sufficient sophistication and integration of data, providers and 
methods, despite available enabling technologies.82 Focused reviews that utilize claims-
generated profiles, in combination with collaborative activities that individualize care,83 such 
as DRR reviews, may be a better strategy for PDPs to adopt through the MTMP service 
requirement.  
Robust, multi-center studies are warranted that evaluate downstream health 
outcomes effects of pharmacist interventions in long-term-care settings.  Of the three 
formal evaluations of the initiative, only Evaluation #3 considered both processes of care as 
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well as global health outcomes resulting from pharmacist activities.  Rates of hospitalization 
were likely an insensitive measure of quality in this study, especially when considering only 
three months of post-intervention follow-up.  
Despite this shortcoming, findings of this study are of great value when viewed in the 
context of other studies conducted to date.  There are a limited number of well-designed 
studies that focus on pharmacist-physician interventions to improve/change medication 
therapies in the long-term-care arena.  I was able to find only two review articles that studied 
pharmacist activities that aimed to improve medication use in long-term-care settings.  
Hanlon et al.84 found 14 randomized controlled studies using a MEDLINE search 
through March of 2003 that evaluated pharmacist interventions in the elderly, yet only two 
were conducted in long term care settings (five in home settings, three at hospital discharge, 
three in medical clinics, and one in a community pharmacy setting).  They concluded that 
while evidence of reductions in drug-related problems (DRPs) exists, larger studies involving 
large numbers of patients, in multiple locations should be conducted.84
In an effort to argue for similar legislation in the United Kingdom, Hughes85 writes 
one of the few journal articles in existence that specifically outlines the requirements of 
OBRA 87 legislation and reviews evidence of its impact in the U.S.    Findings of change in 
processes of care were evident in the two studies reviewed, though evidence of translation to 
improved outcomes remained elusive.85  Specific evidence of process of care improvements 
in long-term-care settings include: reductions in antipsychotic prescribing,86 reductions in 
psychotropic (antipsychotic, antidepressant, anti-anxiety) medications,87 targeting of NSAID 
therapy for cost-effective alternatives,88 a reduction in preventable adverse drug reactions 
(ADRs),89 cost-effective drug substitution,90 a decrease in polypharmacy and drug costs,91
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and a strong need for transitional assistance from other institutionalized settings.92 However, 
none of these studies demonstrated improved health outcomes.  
Robust evaluations of downstream intervention effects have been inhibited by the 
inability to produce robust study designs in lieu of randomization, the difficulty of capturing 
essential data and lack of a suitable measure of quality of life.93 These “real world” 
constraints have proven challenging to researchers.  Few, if any, studies exist that 
demonstrate with little doubt that pharmacist interventions improve global health outcomes 
in long-term-care settings, though it is well known that pharmaceutically related problems 
exist,11,18,94-98 and that residents of long-term care facilities desire to have these services 
available to them.99
One ongoing examination attempts to fill this void.  The American Society of 
Consultant Pharmacists Foundation is underwriting a multi-phase, multi-year study of drug 
therapeutic concerns and safety issues labeled, the “Fleetwood Project”.100 For consultant 
pharmacists in nursing homes involved in the project, a new model of care was employed 
that emphasized prospective interventions, face-to-face contact and evaluation of high risk 
patients.  The project and its evaluations were conceived in three phases.  
Phase 1 was a macro-level pharmacoeconomic evaluation of drug-related morbidity 
and mortality that would serve as an evaluation model for future Fleetwood evaluations.  
Results for this preliminary work were based upon survey results from an expert panel that 
determined the conditional probability of sub-optimal health outcomes.  Phase 1 of the 
Fleetwood project proposed that as much as 3.6 billion is currently saved annually from 
existing consultant pharmacist activities.16  
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Phase 2 of the project was to serve as a pilot project for conception of Phase 3 that 
determined which operational activities generate the greatest impact on resident health and 
cost-related outcomes.  This phase served the Fleetwood project in much the same manner as 
the Pilot Project did for the Initiative using the PDSA strategy of informing future project 
phases.  Phase 2 was to determine the feasibility of a new model of care that placed more 
emphasis on prospective interventions, face-to-face contact and evaluation of high risk 
patients.  Phase 2 results revealed that the new model increased clinical involvement of the 
pharmacist, reduced time spent on DRR, greater recognition of pharmacist value within 
interdisciplinary teams, better communication among team members, and increased 
workplace efficiency.101
The results of Phase 2 were used in the planning of Phase 3, a large-scale 
demonstration project conducted in NC simultaneously with this project.  Phase 3 was a 
randomized trial involving 26 nursing facilities that evaluated the six specific aims of the 
Fleetwood Project model:  1) reducing the prevalence of potentially inappropriate medication 
use, 2) reducing under-treatment of disease, 3) reducing adverse drug events, 4) reducing 
Resident Assessment Protocols, 5) improved efficiency, workflow, workload and satisfaction 
among pharmacy staff, and 6) differentiation of nursing homes implementing the new 
model.102 All 26 homes involved in the Fleetwood project were exempted from Initiative 
activities during the course of the trial.  Phase 3 results are expected to be published in 2006.  
Since the Fleetwood Phase 3 closely approximated some of the goals of this project, 
and occurred within NC at about the same time, it is important to denote the similarities and 
differences between programs.   Both studies involved interventions to identify potential drug 
therapy problems in nursing home settings, but in different ways.  Compared to Initiative 
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activities and subsequent evaluation, phase 3 of the Fleetwood project employed much more 
comprehensive and explicitly framed intervention to make specific recommendations for 
drug therapy with multi-year follow-up.103,104 For Fleetwood, the new model of care and 
subsequent care algorithms were developed over the course of many years100 instead of  
weeks, as was the case with the Initiative.  
This project and study herein differs from the Fleetwood project in that it was 
conceived and implemented relatively quickly, with the goal of reducing drug costs as 
quickly as possible without compromising health.  The Initiative sought to acquire additional 
drug savings, above and beyond what was already being attained as the result of consultant 
pharmacist activities.  The Fleetwood project, at its core, was designed to test a new model of 
consultant pharmacy.  In this study, I show that a supplementary review of existing DRR 
activities using administrative claims data can be successfully launched relatively quickly on 
a large scale.  
Both pharmacist-initiated prospective interventions and program-initiated 
retrospective interventions were successful in reducing drug costs and PDTP alerts.   
Little variation was found among the relative success of prospective-type and retrospective-
type interventions as employed by the Initiative.  However, care must be taken in 
interpretation of this finding as it relates to future programmatic planning.  During the 
Initiative, persons that were at high risk (having at least 18 drug fills in the 90-day pre-
intervention period) were targeted for retrospective reviews through claims-based profile 
generation on the part of program administrators.  Persons deemed not to be at high risk 
(having less than 18 drug fills in 90 days) were selected out by pharmacists at the home for 
recommended drug therapy changes.  Results from the evaluation herein do not indicate that 
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non-targeted prospective interventions are equally effective in producing drug cost savings as 
targeted retrospective interventions wholesale.  That is, the finding of equipotentcy should 
only be considered in light of the screening criteria employed a given program.  Variations in 
screening criteria may have produced different results, namely the superior effectiveness of 
one type of intervention over another, depending on the accuracy and precision of the screen.
Consultant pharmacists should be explicitly compensated for specific, targeted 
DRR activities by third-party payors, regardless of the level of care provided, or the 
relative success of reviews, recommendations, and resultant drug changes.   This study
found that a program of pharmacist review and intervention achieved reductions in drug costs 
that were far in excess of the amount paid to pharmacists for the service (i.e., $12.50 for each 
retrospective review), with additional benefits accruing from enhancing the quality of 
prescribed drug therapy.  Evaluations #1, #2, and #3 found an average reduction in drug costs 
of $30.33, $19.04, and $21.36 PMPM respectively for the review level of care.  That is, on 
average, these savings were generated regardless of the finding of a PDTP, and were cost-
beneficial within the first month of drug cost savings accrual.  For the primary comparison 
group at the Recommendation Level of treatment, average drug cost savings were found to 
be $30.64 PMPM, while the Drug Change Level generated an average drug cost savings of 
$38.05 PMPM.  
The corollary scenario would be pay-for-performance policies currently being 
debated at the federal level for Medicare payments to physicians.  One alternative method for 
MTMP programs is to “pay for results,” that is, pay pharmacists only for interventions that 
produce changes in drug therapy (with prescriber consent).  This was how pharmacists were 
paid in the prospective review portion of this study.  
150
An advantage of applying an across the board “pay for results” formula (i.e., for both 
prospective and retrospective reviews) is that compensation would be efficiently used to 
generate cost savings.  A disadvantage is that this form of compensation would provide 
economic incentives to focus only on drug cost savings, irrespective of other goals (e.g., 
improving drug safety or quality).  Further, pharmacists may be reluctant to participate in 
such a plan at a high level because it is not always possible determine which patients would 
be candidates for drug cost reductions prior to reviews, resulting in uncompensated activities.  
Thus, payment based on changes in drug therapy may find few willing pharmacists to 
participate in such a payment plan.  In this study, pharmacists completed and submitted 
patient reviews on an exceptionally high proportion of targeted patient drug profiles that 
were sent to them for review (85%, 6344/7472).  Under a different payment scheme, the 
percent of reviews conducted relative to the number of residents targeted would likely be 
less, though the resultant effect on overall return on investment remains unknown and 
untested.  
Activities performed by consultant pharmacists for the North Carolina 
Polypharmacy Initiative may be reproducible in non-nursing home settings, but with 
more difficulty.  There is evidence that PDTPs are common among ambulatory elderly, as 
well as in elderly-oriented board and care or assisted living settings. 105-111 Established 
relationships between pharmacists and prescribers, a trait found to be well-nourished in the 
Initiative, may not be as prevalent in community pharmacy settings where only early stages 
of collaboration may have developed.112 Yet pharmaceutical care programs for ambulatory 
patients in clinic settings with high levels of collaboration have shown success,113,114
suggesting a point-of-care approach nurtures collaboration.  Additionally, some success has 
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been found using home health care referrals as a mechanism of targeting,115 though 
collaboration among health care providers is more common in that setting as well.  
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APPENDIX A:  BIAS REDUCTION TABLES: COMPARISONS 2-10
Table A.1: Bias Reduction (Comparison #2)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.7 79.4 -13.4 -5.77 0.000
Matched 77.7 78.7 -8.1 39% -3.69 0.000
(Age)2 Unmatched 6,186 6,455 -15.2 -6.52 0.000
Matched 6,186 6,315 -7.3 52% -3.29 0.001
Race Unmatched 32.6% 24.9% 17 7.33 0.000
(Non-White) Matched 32.6% 30.9% 3.8 78% 1.57 0.117
Sex Unmatched 75.7% 78.8% -7.4 -3.21 0.001
(Female) Matched 75.7% 76.8% -2.7 64% -1.13 0.257
Total Number of Drugs Unmatched 27.0 20.4 57.2 24.62 0.000
Matched 27.0 25.6 12.3 79% 5.55 0.000
Total Amount Paid Unmatched $1,451 $1,088 40.8 17.6 0.000
Matched $1,451 $1,347 11.7 71% 5.19 0.000
Total Number of Alerts Unmatched 9.61 6.73 52 22.41 0.000
Matched 9.61 9.02 10.7 80% 4.66 0.000
Number of Duplication Alerts Unmatched 4.38 3.04 39.2 16.91 0.000
Matched 4.38 4.02 10.5 73% 4.55 0.000
Number of Beers List Alerts Unmatched 0.706 0.522 20.4 8.8 0.000
Matched 0.706 0.670 4 80% 1.64 0.101
Number of PAL List Alerts Unmatched 1.60 1.14 39.1 16.87 0.000
Matched 1.60 1.54 5.4 86% 2.27 0.023
Number of  Clinical Initiatives Alerts Unmatched 2.78 1.89 52.6 22.64 0.000
Matched 2.78 2.65 7.4 86% 3.22 0.001
Number of Consider Length Alerts Unmatched 0.139 0.135 0.9 0.39 0.700
Matched 0.139 0.133 1.6 -74% 0.65 0.518
(Number of Duplication Alerts)2 Unmatched 31.7 20.1 24 10.33 0.000
Matched 31.7 26.3 11.2 53% 4.91 0.000
(Number of Beers List Alerts)2 Unmatched 1.42 0.98 14.7 6.34 0.000
Matched 1.42 1.29 4.6 69% 1.85 0.065
(Number of PAL List Alerts)2 Unmatched 4.10 2.60 28.9 12.47 0.000
Matched 4.10 3.70 7.7 73% 3.1 0.002
(Number of Clinical Initiatives Alerts)2 Unmatched 10.58 6.33 37.3 16.12 0.000
Matched 10.58 9.55 9.1 76% 3.7 0.000
(Number of Consider Length Alerts)2 Unmatched 0.214 0.187 3.1 1.32 0.188
Matched 0.214 0.203 1.3 58% 0.52 0.606
Total Number of Alerts x Total Number of Drugs Unmatched 305.7 187.8 40.9 17.64 0.000
Matched 305.7 271.0 12 71% 5.13 0.000
Total Amount Paid x Total Number of Drugs Unmatched 45,586 29,281 37.1 16.01 0.000
Matched 45,586 39,970 12.8 66% 5.44 0.000
Total Amount Paid x Total Number of Alerts Unmatched 16,659 10,170 36.6 15.81 0.000
Matched 16,659 14,453 12.5 66% 5.27 0.000
Average Bias Unmatched 28.90
Matched 7.83 73%
  Pseudo R2 Unmatched 0.108
Matched 0.008
Comparison #2 (Recommendation Level, All Intervention Types)
Sample Sizes:  Study Group n=3,618                                                                                                                                                                                         
Unmatched Comparison Group n=3,801  
153
Table A.2: Bias Reduction (Comparison #3)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.7 79.4 -13 -5.06 0.000
Matched 77.7 78.8 -8.3 36% -3.17 0.002
(Age)2 Unmatched 6,193 6,455 -14.8 -5.73 0.000
Matched 6,193 6,325 -7.4 50% -2.82 0.005
Race Unmatched 32.4% 24.9% 16.5 6.47 0.000
(Non-White) Matched 32.4% 30.8% 3.4 79% 1.18 0.237
Sex Unmatched 75.8% 78.8% -7.1 -2.79 0.005
(Female) Matched 75.8% 77.0% -2.8 60% -1 0.319
Total Number of Drugs Unmatched 27.2 20.4 57.6 22.39 0.000
Matched 27.2 25.8 12 79% 4.46 0.000
Total Amount Paid Unmatched $1,460 $1,088 41.8 16.38 0.000
Matched $1,460 $1,358 11.5 73% 4.24 0.000
Total Number of Alerts Unmatched 9.78 6.73 54.7 21.39 0.000
Matched 9.78 9.16 11.1 80% 4 0.000
Number of Duplication Alerts Unmatched 4.44 3.04 40.4 15.88 0.000
Matched 4.44 4.06 10.9 73% 3.9 0.000
Number of Beers List Alerts Unmatched 0.714 0.522 21 8.3 0.000
Matched 0.714 0.677 4.1 81% 1.38 0.168
Number of PAL List Alerts Unmatched 1.65 1.14 43.4 17.02 0.000
Matched 1.65 1.58 5.9 86% 2.09 0.036
Number of  Clinical Initiatives Alerts Unmatched 2.84 1.89 56.3 21.98 0.000
Matched 2.84 2.71 7.5 87% 2.7 0.007
Number of Consider Length Alerts Unmatched 0.131 0.135 -1 -0.4 0.686
Matched 0.131 0.124 1.7 -63% 0.59 0.557
(Number of Duplication Alerts)2 Unmatched 32.7 20.1 25.8 10.18 0.000
Matched 32.7 27.0 11.7 55% 4.27 0.000
(Number of Beers List Alerts)2 Unmatched 1.46 0.98 15.4 6.19 0.000
Matched 1.46 1.31 4.8 69% 1.58 0.113
(Number of PAL List Alerts)2 Unmatched 4.24 2.60 31.7 12.66 0.000
Matched 4.24 3.83 8 75% 2.7 0.007
(Number of Clinical Initiatives Alerts)2 Unmatched 11.00 6.33 40.8 16.27 0.000
Matched 11.00 9.96 9.1 78% 3.08 0.002
(Number of Consider Length Alerts)2 Unmatched 0.209 0.187 2.4 0.96 0.338
Matched 0.209 0.197 1.3 46% 0.43 0.665
Total Number of Alerts x Total Number of Drugs Unmatched 314.1 187.8 43.1 17.09 0.000
Matched 314.1 277.8 12.4 71% 4.36 0.000
Total Amount Paid x Total Number of Drugs Unmatched 46,334 29,281 38.3 15.18 0.000
Matched 46,334 40,659 12.7 67% 4.5 0.000
Total Amount Paid x Total Number of Alerts Unmatched 17,115 10,170 38.5 15.35 0.000
Matched 17,115 14,825 12.7 67% 4.46 0.000
Average Bias Unmatched 30.18
Matched 7.97 74%
  Pseudo R2 Unmatched 0.108
Matched 0.008
Comparison #3 (Drug Change Level, All Intervention Types)
Sample Sizes:  Study Group n=2,517                                                                                                                                                                                             
Unmatched Comparison Group n=3,8
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Table A.3: Bias Reduction (Comparison #4)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.3 78.3 -8.1 -2.88 0.004
Matched 77.3 78.1 -6.5 20% -2.88 0.004
(Age)2 Unmatched 6,128 6,278 -8.5 -3.02 0.003
Matched 6,128 6,223 -5.4 36% -2.4 0.016
Race Unmatched 31.3% 23.5% 17.6 6.16 0.000
(Non-White) Matched 31.3% 29.6% 3.8 78% 1.58 0.114
Sex Unmatched 74.7% 78.9% -9.9 -3.48 0.000
(Female) Matched 74.7% 75.6% -2.2 78% -0.9 0.371
Total Number of Drugs Unmatched 28.4 28.9 -5.1 -1.82 0.069
Matched 28.4 27.7 7.2 -42% 3.33 0.001
Total Amount Paid Unmatched $1,511 $1,527 -1.1 -0.36 0.716
Matched $1,511 $1,422 6.1 -443% 2.65 0.008
Total Number of Alerts Unmatched 9.78 9.81 -0.6 -0.2 0.839
Matched 9.78 9.38 7.3 -1192% 3.34 0.001
Number of Duplication Alerts Unmatched 4.82 4.64 5 1.79 0.074
Matched 4.82 4.54 7.8 -56% 3.57 0.000
Number of Beers List Alerts Unmatched 0.715 0.778 -6.5 -2.34 0.019
Matched 0.715 0.674 4.3 35% 1.93 0.054
Number of PAL List Alerts Unmatched 1.48 1.58 -8.5 -3.02 0.003
Matched 1.48 1.46 1.3 85% 0.56 0.577
Number of  Clinical Initiatives Alerts Unmatched 2.61 2.64 -1.5 -0.55 0.584
Matched 2.61 2.55 3.5 -128% 1.58 0.115
Number of Consider Length Alerts Unmatched 0.159 0.175 -3.3 -1.16 0.245
Matched 0.159 0.153 1.3 59% 0.58 0.560
(Number of Duplication Alerts)2 Unmatched 35.1 34.9 0.3 0.1 0.920
Matched 35.1 30.4 8.4 -2968% 4.15 0.000
(Number of Beers List Alerts)2 Unmatched 1.39 1.58 -5.8 -2.07 0.039
Matched 1.39 1.22 4.9 16% 2.3 0.022
(Number of PAL List Alerts)2 Unmatched 3.66 4.01 -6.3 -2.26 0.024
Matched 3.66 3.41 4.4 31% 2.03 0.042
(Number of Clinical Initiatives Alerts)2 Unmatched 9.64 10.01 -3.1 -1.1 0.272
Matched 9.64 8.96 5.6 -83% 2.58 0.010
(Number of Consider Length Alerts)2 Unmatched 0.244 0.254 -0.9 -0.33 0.742
Matched 0.244 0.232 1.2 -24% 0.5 0.620
Total Number of Alerts x Total Number of Drugs Unmatched 310.7 322.5 -3.9 -1.41 0.159
Matched 310.7 288.7 7.3 -86% 3.47 0.001
Total Amount Paid x Total Number of Drugs Unmatched 47,993 49,324 -1.7 -0.54 0.592
Matched 47,993 43,069 6.1 -270% 2.7 0.007
Total Amount Paid x Total Number of Alerts Unmatched 17,120 17,333 -0.7 -0.24 0.810
Matched 17,120 15,145 6.8 -828% 3.02 0.003
Average Bias Unmatched 4.92
Matched 5.06 -3%
  Pseudo R2 Unmatched 0.014
Matched 0.008
Comparison #4 (Review Level, Retrospective-Only Type Intervention)
Sample Sizes:  Study Group n=3,638                                                                                                                                                                                           
Unmatched Comparison Group n=1,928
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Table A.4: Bias Reduction (Comparison #5)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.3 78.3 -8.1 -2.55 0.011
Matched 77.3 78.4 -8.8 -9% -3.01 0.003
(Age)2 Unmatched 6,124 6,278 -8.8 -2.78 0.005
Matched 6,124 6,258 -7.7 13% -2.6 0.009
Race Unmatched 31.7% 23.5% 18.5 5.83 0.000
(Non-White) Matched 31.7% 29.8% 4.2 77% 1.31 0.189
Sex Unmatched 75.2% 78.9% -8.7 -2.74 0.006
(Female) Matched 75.2% 76.2% -2.3 73% -0.73 0.468
Total Number of Drugs Unmatched 29.3 28.9 3.8 1.2 0.229
Matched 29.3 28.2 10.1 -164% 3.43 0.001
Total Amount Paid Unmatched $1,553 $1,527 2.9 0.91 0.364
Matched $1,553 $1,460 10.2 -257% 3.57 0.000
Total Number of Alerts Unmatched 10.33 9.81 9.5 3 0.003
Matched 10.33 9.80 9.7 -2% 3.34 0.001
Number of Duplication Alerts Unmatched 4.83 4.64 5.2 1.66 0.097
Matched 4.83 4.51 9 -72% 3.13 0.002
Number of Beers List Alerts Unmatched 0.759 0.778 -2 -0.62 0.533
Matched 0.759 0.717 4.3 -116% 1.43 0.154
Number of PAL List Alerts Unmatched 1.70 1.58 9.6 3.04 0.002
Matched 1.70 1.65 4.1 57% 1.36 0.173
Number of  Clinical Initiatives Alerts Unmatched 2.90 2.64 15.2 4.79 0.000
Matched 2.90 2.79 6.4 58% 2.17 0.030
Number of Consider Length Alerts Unmatched 0.148 0.175 -5.9 -1.85 0.064
Matched 0.148 0.141 1.6 73% 0.53 0.599
(Number of Duplication Alerts)2 Unmatched 35.0 34.9 0.2 0.08 0.940
Matched 35.0 30.0 9.2 -3767% 3.39 0.001
(Number of Beers List Alerts)2 Unmatched 1.51 1.58 -2 -0.62 0.532
Matched 1.51 1.34 5.1 -157% 1.75 0.081
(Number of PAL List Alerts)2 Unmatched 4.42 4.01 7 2.22 0.027
Matched 4.42 4.05 6.4 9% 2.14 0.032
(Number of Clinical Initiatives Alerts)2 Unmatched 11.14 10.01 9.1 2.88 0.004
Matched 11.14 10.18 7.8 15% 2.62 0.009
(Number of Consider Length Alerts)2 Unmatched 0.224 0.254 -2.9 -0.93 0.353
Matched 0.224 0.210 1.4 52% 0.47 0.635
Total Number of Alerts x Total Number of Drugs Unmatched 337.0 322.5 4.7 1.49 0.137
Matched 337.0 307.0 9.7 -106% 3.38 0.001
Total Amount Paid x Total Number of Drugs Unmatched 50,319 49,324 2.1 0.66 0.509
Matched 50,319 45,307 10.5 -404% 3.67 0.000
Total Amount Paid x Total Number of Alerts Unmatched 18,254 17,333 4.8 1.51 0.132
Matched 18,254 16,172 10.8 -126% 3.76 0.000
Average Bias Unmatched 6.55
Matched 6.97 -6%
  Pseudo R2 Unmatched 0.021
Matched 0.009
Comparison #5 (Recommendation Level, Retrospective-Only Type Intervention)
Sample Sizes:  Study Group n=2,064                                                                                                                                                                                          
Unmatched Comparison Group n=1,928 
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Table A.5: Bias Reduction (Comparison #6)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.3 78.3 -7.8 -2.21 0.027
Matched 77.3 78.3 -8.1 -5% -2.3 0.022
(Age)2 Unmatched 6,130 6,278 -8.5 -2.42 0.015
Matched 6,130 6,250 -6.9 19% -1.93 0.053
Race Unmatched 31.1% 23.5% 17.2 4.93 0.000
(Non-White) Matched 31.1% 28.9% 5 71% 1.28 0.202
Sex Unmatched 75.6% 78.9% -7.9 -2.27 0.023
(Female) Matched 75.6% 76.1% -1.4 83% -0.35 0.724
Total Number of Drugs Unmatched 29.6 28.9 7.2 2.05 0.040
Matched 29.6 28.6 10.1 -40% 2.81 0.005
Total Amount Paid Unmatched $1,573 $1,527 5.1 1.46 0.144
Matched $1,573 $1,481 10.3 -100% 2.98 0.003
Total Number of Alerts Unmatched 10.53 9.81 13.2 3.75 0.000
Matched 10.53 10.03 9.2 31% 2.58 0.010
Number of Duplication Alerts Unmatched 4.92 4.64 7.7 2.19 0.029
Matched 4.92 4.61 8.4 -9% 2.38 0.018
Number of Beers List Alerts Unmatched 0.749 0.778 -3 -0.86 0.391
Matched 0.749 0.719 3.1 -2% 0.84 0.399
Number of PAL List Alerts Unmatched 1.76 1.58 14.8 4.21 0.000
Matched 1.76 1.70 4.8 68% 1.32 0.188
Number of  Clinical Initiatives Alerts Unmatched 2.97 2.64 19.2 5.45 0.000
Matched 2.97 2.87 5.9 69% 1.67 0.095
Number of Consider Length Alerts Unmatched 0.140 0.175 -7.5 -2.13 0.033
Matched 0.140 0.131 2 73% 0.56 0.574
(Number of Duplication Alerts)2 Unmatched 36.5 34.9 2.9 0.81 0.416
Matched 36.5 31.6 8.9 -208% 2.61 0.009
(Number of Beers List Alerts)2 Unmatched 1.49 1.58 -2.5 -0.7 0.482
Matched 1.49 1.35 4.1 -68% 1.16 0.245
(Number of PAL List Alerts)2 Unmatched 4.61 4.01 10.4 2.97 0.003
Matched 4.61 4.21 6.8 34% 1.87 0.061
(Number of Clinical Initiatives Alerts)2 Unmatched 11.58 10.01 12.7 3.62 0.000
Matched 11.58 10.60 7.9 38% 2.22 0.027
(Number of Consider Length Alerts)2 Unmatched 0.217 0.254 -3.7 -1.04 0.298
Matched 0.217 0.199 1.8 51% 0.51 0.611
Total Number of Alerts x Total Number of Drugs Unmatched 348.0 322.5 8.2 2.33 0.020
Matched 348.0 317.9 9.6 -18% 2.71 0.007
Total Amount Paid x Total Number of Drugs Unmatched 51,637 49,324 4.8 1.37 0.170
Matched 51,637 46,456 10.8 -124% 3.07 0.002
Total Amount Paid x Total Number of Alerts Unmatched 18,929 17,333 8.1 2.31 0.021
Matched 18,929 16,788 10.9 -34% 3.07 0.002
Average Bias Unmatched 8.61
Matched 6.80 21%
  Pseudo R2 Unmatched 0.025
Matched 0.01
Comparison #6 (Drug Change Level, Retrospective-Only Type Intervention)
Sample Sizes:  Study Group n=1,404                                                                                                                                                                                          
Unmatched Comparison Group n=1,928 
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Table A.6: Bias Reduction (Comparison #7)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.4 78.3 7.6 -1.93 0.053
Matched 77.4 78.6 10 -32% -2.34 0.019
(Age)2 Unmatched 6,136 6,278 8.2 -2.09 0.037
Matched 6,136 6,294 9.1 -12% -2.12 0.034
Race Unmatched 30.3% 23.5% 15.4 4 0.000
(Non-White) Matched 30.3% 28.6% 3.9 75% 0.84 0.401
Sex Unmatched 77.4% 78.9% 3.6 -0.93 0.350
(Female) Matched 77.4% 79.2% 4.4 -21% -0.98 0.326
Total Number of Drugs Unmatched 30.8 28.9 18.2 4.65 0.000
Matched 30.8 29.6 11.2 38% 2.58 0.010
Total Amount Paid Unmatched $1,648 $1,527 12.9 3.34 0.001
Matched $1,648 $1,558 9.6 26% 2.27 0.023
Total Number of Alerts Unmatched 11.04 9.81 21.4 5.51 0.000
Matched 11.04 10.52 8.9 58% 2.04 0.042
Number of Duplication Alerts Unmatched 5.12 4.64 13 3.34 0.001
Matched 5.12 4.85 7.3 44% 1.69 0.091
Number of Beers List Alerts Unmatched 0.856 0.778 7.6 1.97 0.049
Matched 0.856 0.788 6.6 13% 1.47 0.141
Number of PAL List Alerts Unmatched 1.77 1.58 14.8 3.8 0.000
Matched 1.77 1.71 4.3 71% 0.98 0.329
Number of  Clinical Initiatives Alerts Unmatched 3.14 2.64 28.1 7.22 0.000
Matched 3.14 3.03 6.4 77% 1.45 0.147
Number of Consider Length Alerts Unmatched 0.154 0.175 4.3 -1.11 0.266
Matched 0.154 0.146 1.7 61% 0.38 0.702
(Number of Duplication Alerts)2 Unmatched 40.0 34.9 8.4 2.16 0.031
Matched 40.0 34.4 9.2 -10% 2.2 0.028
(Number of Beers List Alerts)2 Unmatched 1.86 1.58 7.7 2 0.045
Matched 1.86 1.60 7.3 6% 1.6 0.109
(Number of PAL List Alerts)2 Unmatched 4.81 4.01 13.1 3.42 0.001
Matched 4.81 4.33 7.8 41% 1.73 0.084
(Number of Clinical Initiatives Alerts)2 Unmatched 13.14 10.01 23.1 6.06 0.000
Matched 13.14 11.91 9.1 61% 1.99 0.047
(Number of Consider Length Alerts)2 Unmatched 0.252 0.254 0.2 -0.05 0.960
Matched 0.252 0.237 1.3 -573% 0.28 0.779
Total Number of Alerts x Total Number of Drugs Unmatched 380.4 322.5 17.6 4.57 0.000
Matched 380.4 346.1 10.4 41% 2.42 0.015
Total Amount Paid x Total Number of Drugs Unmatched 56,100 49,324 13.6 3.51 0.000
Matched 56,100 50,844 10.5 22% 2.44 0.015
Total Amount Paid x Total Number of Alerts Unmatched 20,717 17,333 16.3 4.25 0.000
Matched 20,717 18,506 10.7 35% 2.45 0.015
Average Bias Unmatched 12.75
Matched 7.48 41%
  Pseudo R2 Unmatched 0.026
Matched 0.011
Comparison #7 (Recommendation Level, Dual-Type Intervention)
Sample Sizes:  Study Group n=986                                                                                                                                                                                          
Unmatched Comparison Group n=1,928   
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Table A.7: Bias Reduction (Comparison #8)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.2 78.3 -8.6 -1.94 0.052
Matched 77.2 78.5 -10.5 -22% -2.05 0.041
(Age)2 Unmatched 6,119 6,278 -9 -2.05 0.041
Matched 6,119 6,283 -9.4 -4% -1.83 0.067
Race Unmatched 30.2% 23.5% 15.1 3.46 0.001
(Non-White) Matched 30.2% 28.9% 3 80% 0.53 0.595
Sex Unmatched 77.7% 78.9% -2.9 -0.65 0.513
(Female) Matched 77.7% 79.6% -4.6 -59% -0.86 0.392
Total Number of Drugs Unmatched 31.3 28.9 23 5.23 0.000
Matched 31.3 30.2 10.7 53% 2.02 0.043
Total Amount Paid Unmatched $1,681 $1,527 16.1 3.72 0.000
Matched $1,681 $1,587 9.8 39% 1.93 0.054
Total Number of Alerts Unmatched 11.43 9.81 28.2 6.43 0.000
Matched 11.43 10.86 9.8 65% 1.86 0.063
Number of Duplication Alerts Unmatched 5.27 4.64 16.9 3.82 0.000
Matched 5.27 4.95 8.4 50% 1.63 0.104
Number of Beers List Alerts Unmatched 0.923 0.778 13.7 3.18 0.001
Matched 0.923 0.856 6.4 54% 1.15 0.250
Number of PAL List Alerts Unmatched 1.84 1.58 20.6 4.66 0.000
Matched 1.84 1.77 5.2 75% 0.99 0.322
Number of  Clinical Initiatives Alerts Unmatched 3.26 2.64 34.9 7.92 0.000
Matched 3.26 3.15 6.4 82% 1.2 0.230
Number of Consider Length Alerts Unmatched 0.141 0.175 -7 -1.59 0.113
Matched 0.141 0.136 1.2 83% 0.23 0.820
(Number of Duplication Alerts)2 Unmatched 41.8 34.9 11.3 2.58 0.010
Matched 41.8 35.4 10.5 7% 2.12 0.034
(Number of Beers List Alerts)2 Unmatched 2.09 1.58 13.2 3.15 0.002
Matched 2.09 1.82 7 47% 1.23 0.220
(Number of PAL List Alerts)2 Unmatched 5.00 4.01 16.4 3.81 0.000
Matched 5.00 4.51 8.1 51% 1.49 0.136
(Number of Clinical Initiatives Alerts)2 Unmatched 13.92 10.01 28.5 6.72 0.000
Matched 13.92 12.75 8.6 70% 1.56 0.120
(Number of Consider Length Alerts)2 Unmatched 0.246 0.254 -0.6 -0.15 0.879
Matched 0.246 0.241 0.5 20% 0.09 0.929
Total Number of Alerts x Total Number of Drugs Unmatched 400.1 322.5 23.3 5.38 0.000
Matched 400.1 363.6 10.9 53% 2.09 0.037
Total Amount Paid x Total Number of Drugs Unmatched 58,064 49,324 17.2 3.97 0.000
Matched 58,064 52,646 10.7 38% 2.06 0.040
Total Amount Paid x Total Number of Alerts Unmatched 21,635 17,333 20.5 4.78 0.000
Matched 21,635 19,295 11.2 46% 2.15 0.032
Average Bias Unmatched 16.36
Matched 7.64 53%
  Pseudo R2 Unmatched 0.036
Matched 0.012
Comparison #8 (Drug Change Level, Dual-Type Intervention)
Sample Sizes:  Study Group n=686                                                                                                                                                                                          
Unmatched Comparison Group n=1,928   
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Table A.8: Bias Reduction (Comparison #9)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 79.7 80.5 -6.1 -1.25 0.212
Matched 79.7 80.8 -8.9 -46% -1.63 0.104
(Age)2 Unmatched 6,496 6,638 -7.9 -1.63 0.104
Matched 6,496 6,645 -8.3 -5% -1.51 0.130
Race Unmatched 39.8% 26.4% 28.7 6.16 0.000
(Non-White) Matched 39.8% 36.6% 6.8 76% 1.1 0.272
Sex Unmatched 74.3% 78.7% -10.4 -2.21 0.027
(Female) Matched 74.3% 76.4% -5 52% -0.83 0.409
Total Number of Drugs Unmatched 12.5 11.7 18 3.58 0.000
Matched 12.5 12.3 2.6 85% 0.5 0.617
Total Amount Paid Unmatched $740 $636 21.4 4.42 0.000
Matched $740 $707 6.8 68% 1.25 0.212
Total Number of Alerts Unmatched 4.52 3.56 33.3 7 0.000
Matched 4.52 4.26 8.9 73% 1.53 0.126
Number of Duplication Alerts Unmatched 1.50 1.40 6 1.26 0.207
Matched 1.50 1.39 6.3 -5% 1.09 0.275
Number of Beers List Alerts Unmatched 0.257 0.258 -0.3 -0.05 0.958
Matched 0.257 0.252 1 -287% 0.17 0.867
Number of PAL List Alerts Unmatched 0.98 0.68 34.7 7.39 0.000
Matched 0.98 0.92 6.4 82% 1.07 0.286
Number of  Clinical Initiatives Alerts Unmatched 1.70 1.12 50.9 10.58 0.000
Matched 1.70 1.61 7.4 86% 1.29 0.198
Number of Consider Length Alerts Unmatched 0.083 0.095 -3.7 -0.78 0.438
Matched 0.083 0.077 1.6 57% 0.27 0.784
(Number of Duplication Alerts)2 Unmatched 5.2 4.9 3.7 0.77 0.440
Matched 5.2 4.6 6.5 -75% 1.19 0.234
(Number of Beers List Alerts)2 Unmatched 0.35 0.36 -1.4 -0.28 0.780
Matched 0.35 0.34 0.5 64% 0.09 0.932
(Number of PAL List Alerts)2 Unmatched 1.74 1.14 24.8 5.57 0.000
Matched 1.74 1.56 7.3 71% 1.15 0.252
(Number of Clinical Initiatives Alerts)2 Unmatched 4.11 2.55 33.6 7.4 0.000
Matched 4.11 3.70 8.9 74% 1.45 0.148
(Number of Consider Length Alerts)2 Unmatched 0.114 0.119 -0.7 -0.16 0.873
Matched 0.114 0.109 0.9 -29% 0.15 0.881
Total Number of Alerts x Total Number of Drugs Unmatched 62.2 49.2 23.5 4.87 0.000
Matched 62.2 58.5 6.6 72% 1.14 0.256
Total Amount Paid x Total Number of Drugs Unmatched 10,140 8,651 17.2 3.59 0.000
Matched 10,140 9,573 6.6 62% 1.17 0.241
Total Amount Paid x Total Number of Alerts Unmatched 3,818 2,797 26.8 5.74 0.000
Matched 3,818 3,507 8.2 70% 1.36 0.175
Average Bias Unmatched 17.66
Matched 5.78 67%
  Pseudo R2 Unmatched 0.081
Matched 0.007
Comparison #9 (Recommendation Level, Prospective-Only Type Intervention)
Sample Sizes:  Study Group n=568                                                                                                                                                                                          
Unmatched Comparison Group n=1,873   
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Table A.9: Bias Reduction (Comparison #10)
Mean Mean %reduction t-test t-test
Variables Sample Treated Comparison %bias in bias t-value p>t
Age Unmatched 77.6 80.5 -4.7 -0.84 0.399
Matched 77.6 81.0 -8.9 -92% -1.45 0.149
(Age)2 Unmatched 6,175 6,638 -6.8 -1.23 0.217
Matched 6,175 6,668 -8.5 -24% -1.35 0.176
Race Unmatched 32.2% 26.4% 29.2 5.64 0.000
(Non-White) Matched 32.2% 37.5% 5.5 81% 0.77 0.440
Sex Unmatched 75.1% 78.7% -12.1 -2.32 0.021
(Female) Matched 75.1% 76.1% -6 50% -0.87 0.386
Total Number of Drugs Unmatched 26.9 11.7 19 3.36 0.001
Matched 26.9 12.4 2.6 87% 0.43 0.669
Total Amount Paid Unmatched $1,442 $636 20.4 3.72 0.000
Matched $1,442 $693 8.6 58% 1.4 0.161
Total Number of Alerts Unmatched 9.37 3.56 37 7.03 0.000
Matched 9.37 4.33 10.8 71% 1.59 0.112
Number of Duplication Alerts Unmatched 4.47 1.40 8.3 1.58 0.115
Matched 4.47 1.42 7 17% 1.03 0.304
Number of Beers List Alerts Unmatched 0.686 0.258 0.7 0.13 0.894
Matched 0.686 0.255 1.3 -81% 0.19 0.848
Number of PAL List Alerts Unmatched 1.47 0.68 36.7 7.06 0.000
Matched 1.47 0.93 7.9 79% 1.12 0.262
Number of  Clinical Initiatives Alerts Unmatched 2.60 1.12 55.2 10.32 0.000
Matched 2.60 1.64 9.9 82% 1.47 0.142
Number of Consider Length Alerts Unmatched 0.150 0.095 -3.2 -0.6 0.548
Matched 0.150 0.077 2.1 35% 0.31 0.759
(Number of Duplication Alerts)2 Unmatched 32.4 4.9 7 1.31 0.190
Matched 32.4 4.8 7.7 -10% 1.17 0.241
(Number of Beers List Alerts)2 Unmatched 1.35 0.36 -0.6 -0.12 0.904
Matched 1.35 0.35 0.6 1% 0.09 0.925
(Number of PAL List Alerts)2 Unmatched 3.63 1.14 27.6 5.67 0.000
Matched 3.63 1.61 8.4 70% 1.14 0.256
(Number of Clinical Initiatives Alerts)2 Unmatched 9.62 2.55 38 7.69 0.000
Matched 9.62 3.86 10.7 72% 1.48 0.140
(Number of Consider Length Alerts)2 Unmatched 0.230 0.119 0.6 0.11 0.911
Matched 0.230 0.115 1.2 -116% 0.16 0.873
Total Number of Alerts x Total Number of Drugs Unmatched 293.7 49.2 26.6 4.99 0.000
Matched 293.7 59.8 7.8 71% 1.15 0.252
Total Amount Paid x Total Number of Drugs Unmatched 44,936 8,651 16.4 3.02 0.003
Matched 44,936 9,370 8 51% 1.26 0.207
Total Amount Paid x Total Number of Alerts Unmatched 16,183 2,797 28.5 5.5 0.000
Matched 16,183 3,501 10.1 65% 1.46 0.145
Average Bias Unmatched 18.93
Matched 6.67 65%
  Pseudo R2 Unmatched 0.085
Matched 0.01
Comparison #10 (Drug Change Level, Prospective-Only Type Intervention)
Sample Sizes:  Study Group n=427                                                                                                                                                                                          
Unmatched Comparison Group n=1,873   
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APPENDIX B:  DIFFERENCE IN DIFFERENCE RESULTS TABLES: 
COMPARISONS 2-10
Table B.1: Difference in Difference Results (Comparison #2)
Variable Group p-value
Total amount paid Review $1,451 -32.11 -2.2%
Comparison $1,347 59.83 4.4% -91.94 -6.3% 0.000
Total number of drugs Review 27.0 -0.18 -0.7%
Comparison 25.6 -0.37 -1.4% 0.19 0.7% 0.340
Number of PAL list alerts Review 1.60 -0.53 -33.2%
Comparison 1.54 -0.18 -11.9% -0.35 -21.7% 0.000
Number of  Clinical Initiatives alerts Review 2.78 -0.28 -10.2%
Comparison 2.65 -0.037 -1.4% -0.25 -8.9% 0.000
Number of Beers List alerts Review 0.71 -0.07 -9.5%
Comparison 0.67 -0.05 -7.3% -0.02 -2.6% 0.373
Number of duplication alerts Review 4.38 -0.19 -4.3%
Comparison 4.02 -0.12 -3.1% -0.07 -1.5% 0.415
Number of Consider Length alerts Review 0.14 0.00 -2.6%
Comparison 0.13 0.004 2.7% -0.01 -5.2% 0.565
Sample Sizes:  Study Group n=3,618                                                                                                                                                                                               
Unmatched Comparison Group n=3
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #2 (Recommendation Level, All Intervention Types)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.2: Difference in Difference Results (Comparison #3)
Variable Group p-value
Total amount paid Review $1,460 -64.82 -4.4%
Comparison $1,358 49.33 3.6% -114.15 -7.8% 0.000
Total number of drugs Review 27.2 -0.50 -1.9%
Comparison 25.8 -0.41 -1.6% -0.09 -0.3% 0.701
Number of PAL list alerts Review 1.65 -0.65 -39.5%
Comparison 1.58 -0.21 -13.5% -0.44 -26.6% 0.000
Number of  Clinical Initiatives alerts Review 2.84 -0.36 -12.8%
Comparison 2.71 -0.052 -1.9% -0.31 -10.9% 0.000
Number of Beers List alerts Review 0.71 -0.08 -11.5%
Comparison 0.68 -0.05 -7.6% -0.03 -4.2% 0.231
Number of duplication alerts Review 4.44 -0.28 -6.3%
Comparison 4.06 -0.18 -4.4% -0.10 -2.4% 0.292
Number of Consider Length alerts Review 0.13 0.00 -2.1%
Comparison 0.12 0.008 6.1% -0.01 -7.9% 0.484
Sample Sizes:  Study Group n=2,517                                                                                                                                                                                               
Unmatched Comparison Group n=3
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #3 (Drug Change Level, All Intervention Types)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.3: Difference in Difference Results (Comparison #4)
Variable Group p-value
Total amount paid Review $1,510 -3.91 -0.3%
Comparison $1,422 58.48 4.1% -62.39 -4.1% 0.000
Total number of drugs Review 28.4 -0.65 -2.3%
Comparison 27.7 -0.61 -2.2% -0.03 -0.1% 0.861
Number of PAL list alerts Review 1.47 -0.40 -26.9%
Comparison 1.46 -0.13 -8.9% -0.27 -18.1% 0.000
Number of  Clinical Initiatives alerts Review 2.61 -0.26 -9.9%
Comparison 2.55 0.044 1.7% -0.30 -11.6% 0.000
Number of Beers List alerts Review 0.72 -0.06 -8.5%
Comparison 0.67 -0.03 -4.6% -0.03 -4.2% 0.140
Number of duplication alerts Review 4.82 -0.42 -8.7%
Comparison 4.54 -0.09 -1.9% -0.33 -6.9% 0.000
Number of Consider Length alerts Review 0.16 -0.01 -7.2%
Comparison 0.15 -0.003 -2.2% -0.01 -5.2% 0.526
Sample Sizes:  Study Group n=3,638                                                                                                                                                                                               
Unmatched Comparison Group n=1
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #4 (Review Level, Retrospective-Only Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.4: Difference in Difference Results (Comparison #5)
Variable Group p-value
Total amount paid Review $1,553 -36.01 -2.3%
Comparison $1,460 55.56 3.8% -91.58 -5.9% 0.000
Total number of drugs Review 29.3 -0.57 -1.9%
Comparison 28.2 -0.61 -2.2% 0.05 0.2% 0.860
Number of PAL list alerts Review 1.70 -0.56 -32.8%
Comparison 1.65 -0.20 -11.9% -0.36 -21.3% 0.000
Number of  Clinical Initiatives alerts Review 2.90 -0.32 -11.0%
Comparison 2.79 -0.015 -0.5% -0.30 -10.4% 0.000
Number of Beers List alerts Review 0.76 -0.08 -10.9%
Comparison 0.72 -0.06 -8.5% -0.02 -2.8% 0.429
Number of duplication alerts Review 4.83 -0.30 -6.2%
Comparison 4.51 -0.13 -2.9% -0.17 -3.5% 0.138
Number of Consider Length alerts Review 0.15 0.00 -3.0%
Comparison 0.14 -0.004 -3.1% 0.00 0.0% 1.000
Sample Sizes:  Study Group n=2,064                                                                                                                                                                                               
Unmatched Comparison Group n=1
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #5 (Recommendation Level, Retrospective-Only Type Review)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.5: Difference in Difference Results (Comparison #6)
Variable Group p-value
Total amount paid Review $1,573 -71.24 -4.5%
Comparison $1,481 54.65 3.7% -125.89 -8.0% 0.000
Total number of drugs Review 29.6 -0.97 -3.3%
Comparison 28.6 -0.51 -1.8% -0.46 -1.6% 0.156
Number of PAL list alerts Review 1.76 -0.70 -39.8%
Comparison 1.70 -0.21 -12.3% -0.49 -27.9% 0.000
Number of  Clinical Initiatives alerts Review 2.97 -0.40 -13.3%
Comparison 2.87 -0.030 -1.0% -0.37 -12.3% 0.005
Number of Beers List alerts Review 0.75 -0.09 -12.1%
Comparison 0.72 -0.06 -7.9% -0.03 -4.5% 0.314
Number of duplication alerts Review 4.92 -0.38 -7.8%
Comparison 4.61 -0.19 -4.1% -0.19 -3.9% 0.160
Number of Consider Length alerts Review 0.14 0.00 -3.6%
Comparison 0.13 0.004 3.3% -0.01 -6.6% 0.649
Sample Sizes:  Study Group n=1,404                                                                                                                                                                                               
Unmatched Comparison Group n=1
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #6 (Drug Change Level, Retrospective-Only Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.6: Difference in Difference Results (Comparison #7)
Variable Group p-value
Total amount paid Review $1,648 -50.20 -3.0%
Comparison $1,558 -13.02 -0.8% -37.18 -2.3% 0.280
Total number of drugs Review 30.8 -0.53 -1.7%
Comparison 29.6 -1.33 -4.5% 0.81 2.6% 0.052
Number of PAL list alerts Review 1.77 -0.60 -34.2%
Comparison 1.71 -0.25 -14.3% -0.36 -20.3% 0.000
Number of  Clinical Initiatives alerts Review 3.14 -0.32 -10.3%
Comparison 3.03 -0.103 -3.4% -0.22 -7.0% 0.001
Number of Beers List alerts Review 0.86 -0.09 -10.5%
Comparison 0.79 -0.06 -7.9% -0.03 -3.3% 0.515
Number of duplication alerts Review 5.12 -0.26 -5.0%
Comparison 4.85 -0.37 -7.7% 0.12 2.3% 0.503
Number of Consider Length alerts Review 0.15 -0.02 -12.5%
Comparison 0.15 -0.003 -2.1% -0.02 -10.5% 0.504
Sample Sizes:  Study Group n=986                                                                                                                                                                                               
Unmatched Comparison Group n=1,9
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #7 (Recommendation Level, Dual-Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.7: Difference in Difference Results (Comparison #8)
Variable Group p-value
Total amount paid Review $1,681 -95.41 -5.7%
Comparison $1,587 -11.57 -0.7% -83.84 -5.0% 0.052
Total number of drugs Review 31.3 -1.06 -3.4%
Comparison 30.2 -1.47 -4.9% 0.41 1.3% 0.419
Number of PAL list alerts Review 1.84 -0.69 -37.8%
Comparison 1.77 -0.22 -12.7% -0.47 -25.6% 0.000
Number of  Clinical Initiatives alerts Review 3.26 -0.42 -12.8%
Comparison 3.15 -0.105 -3.3% -0.31 -9.6% 0.000
Number of Beers List alerts Review 0.92 -0.13 -13.9%
Comparison 0.86 -0.09 -10.2% -0.04 -4.4% 0.462
Number of duplication alerts Review 5.27 -0.42 -8.0%
Comparison 4.95 -0.44 -8.9% 0.02 0.3% 0.940
Number of Consider Length alerts Review 0.14 -0.02 -12.4%
Comparison 0.14 0.004 3.2% -0.02 -15.5% 0.448
Sample Sizes:  Study Group n=686                                                                                                                                                                                               
Unmatched Comparison Group n=1,9
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #8 (Drug Change Level, Dual-Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.8: Difference in Difference Results (Comparison #9)
Variable Group p-value
Total amount paid Review $740 13.49 1.8%
Comparison $707 124.32 17.6% -110.83 -15.0% 0.000
Total number of drugs Review 12.5 1.82 14.6%
Comparison 12.3 1.66 13.5% 0.16 1.3% 0.626
Number of PAL list alerts Review 0.98 -0.32 -32.2%
Comparison 0.92 -0.02 -1.7% -0.30 -30.6% 0.000
Number of  Clinical Initiatives alerts Review 1.70 -0.09 -5.1%
Comparison 1.61 0.088 5.5% -0.17 -10.3% 0.005
Number of Beers List alerts Review 0.26 0.03 10.3%
Comparison 0.25 0.07 27.3% -0.04 -16.4% 0.263
Number of duplication alerts Review 1.50 0.32 21.2%
Comparison 1.39 0.35 25.4% -0.04 -2.3% 0.783
Number of Consider Length alerts Review 0.08 0.03 31.9%
Comparison 0.08 0.056 72.7% -0.03 -36.2% 0.226
Sample Sizes:  Study Group n=568                                                                                                                                                                                               
Unmatched Comparison Group n=1,8
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #9 (Recommendation Level, Prospective-Only Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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Table B.9: Difference in Difference Results (Comparison #10)
Variable Group p-value
Total amount paid Review $733 5.44 0.7%
Comparison $693 125.59 18.1% -120.15 -16.4% 0.000
Total number of drugs Review 12.5 1.93 15.4%
Comparison 12.4 1.78 14.4% 0.15 1.2% 0.712
Number of PAL list alerts Review 1.00 -0.43 -42.6%
Comparison 0.93 -0.05 -5.3% -0.38 -37.7% 0.000
Number of  Clinical Initiatives alerts Review 1.75 -0.17 -9.5%
Comparison 1.64 0.077 4.7% -0.24 -13.9% 0.001
Number of Beers List alerts Review 0.26 0.02 8.0%
Comparison 0.26 0.06 22.9% -0.04 -14.3% 0.398
Number of duplication alerts Review 1.55 0.27 17.7%
Comparison 1.42 0.36 25.3% -0.09 -5.6% 0.572
Number of Consider Length alerts Review 0.08 0.03 33.3%
Comparison 0.08 0.052 66.7% -0.02 -27.8% 0.419
Sample Sizes:  Study Group n=427                                                                                                                                                                                               
Unmatched Comparison Group n=1,8
Notes: 1)  Difference in Difference of Means is calculated by subtracting the Mean Change from the Comparison Group from the Mean Change 
of the Study Group  2) Difference in Difference of Means Percentage is calculated taking the Difference in Difference 
Comparison #10 (Drug Change Level, Prospective-Only Type Intervention)
Pre-Period Mean Mean 
Change
Difference in 
Difference of 
Means % change 
Difference in 
Difference of 
Means%
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APPENDIX C:  ASSESSMENT OF THE POLYPHARMACY INITIATIVE IN 
NURSING HOMES (PILOT PROJECT RESULTS)70
Assessment of the Polypharmacy Initiative in Nursing Homes
A Preliminary Analysis
By 
Dale Christensen, R.Ph., Ph.D. and Troy Trygstad, Pharm. D.
University of North Carolina, School of Pharmacy
July 2002
Executive Summary
Background, Methods, and Objectives
Beginning in March 2002, the Access II & III Programs initiated an effort to examine drug 
usage by elderly Medicaid enrollees in North Carolina nursing homes.  The intervention 
consisted of a drug therapy management service provided by a pharmacist-physician team. 
The team 1) reviewed drug profiles and other medical records of Medicaid patients in nursing 
homes, 2) determined if a drug therapy problem existed, 3) recommended a change, and 4) 
followed up to determine if the change was implemented.
The overall aim was to determine if the team could save drug costs while simultaneously 
improving quality of pharmaceutical care available to elderly Medicaid recipients. The 
specific objectives of this report are to describe:  1) the frequency of each recommendation 
type, and 2) the drug cost impact of interventions performed by the team. 
The analysis was done by assessing the baseline drug usage and costs, noting specific drug 
therapy change recommendations made and followed, and determining the resulting cost and 
quality impact.
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Major Findings
 At baseline, Medicaid nursing home patients used, on average, 6.1 prescriptions per 
month (median = 6, standard deviation = 3.3, range = 1-18).  The average cost of a 
single prescription for a 30 day supply of a drug was $54.81.  The average cost per 
patient per month for prescription drugs was $336.68 (median cost = $269.19)
 The pharmacist-physician team made drug change recommendations for 37.7%
(254/673) of all patients reviewed. There was considerable variability across nursing 
homes in the percentage of patients receiving change recommendations by the team.
 Of 408 drug change recommendations made by the consultant/pharmacist, 236 
(57.8%) were acted upon (accepted or rejected) by the physician.  A recommendation 
to discontinue a drug occurred in 124 or 30%, and another 69 (17%) involved a 
recommendation to change therapy from one drug to another. 
 The baseline costs for one month of prescription drug usage across 12 nursing home 
sites was $226,588.  The resultant cost after the reviews was $217,143, representing a 
4.2% savings of $9,445 for the first month.  An annualized gross annual savings of 
$113,340 would be achieved assuming these changes in drug therapy persisted for the 
entire year for all patients reviewed.  
 Subtracting the $8,700 cost to hire pharmacist consultants and reimburse special 
physician consultant panels for their review services, the first year annual savings to 
costs ratio is estimated at 13 to 1.  
Conclusions
 A program of review of Medicaid nursing home patients by pharmacist- physician 
consultants was cost-beneficial based solely on drug cost savings. 
 Assuming that the drug use experiences of other NC Medicaid nursing home patients 
is similar to those in these homes, there is a need for a different approach to address 
drug therapy problems and save prescription drug costs among NC nursing home 
Medicaid patients.  
 One viable approach involves having pharmacist-physician review teams make 
periodic visits to targeted nursing homes to perform both quality and cost of drug 
therapy reviews.  Targeting patients in advance for specific review would appear to 
be a time- and cost-efficient strategy.     
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Assessment of Polypharmacy Initiative in Nursing Homes
A Preliminary Analysis
(Pilot Project)
BACKGROUND
Elderly persons are especially vulnerable to drug-related problems. Literature shows 
that drug-related morbidity and mortality are major problems in the elderly, and that the 2 
major causes are therapeutic failure (i.e., inadequate drug therapy) and adverse drug 
reactions.1-4  Two studies in particular have linked hospital readmissions in the elderly to 
drug related problems in 18%- 28% of the cases.5,6 Compounding the problem is high 
prescription drug use; elders are at greater risk for experiencing sub-optimal drug therapy 
(i.e., polypharmacy, inappropriate use, or underutilization), which can lead to therapeutic 
failure or adverse drug reactions.7-9
Beginning in March, 2002, the Access II & III Programs initiated an effort to examine 
drug usage by elderly Medicaid enrollees in North Carolina nursing homes.  This initiative 
was undertaken for three reasons.  First, pharmacy costs in the Medicaid program are 
growing at an alarming and unprecedented rate.  Second, elderly citizens use the most drugs 
per capita, and are most vulnerable to the adverse effects associated with inappropriate drug 
prescribing and prescription use.  Finally, a review of current research suggested that 
pharmacy review programs coordinated by pharmacist-physician peer pairs can be effective 
in reducing inappropriate drug use in elderly patients. 
The intervention consisted of a drug therapy management service provided by a 
pharmacist-physician team. Intervention activities consisted of: 1) reviewing drug profiles 
and other medical records of Medicaid patients in nursing homes, 2) determining if a drug 
therapy problem exists; if so, then 3) recommending a modification in the drug regimen, and 
4) follow-up or results data collection.  Pharmacists reviewed patients only after eliciting 
permission of the Department of Medical Assistance and the nursing homes as well as their 
Medical Directors and attending physicians.  Confidentiality agreements were in place as a 
condition for enrollees and providers to participate in Medicaid, so patient confidentiality 
was maintained.
This is a preliminary report on the effectiveness of the first round of the pharmacist-
physician initiative directed to addressing inappropriate drug use in the elderly nursing home 
population.
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STUDY AIMS and OBJECTIVES
The overall aim of this intervention is to improve the overall quality of drug therapy 
while simultaneously improving the cost efficiency of current drug regimens.  The specific 
objectives of this report are to:
1) describe the frequency of drug related problems encountered, recommendations 
made, and drug therapy changes that occurred as a result of the interventions
2) assess the drug cost impact of interventions performed by the team. 
This pilot study report describes baseline patient drug regimens, recommendations 
made by the pharmacist-physician team, and results of those recommendations.  The 
assessment of the resultant drug regimen changes was limited to their impact on drug costs.   
The effects of changes on patient outcomes such as an improvement (or reduction) in their 
health status or in use of health care services were not considered.  A subsequent analysis is 
planned, which will include a longer follow-up period, as well as a concurrent assessment of 
a comparison group of patients in nursing homes without the pharmacist-physician team.  
METHODS
Beginning in March of 2002, records were retrieved and examined for Medicaid 
recipients’ prescription usage for 13 selected nursing homes served by physicians in the 
Access network.  Patient drug profiles for each nursing home were then created.  Algorithms 
were developed to screen patient records for signs of potential inappropriate and/or 
polypharmacy drug therapy problems such as therapeutic duplication, inappropriate drugs 
being used (based on the Beers drug list), multiple prescribers, and higher than normal drug 
usage.  The consultant/ pharmacist verified the completeness of the patient database as well 
as the completeness of the drug profile for each patient during the first visit to the nursing 
home facility.  Over-the-Counter (OTC) and “take-as-needed” (PRN) drugs were not 
considered in this analysis.  The consultant/pharmacist reviewed and confirmed the patients’ 
prescription regimen and then made recommendations to prescribers.  
Five nursing homes in Cabarrus County utilized medical residents as part of the 
pharmacist-physician team.  In these homes, recommendations were reviewed with ACCESS 
II and III Medical Directors.  Subsequently, the pharmacist/consultant and medical directors 
met with attending physicians to discuss specific recommendations. 
Based on those recommendations, the prescriber decided on one of three alternatives: 
(1) no change/recommendation rejected, (2) recommendation accepted, or (3) 
recommendation accepted with other changes.  Consultant/pharmacists documented their 
process activities, including: which patients were reviewed, the type of recommendation 
made, whether or not the recommendations were accepted, and what drug therapy changes 
were made.   Supplemental notes, records, and hard copies of the recommendation orders 
were maintained by participating pharmacist-physician pairs to verify the integrity of the 
databases and maintain consistency of data entry across nursing homes.
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To assess cost impact, each specific drug recommendation was tracked and labeled as 
to whether or not it led to a therapy change, discontinued drug or added drug for each 
patient.  For each drug change (addition or deletion), its cost impact was calculated by 
determining the average baseline drug cost per month and projecting these costs to the after 
period (one year).  The baseline drug cost was determined by taking the average amount paid 
by Medicaid for a month’s supply of each prescription identified by its unique drug name and 
dose (if available).  The data source for determining costs was baseline Medicaid claims data 
for three months prior to the start of the intervention (i.e., November 1, 2001 to January 31, 
2002) in the pilot nursing homes. 
A payer perspective was used, recognizing the amount paid by Medicaid to 
pharmacies.  While North Carolina Medicaid has a 6 prescription per patient per month 
benefit cap, many elderly patients had exceeded this cap under an exception procedure.   
Many patients without documented exemptions nevertheless received prescriptions but their 
drug claims (greater than 6) were paid directly by the nursing home.  All such prescriptions 
were captured, and applied the average cost per prescription from non-exceptional drug 
claims.
Of the 13 pilot nursing homes, one home did not complete the intervention nor had 
data available by the end of the requested period, and was excluded from the results.
RESULTS
Baseline drug usage and costs (Table 1)
 At baseline, Medicaid nursing home patients used, on average, 6.1 prescriptions per 
month (median = 6, standard deviation = 3.3, range = 1-18). 
 The cost of a single prescription drug used averaged $54.81 for a 30-day supply.  The 
average cost per patient per month for prescription drugs was $336.68.  The median 
cost per month was $269.19, indicating some outliers on the upper end when 
compared with the average.  Baseline 30 days’ supply costs ranged from $3.54 to 
$4,588 per patient.
Result of interventions 
     Analysis by patient (Table 2)
 Consultant/pharmacists reviewed 673 Medicaid patients in the assigned nursing 
homes.  Across nursing homes, the number of patients reviewed ranged from 12 to 
195.  
 The pharmacist-physician team made some type of recommendation for change in 
drug therapy for 37.7% (254/673) of the patients reviewed. There was considerable 
variability across nursing homes.  Patients with problems identified and 
recommendations made ranged from 5% to 100% across nursing homes. An 
additional 4 patients were prescribed drugs for a new indication independent of a 
specific recommendation from the consultant pharmacist.  In all, 20 drugs were added 
to patients’ regimens for new indications. 
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 A recommendation that resulted in a discontinued drug occurred in 94 (37%) of 
patient cases with identified drug therapy problems.  Changed drugs (e.g, discontinue 
a current drug and add another in its place) occurred in an additional 60 (24%) of the 
patient cases.  A result of some other type occurred in 40 (16%) of the patient cases.  
“No changes” (including “no action” or “not determined”) occurred in 142 (56%) of 
the patient cases, and drugs were added in 18 (7%) patient cases.   There was 
considerable variation across nursing homes. 
     Analysis by drug (Table 3)
 Of the 4,134 prescriptions reviewed, 408 (10%) had a recommendation for some type 
of change. 
 There were 256 prescription changes to patients’ drug therapy regimens. There were 
408 consultant/pharmacist recommendations.  Of these, 236 (58%) were acted upon 
(accepted or rejected) by the physician (20 other drugs were added for new 
indications). There were 124 (30%) recommendations to discontinue a drug, and 
another 69 (17%) were recommendations to change therapy by having a drug 
discontinued and another added.  A result with another type of recommendation 
occurred in 43 (11%) cases.  
 No change occurred in 172 (42%) of the prescriptions.   Again, there was 
considerable variation across nursing homes. 
 The drugs most frequently involved in drug discontinuation and change decisions 
were, in descending order of frequency, Prevacid, Prilosec, Celebrex, Zyprexa, and 
Norvasc. (Table 4)
Cost impact.  (Tables 6, 7, and 8)
 The baseline costs for one month across all 12 nursing home sites that had complete 
data was $226,588 (Table 1) and the resultant costs after the reviews was $217,143.   
This was a 4.2% savings (or $9,445 less).  Assuming the benefits persist for one year, 
an annualized gross annual savings of $113,335 would be achieved within the pilot 
nursing homes over one year.  
 Subtracting the $8,700 cost for pharmacist consultants as well as for physician 
reviewers, the first year annual savings to costs ratio is estimated at 13 to 1.
 The average drug cost impact per patient reviewed was $14.03 ($9,445 saved/673 
patients reviewed) for the first month. This cost difference was statistically significant 
at p = 0.0001 (paired T test results). 
 The cost impact was also computed on a per prescription basis.  As a result of the 
reviews, there were 124 prescriptions discontinued.  There were also 69 prescriptions 
for which one drug was replaced with another. (Table 3) The average savings from a 
prescription discontinuation was $57.68.  The average savings for the replacement of 
one drug with another was $33.23 for a month’s supply.
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DISCUSSION 
Several points were notable in this review.  First, there was considerable variation 
across nursing home settings in terms of the number and costs of prescriptions consumed by 
elderly residents.  There was also considerable variation in the number of reviews conducted 
by consultants/pharmacists.  In some cases, all of the patients in a home were reviewed, 
while in others (five nursing homes in Cabarrus County), only targeted patients (i.e., those 
flagged with possible drug therapy problems) were reviewed.
Findings showing that nursing home patients used a high number of drugs at high cost 
to Medicaid are consistent with what is generally known about elderly nursing home 
patients’ drug use patterns nationally.  The finding that patients used a median of 6 
prescriptions per month indicates that most likely half of them must obtain drugs through an 
exceptional use procedure or have their medications covered directly by the nursing home 
itself. 
Although the original intent of the pilot study was to focus only on patients 
previously identified as having exceptional drug therapy regimens as targets for review, 
pharmacist-physician reviewers chose to review all patients in the home at the majority of 
sites. This is one reason for the variability seen across nursing homes in the percentage of 
patients receiving change recommendations by the team.  Across all settings, the 
pharmacist-physician team made drug change recommendations for 38% of all patients 
reviewed.  
It was noteworthy that over half of the therapy recommendations made were acted 
upon within a relatively short time frame.  Most of these involved a recommendation to 
discontinue a drug (30%) or to change therapy from one drug to another (17%). These 
findings, even if preliminary, support the conclusions of other researchers that drug therapy 
received by the elderly could be improved from a qualitative as well as a cost-effectiveness 
standpoint.  
Additionally, these findings support the role of pharmacists working collaboratively 
with physicians in this activity. A recent Cochrane database review indicated that clinical 
pharmacists, working collaboratively with physicians, can be effective in addressing drug 
related problems among patients.1  These studies imply that interventions of the type 
conducted in this pilot study have the potential for additional savings from reduced 
hospitalizations and other health care system costs.
It was not determined why the pilot program was more successful in some of the 
nursing homes than in others, especially recognizing that all have, by regulatory 
requirement, review and quality assurance systems in place as outlined in OBRA 87
regulations and updates.  Some possibilities may be that, first, existing consultants typically 
audit for safety, compliance, quality, and legalities or liabilities/risk exposure but give less 
emphasis to cost effectiveness.  In this pilot, however, a special emphasis was given to the 
potential for cost savings.   Secondly, perhaps “another pair of eyes” provided by the 
pharmacist-physician team detected more problems or more opportunities for drug cost 
savings.  Third, it may be that problems/opportunities were previously detected or noted in 
records by consulting pharmacists, but simply not acted upon because of the lack of follow-
up. 
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LIMITATIONS 
This preliminary report was limited to an assessment of the impact of the pharmacist 
consultant program after only one month of operation.  Changes from baseline using 
documented recommendations made and followed were described, cost impact using baseline 
drug costs derived from claims data were assessed. 
There are several limitations.  First, assessments of changes were based only on the 
first round of interventions (i.e., one month).  Over time, one might expect the pharmacist-
physician team to become more familiar with, and more time efficient at these reviews.  
Documentation of reviews and interventions by pharmacist-physician consultant teams was, 
at times, incomplete.  This assessment of cost impact to those interventions involving drug 
discontinuations, changes and adds is therefore limited.  We are confident that we captured 
all recommendations made and followed, and that the cost savings realized were reasonable 
estimates.  In a few cases, estimates of the cost savings impact were made because of 
incomplete data.  For example, when a drug change was noted but details about the strength 
or daily dosage was missing, usual dosage criteria for the elderly were applied and a 30 days’ 
supply in estimating the cost impact was assumed.  Only the cost billed to Medicaid was 
considered.  Any rebates received by Medicaid were not considered.  For a few prescriptions 
(less than 10%), cost data was missing and was estimated using Medicaid reimbursement 
formulae.  
The cost saving observed was annualized.  In general, nursing home residents taking 
chronic medications do not frequently undergo drug regimen changes, and any economic 
benefits of a change in therapy would accrue over time. It is possible the drug regimens may 
change again sooner than one year or, conversely, the benefits may accrue for longer than 
one year.  As to program costs, only the labor cost component of the intervention was 
considered.  Startup costs and other indirect costs were not included. 
The analysis did not include a formal assessment of the quality of drug therapy 
changes, nor of the impact on quality of health care. Since the screening criteria included 
drugs considered to be inappropriate for use in the elderly, as well as polypharmacy, the 
working assumption was that the “other pairs of eyes” examining patients’ drug profiles 
would result in at least no change in quality of care, and would probably result in an 
improvement.  Due to the short time period involved, the cost impact of changes in 
utilization of such services as emergency room visits or hospitalizations possibly related to 
drug therapy changes were not examined.
Finally, this preliminary assessment did not include a comparison group assessment 
involving nursing homes not involved in the demonstration.  It is possible that the changes 
identified by pharmacists and physicians would have eventually been noted independently of 
this intervention. A planned follow-up and final assessment will address these issues more 
fully. 
CONCLUSIONS  
 Preliminary findings from this demonstration indicate that drug usage is high, and 
there exists a potential for reducing drug costs while maintaining or improving drug 
therapy for elderly nursing home residents in North Carolina. The frequency of drug 
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related problems among Medicaid patients varies considerably across nursing home 
settings.  
 A program of review of Medicaid nursing home patients by pharmacist- physician 
consultants was cost-beneficial.  Based on this preliminary analysis, the economic 
benefits appear to outweigh the investment of implementing this program by a ratio 
of 13 to 1 when monthly savings are annualized.  
 Assuming that the drug use experiences of other Medicaid nursing home patients is 
similar to those in these homes, there is a need for a different approach to address 
drug therapy problems and save prescription drug costs among NC nursing home 
Medicaid patients.  
 One viable approach involves having pharmacist-physician review teams make 
periodic visits to targeted nursing homes to perform both quality and cost of drug 
therapy reviews.  Targeting patients in advance for specific review would appear to 
be a time and cost-efficient strategy.     
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Table 1:  Baseline drug costs of Medicaid recipients: analysis by patient
276 341 388 18,882 15237734556
Average 
Across Sites**
234 403 427 5,128 1423.466.37512Universal
165 528 507 7,602 1533.1109.614415Transitional
290 470 524 12,059 1733.499.321323FiveOaks
191 419 434 6,510 1623.578.112215BrianCenter
266 350 423 10,582 1723.677.819425Avante
295 210 295 36,847 1313.255.6703125WhiteOak
228 350 403 11,699 1823.878.123429Southwood
201 329 347 24,651 1413.277.049671MaryGran
408 226 291 56,770 1512.955.41,052195Huntersville
326 247 325 18,858 1713.366.336758
ClevelandPine
s
527 238 344 27,896 1212.754.940081Britthaven
175 323 333 7,986 1012.865.613424Baptist
$353 $269 $337 
$226,58
8 1813.366.14,134673All Settings
Standar
d 
Deviatio
n
Media
nMean
Baseline 
TotalMaxMin
Standar
d 
Deviatio
n
Media
n
Mea
n
Estimated 30 Day Patient Drug Cost* 
($)
Range of 
Rx/ResidentNumber of Rx/Resident 
Current 
Number of 
Prescription
s (Rx)
Total 
Medicaid 
Residents 
Reviewed
Nursing 
Home
Baseline Drug Costs of Medicaid Recipients (Analysis by Patient)
* Drug costs represent amount paid by Medicaid to suppliers.  It includes pharmacy dispensing fees but excludes manufacturer rebates. 
** Note this row determines averages using the # NH’s as the denominator, whereas “all settings” uses averages across all patients.  
Same distinction exists for other tables.
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Table 2:  Review activities and drug therapy recommendations made by pharmacists/physicians: analysis by patient
4112 92 223 255 5188114 5621 56
Average 
Across Sites
25333425325383
1
01001210012 12Universal
54731423331477
1
092128713 15Transitional
47921411232674
1
495188319 23FiveOaks
00003336767871009609 15BrianCenter
551227623514355
1
29120 8822 25Avante
43190020925
1
134
1
570313544 125WhiteOak
8218002767141964147622 29Southwood
38150010453
2
125
1
075305640 71MaryGran
1005400000000002854 195Huntersville
000025100753100474 58
ClevelandPine
s
000050200502100454 81Britthaven
455001824551828294611 24Baptist
56%
14
2
7
%
1
8
16
%
4
0
24
%
6
0
37
%
9
464%163 38%254 673All Settings
No 
Change
Result: 
Add 
Drug***
[N, % of 
all pts 
with 
problems]
Result: 
Other**
[N, % of 
all pts with 
problems]
Result: 
Therapy 
Change*
[N, % of all 
pts with 
problems]
Result: 
D/C
[N, % of 
all pts with 
problems]
Any Result:
(D/C, Therapy 
Change, Other 
or Add Drug)
[N, % of all pts 
with problems]
% of pts 
review’
dNumberNumber
All Patients with a Result in the following categories****
All Patients with 
Problems Identified 
in their Drug 
Regimen
Patients with Problem Identified (Recommendation Issued)
Total 
Medicaid 
Residents 
Reviewed
Nursing 
Home
Review Activities and Drug Therapy Recommendations Made by RPh/MD (Analysis by Patient)
*      A “Therapy Change” is the substitution of one drug entity for another.
**   “Other” category results include: “Drug added” (as the result of a pharmacist/consultant recommendation), “Dosage Interval Changed”, 
“Dose Changed”, “Drug Decreased”, or “Admin route change”
***  An “Add Drug” is one that is included as a result of treating a new indication and not as a result of a problem identified by the 
consultant/pharmacist.  Therefore, these are not included in the baseline of Rx with problems identified.
**** Since there is often more than one Rx per patient, it is possible for any particular patient to have results in more than one category.  
Therefore, the totals will not equal 100.
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Table 3:  Drug therapy recommendations made: analysis by Rx.
3214 62 154 166 3710 73211434345Average Across Sites
143246143143591311425292275Universal
3413144114166391576292638144Transitional
311312452146502179332042213FiveOaks
00001434194510100221822122BrianCenter
401719614673401774322243 194Avante
3420001710201229176639859703WhiteOak
56240014621281244191843234Southwood
321900744124201268401259496MaryGran
1005600000000005561,052Huntersville
000025100753100414367ClevelandPines
000050200502100414400Britthaven
447001323151325691216134Baptist
42%1728%2011%4317%6930%12463%25610%408 4,134All Settings
No Change
[N, % of all Rx with 
problems]
Result: Add 
Drug***
[N,% of all Rx with 
problems]
Result: Other**
[N,% of all Rx with 
problems]
Result: Therapy 
Change*
[N,% of all Rx with 
problems]
Result: D/C
[N, % of all Rx with 
problems]
Any Result:
(D/C, Therapy Change, 
Other or Add Drug)
[N, % of all Rx with 
problems]
% of Rx 
review’dNumber
All Rx with a Result in the following categoriesAll Rx with Problems Identified
RX with Problem Identified (Recommendation Issued)
Total Prescriptions 
ReviewedNursing Home
Drug Therapy Recommendations Made (Analysis by Rx)
*      A “Therapy Change” is the substitution of one drug entity for another.
** “Other” category results include: “Drug added” (as the result of a pharmacist/consultant recommendation), “Dosage Interval Changed”, “Dose Changed”, “Drug Decreased”, or “Admin route change”
*** An “Add Drug” is one that is included as a result of treating a new indication and not as a result of a problem identified by the consultant/pharmacist.  Therefore, these are not included in the baseline of Rx with problems identified. 
Example calculation: Any result=256=124+69+43+20.       Any recommendation=408=124+69+43+172
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Table 4:  Drugs most commonly involved in therapy change 
recommendations
245ISOSORBIDE
045DILANTIN
1345CELEBREX
546NEURONTIN
247PAXIL
148METOPROLOL
057SYNTHROID
759LANOXIN
268NOVOLIN
769RISPERDAL
1171ZYPREXA
072ARICEPT
683RANITIDINE
688COUMADIN
190POTASSIUM
296ZOLOFT
399REMERON
9107NORVASC
88111PREVACID
2186FUROSEMIDE
Number of 
Recommendations 
Made
Number of 
Prescriptions 
EncounteredDrug First Name
Top Prescriptions
(by Rx Frequency)
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515ACCUPRIL
526GLUCOTROL
532FOSAMAX
537LORAZEPAM
546NEURONTIN
67ASPIRIN
617CATAPRES-TTS
625LIPITOR
683RANITIDINE
688COUMADIN
715MEGESTROL
739PLAVIX
759LANOXIN
769RISPERDAL
813ACTOS
9107NORVASC
1171ZYPREXA
1345CELEBREX
1820PRILOSEC
88111PREVACID
Number of 
Recommendation
s Made
Number of 
Prescriptions 
EncounteredDrug First Name
Top Prescriptions 
(by Frequency of Recommendations)
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Table 5:  Qualitative analysis of results of drug change recommendations—by type of action
(unit of analysis: pt drug-specific results )
5002Any result not already categorizedOther
210834No response from the physicianNot Determined
98032138
The recommendation is not 
relayed to the physician/no change 
to the regimen post-physician 
review
No Action/No 
Change
25016
Change in any of these 
characteristics
Administration 
Route, Technique 
or Compliance 
altered
250521Reduction in dosageDrug Decreased
70210Usually, a dosage increaseDose Changed
0001
The time at which the drug is 
administered is changed
Dosage Interval 
Changed
210520
An addition not a direct result of a 
recommendation, but as a general 
result of a medical resident or MD 
carefully reviewing patient’s 
overall regimen.  Often for an 
untreated indication.
Add Drug/New 
Drug Prescribed
25013
A direct result of a PharmD 
consultant recommendation Drug Added
4101669A therapeutic substitutionDrug Changed 
46029124
The drug is removed from the 
regimenDrug Discontinued
98%0%100%428All Results
MaxMin
All 
SitesAll Sites
Range 
Across 
Nursing 
Home Sites 
(%)
Total 
Result
s (%)
Total  
Results
* (#)Category DescriptionResult Category
Qualitative Analysis of Prescription Specific Results
* This number exceeds number of recommendations, due to the inclusion of Add Drugs in this list.  
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Table 6:  Projected cost savings of drug therapy changes -- analysis by patient
7.44816322693113552763413871421
Average 
Across 
Sites
17.19544722432743462444034181212Universal
9.68144491374854581655295071214
Transition
al
12.77856672594074582904705241819FiveOaks
15.275406618741936819141943499
Brian 
Center
12.68112542832883702663504232022Avante
3.126092922102852962102943144WhiteOak
4.9400202193153842283504031422
Southwoo
d
6.1370211913083262013293473040MaryGran
0.0000408226291408226291054
Huntersvill
e
1.1160332623732232624732544
Cleveland 
Pines
0.480152723834352723834444Britthaven
6.143020157322312175323333911Baptist
4.241014349257322354269336163254
All 
Settings
% of 
baselin
e costs 
(Mean)
St. 
De
v.
Media
n**
Mea
n
St. 
De
v.
Media
n
Mea
n
St. 
De
v.
Media
n
Mea
n
Estimated Cost 
Savings/Resident Reviewed 
(Entire Regimen, All 
Residents Reviewed, in 
Dollars)
Estimated Cost 
After 
Recommendations 
(Entire Regimen, 
per Resident 
Reviewed, in 
Dollars)
Baseline Rx Cost* 
(Entire Regimen, 
per Resident 
Reviewed, in 
Dollars)
Number of 
Residents 
with at 
Least One 
Result 
(Other than 
No 
Change, 
No Action 
or Not 
Determine
d)
Number of 
Residents with 
Recommendatio
n
Nursing 
Home
* Drugs added after problems were identified were not included in the costs or estimated savings, but are included in the result counts.
Total for added Drugs across sites = $193 (n=20).
** Recall, a majority of the 673 patients reviewed had no drug changes, so it is reasonable to expect that the median is zero. 
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Table 7:  Projected annual cost savings of drug therapy changes (Analysis by Rx)
8,721 (725)9,446787 191 596 6 10 Averages 
across 
sites
9,519 (780)10,299858 (67)925 3 13 Universal
8,006 (780)8,786732 (120)852 6 15 Transitio
nal
17,629 (780)18,409 1,534 161 1,373 6 21 Five 
Oaks
11,110 (780)11,890 991 394 597 9 10 Brian 
__Center
15,287 (780)16,0671,339 128 1,211 3 17 Avante
12,461 (1,060)13,521 1,127 530 597 12 17 White 
Oak
6,766 (160)6,926577 29 548 1 12 Southwo
od
17,449 (520)17,9691,497 871 626 24 12 Mary 
Gran
(1,840)(1,840)0 0 0 0 0 0 Huntersvi
lle
1,967 (440)2,407 201 0 201 0 3 Clevelan
d           
__Pines
910 (320)1,230102 0 102 0 2 Britthave
n
5,382 (460)5,842 487 368 119 5 2 Baptist
$ 104,635 (8,700)113,335$ 9,445 $ 2,293 $ 7,152 69 124 All 
settings
Net Benefit 
(Cost) per 
Nursing 
Home / Year
Consult
ant/
reviewe
r costs  
Gross 
Benefit 
(Cost)/Ye
ar
Gross 
Benefit 
(Cost)/Mo
nth
***
Savings ($) 
from Therapy 
Change**
Savings 
($) from 
D/C *
Results: Rx 
Therapy 
Change
Results: 
D/C Rx
Nursing 
Home
Projected Annual Cost Savings of Drug Therapy Changes (Analysis by Rx)
*    Assuming recommendations were followed and drug was eliminated or added.
**  Therapy change excludes added drugs not pursuant to a recommendation.  Total cost for Add Drugs across sites was $192 (n=20).
*** Sum of savings from discontinuation (D/C) and from Therapy Change.
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Table 8:  Program net cost impact:  preliminary analysis
357 8,721 725 208 517 13 36 345 56 Averages 
across 
sites 
793 9,519 780 500 280 7 28 75 12 Universal 
534 8,006 780 500 280 7 42 144 15 Transition
al 
766 17,629 780 500 280 7 46 213 23 Five 
Oaks 
741 11,110 780 500 280 7 22 122 15 Brian 
Center 
611 15,287 780 500 280 7 49 194 25 Avante
100 12,461 1,060 0 1,060 27 59 703 125 White 
Oak 
233 6,766 160 0 160 4 43 234 29 Southwoo
d
246 17,449 520 0 520 13 59 496 71 Mary 
Gran
(9)(1,840)1,840 0 1,840 46 56 1,052 195 Huntersvil
le 
34 1,967 440 0 440 11 4 367 58 Cleveland 
Pines 
11 910 320 0 320 8 4 400 81 Britthave
n
224 5,382 460 0 460 12 16 134 24 Baptist 
$ 155 $ 104,635 $8,700 $ 2,500 $ 6,200 165 428 4,134 673 All 
settings 
Net Benefit 
(Cost) per 
Patient 
Reviewed 
/Year 
Net Benefit 
(Cost) per 
Nursing 
Home / Year 
(from Table 7)
Total 
Reviewer 
Cost ($)
(from Table 7)
Estimate
d 
Physicia
n 
Reviewer 
Labor 
Cost per 
Site ($)
Pharmaci
st 
Reviewer 
Labor 
Cost ($)
Pharmacis
t Reviewer 
Labor 
(Hours)
Number of 
Problems 
Identified 
(Recommendatio
ns Made)***
Prescription
s Reviewed
Patients 
Reviewed
Nursing 
Home
Program Net Cost Impact (Preliminary Analysis)
*   Assumes $40/hour pharmacist consultant costs
**  Attending physician response time in all sites was not factored nor paid for since this was determined to be part of their normal duties.    Physician 
Consultation time in the five Cabarrus sites, however, was included.
*** Included the 20 Added Drugs.
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APPENDIX D:  PUBLICATION OF EVALUATION #171
Reprinted by permission of the publisher and author(s):
Christensen D, Trygstad T, Sullivan R, Garmise J, Wegner SE.  A pharmacy management 
intervention for optimizing drug therapy for nursing home patients.  Am J Geriatr 
Pharmacother. 2004 Dec;2(4):248-56.
Copyright 2004 by Excerpta Medica Inc.
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Reprinted by permission of the publisher and author(s):
Trygstad TK, Christensen D, Garmise J, Sullivan R, Wegner S.  Pharmacist response to alerts 
generated from Medicaid pharmacy claims in a long-term care setting: results from the North 
Carolina polypharmacy initiative.  J Manag Care Pharm. 2005 Sep;11(7):575-83.
Copyright 2005 by Academy of Managed Care Pharmacy.
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